USRE40086E1 - Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines - Google Patents

Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines Download PDF

Info

Publication number
USRE40086E1
USRE40086E1 US11/318,390 US31839005A USRE40086E US RE40086 E1 USRE40086 E1 US RE40086E1 US 31839005 A US31839005 A US 31839005A US RE40086 E USRE40086 E US RE40086E
Authority
US
United States
Prior art keywords
alkyl
methylpropyl
amino
group
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US11/318,390
Inventor
Joseph J. Hlavka
Phaik-Eng Sum
Yakov Gluzman
Ving J. Lee
Adma A. Ross
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
Wyeth Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings LLC filed Critical Wyeth Holdings LLC
Priority to US11/318,390 priority Critical patent/USRE40086E1/en
Application granted granted Critical
Publication of USRE40086E1 publication Critical patent/USRE40086E1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • C07C237/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton of a ring being part of a condensed ring system formed by at least four rings, e.g. tetracycline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings
    • C07C2603/44—Naphthacenes; Hydrogenated naphthacenes
    • C07C2603/46—1,4,4a,5,5a,6,11,12a- Octahydronaphthacenes, e.g. tetracyclines

Definitions

  • the invention relates to novel [4S-(4,12a ⁇ )]-4-(dimethylamino)-7-(substituted)-9-(substituted amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamides hereinafter called 7-(substituted)-9-(substituted amino)-6-demethyl-6-deoxytetracyclines, which exhibit antibiotic activity against a wide spectrum of organisms including organisms which are resistant to tetracyclines and are useful as antibiotic agents.
  • the invention also relates to novel 7-(substituted)-9-(substituted amino)-6-demethyl-6-deoxytetracycline intermediates useful for making the novel compounds of the present invention and to novel methods for producing the novel compounds and intermediate compounds.
  • tetracycline antibiotics have been synthesized and described for the treatment of infectious diseases in man and animals since 1947. Tetracyclines inhibit protein synthesis by binding to the 30S subunit of the bacterial ribosome preventing binding of aminoacyl RNA (Chopra, Handbook of Experimental Pharmacology, Vol. 78, 317-392, Springer-Verlag, 1985). Resistance to tetracyclines has emerged among many clinically important microorganisms which limit the utility of these antibiotics. There are two major mechanisms of bacterial resistance to tetracyclines: a) energy-dependent efflux of the antibiotic mediated by proteins located in the cytoplasmic membrane which prevents intracellular accumulation of tetracycline (S. B.
  • Resistance genes Class A-E such as Enterbacteriaceae, Pseudomonas, Haemophilus and Aeromonas
  • Gram-positive bacteria resistance genes Class K and L
  • Staphylococcus Bacillus and Streptococcus.
  • TetM resistance determinants
  • N and O resistance determinants designated TetM, N and O and is common in Staphylococcus, Streptococcus, Campylobacter, Gardnerella, Haemophilus and Mycoplasma
  • a particularly useful tetracycline compound is 7-(dimethylamino)-6-demethyl-6-deoxytetracycline, known as minocycline (see U.S. Pat. Nos. 3,148,212, Re. 26,253 and 3,226,436 discussed below).
  • minocycline 7-(dimethylamino)-6-demethyl-6-deoxytetracycline
  • strains harboring the tetB (efflux in gram-negative bacteria) mechanism but not tetK (efflux in Staphylococcus) are resistant to minocycline.
  • strains carrying tetM ribosomal protection
  • This invention describes the synthesis of novel tetracycline compounds which demonstrate significant in vitro and in vivo activity vs. tetracycline and minocycline susceptible strains and some tetracycline and minocycline resistant strains, that is, those harboring the tetM (ribosomal protection) resistance
  • Duggar U.S. Pat. No. 2,482,055, discloses the preparation of Aureomycin®(I) by fermentation which have antibacterial activity.
  • Growich et al. U.S. Pat. No. 3,007,965, disclose improvements to the fermentation preparation of I.
  • Neither of these patents teaches of suggests the 6-demethyl-6-deoxy-tetracyclines. Beereboom et al., U.S. Pat. No.
  • 3,043,875 discloses tetracycline derivatives of the formulae (II) and (III) where R is H or CH 3 ; R 1 is H and when R is CH 3 , OH; R 2 is H and N(CH 3 ) 2 ; X and Y are halogen; Z is H and halogen and B is bromo, chloro and iodo, which have anti-bacterial activity.
  • This patent does not teach or suggest the inclusion of both di(lower alkyl) amino or mono(lower alkyl)amino substitutents (at Y or Z) and an amino function (at B). Boothe et al., U.S. Pat. No. 3,148,212, reissued as Re.
  • U.S. Pat. No. 3,226,436 discloses tetracycline derivatives of the formula (IV) wherein R is hydrogen or methyl and R 1 and R 2 is hydrogen, mono(lower alkyl)amino or di(lower alkyl)amino with the proviso that R 1 and R 2 cannot both be hydrogen, which are useful for treating bacterial infections.
  • This patent does not teach or suggest the inclusion of a 9-amino functionality (at R 2 ).
  • 3,200,149 discloses tetracycline derivatives of the formulae (V) and (VI) and reduction products thereof wherein Y may be hydrogen or hydroxyl, X may be hydrogen, chloro, iodo, or bromo, X 1 may be hydrogen, amino, and lower alkanoyl-amino, X 2 may be hydrogen or nitro and Z is chloro or fluoro which possess microbiological activity.
  • This patent does not teach or suggest the inclusion of both a di(lower alkyl)amino group (at X) and another nitrogen functionality (at X 1 ) on the 6-demethyl-6-deoxy-tetracycline nucleus. Petisi et al., U.S. Pat. No.
  • 3,338,963 discloses tetracycline compounds of the formula (VII) wherein R 1 and R 2 are hydrogen, nitro, amino, formylamino, acetyl-amino, p-(di-hydroxyboryl)benzoylamino, p-(aminobenzene-sulfonyl)amino, chlorine, bromine or diazonium with the proviso that R 1 and R 2 may not both be hydrogen and with the further proviso that when R 1 is chlorine or bromine, R 2 may not be hydrogen and vice versa, R 3 is hydrogen or methyl and R 4 is hydrogen or hydroxy, which have broad-spectrum antibacterial activity.
  • R 1 and R 2 are hydrogen, nitro, amino, formylamino, acetyl-amino, p-(di-hydroxyboryl)benzoylamino, p-(aminobenzene-sulfonyl)amino, chlorine, bromine or diazonium with
  • a preferred embodiment of the general formula (VIII) is when R 5 is ⁇ -hydroxy or ⁇ -hydroxy, R 6 is ⁇ -methyl or ⁇ -methyl, R 7 is di(lower alkyl)amino and R 9 is hydrogen, which have broad-spectrum antibacterial activity.
  • This patent does not teach or suggest the inclusion of both di(lower alkyl)amino or mono(lower alkyl)amino substituents (at R 7 ) and amino substituents (at R 9 ).
  • 3,360,557 discloses 9-hydroxy-tetracyclines of the formula (IX) wherein R 1 is hydrogen or hydroxy, R 2 is hydrogen or hydroxy, R 3 is hydrogen or methyl, R 2 and R 3 taken together is methylene, and R 4 is hydrogen, halogen, nitro, amino, mono(lower alkyl)amino or di(lower alkyl)amino, which have been found to possess antibacterial activity.
  • This patent is restricted to 9-hydroxytetracyclines and does not teach or suggest the presently claimed compounds. Zambrano, U.S. Pat. No.
  • 3,360,561 discloses a process for preparing 9-nitrotetracyclines of the formula (X) wherein R 5 is hydrogen or hydroxy, R 1 is hydrogen or hydroxy, R 6 is hydrogen or methyl, R 1 and R 6 taken together is methylene, R 7 is hydrogen, chloro or nitro and R 9 is hydrogen or nitro with the proviso that R 7 and R 9 cannot both be hydrogen.
  • This patent does not teach or suggest the inclusion of both a di(lower alkyl)amino or mono(lower alkyl)amino substituent (at R 7 ) and an amino functionality (at R 9 ).
  • 3,518,306 discloses 7-and/or 9-(N-nitrosoalkylamino)-6-demethyl-6-deoxy-tetracyclines of the formula (XI) which possess in vivo antibacterial activity.
  • This patent does not teach or suggest the inclusion of both a di(lower alkyl)amino or mono(lower alkyl)amino substituent at (C-7) and an amino functionality (at C-9).
  • none of the above patents teach or suggest the novel compounds of this application.
  • none of the above patents teach or suggest novel tetracycline compounds having activity against tetracycline and minocycline resistant strains as well as strains which are normally susceptible to tetracyclines.
  • This invention is concerned with novel 7-(substituted)-9-(substituted amino)-6-demethyl-6-deoxytetracyclines, represented by formula I and II, which have antibacterial activity; with method of treating infectious diseases in warm blooded animals employing these new compound; with methods of treating or controlling veterinary diseases; with pharmaceutical preparations containing these compounds; with novel intermediate compounds and processes for the production of these compounds. More particularly, this invention is concerned with compounds of formula I and II which have enhanced in vitro and in vivo antibiotic activity against tetracycline resistant strains as well as a high level of activity against strains which are normally susceptible to tetracyclines.
  • X is selected from amino, NR 1 R 2 or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine;
  • R is selected from R 4 (CH 2 ) n CO— or R 4′ (CH 2 ) n SO 2 —;
  • Preferred compounds are compounds according to the above formula I and II in which X is selected from amino, NR 1 R 2 , or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine;
  • R is selected from R 4 (CH 2 ) n CO— or R 4′ (CH 2 ) n SO 2 —;
  • Particularly preferred compounds are compounds according to the above formula I and II in which X is selected from amino, NR 1 R 2 or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine;
  • Most particularly preferred compounds are compounds according to the above formula I and II in which X is selected from amino, NR 1 R 2 , or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine;
  • X is selected from amino, NR 1 R 2 or halogen; the halogen is selected from bromine chlorine, fluorine or iodine;
  • pyrrolyl such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
  • Such intermediate compounds include those having the formula: wherein formula III and IV, Y is NO 2 ;
  • Preferred compounds are compounds according to the above formula III and IV in which Y is NO 2 ;
  • Particularly preferred compounds are compounds according to the above formula III and IV in which Y is NO 2 ;
  • Most particularly preferred compounds are compounds according to the above formula III and IV in which Y is NO 2 ;
  • novel compounds of the present invention may be readily prepared in accordance with the following schemes.
  • compound 2 or its salts is treated with hydrogen in an acidic alcohol solvent, in the presence of a suitable catalyst such as, for example:
  • the 9-(amino)-7-(substituted amino)-6-demethyl-6-deoxytetracyclines, 3, are obtained as inorganic salts such as hydrochloric, hydrobromic, hydroiodic, phosphoric, nitric or sulfate.
  • a 9-(amino)-7-(substituted amino)-6-demethyl-6-deoxytetracycline or its salts, 3 is treated with an acyl chloride, acyl anhydride, mixed acyl anhydride, sulfonyl chloride or sulfonyl anhydride in the presence of a suitable acid scavenger in a variety of solvents to form the corresponding 9-(acyl or sulfonyl amino)-7-(substituted amino)-6-demethyl-6-deoxytetracycline, 4.
  • the acid scavenger is selected from sodium bicarbonate, sodium acetate, pyridine, triethylamine, N,O-bis(trimethylsilyl)acetamide, N,O-bis(trimethylsilyl)trifluoroacetamide or a basic ion-exchange resin.
  • the solvents are selected from water-tetrahydrofuran, N-methylpyrrolidone, 1,3-dimethyl-2-imidazolidone, hexamethylphosphoramide, 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone or 1,2-dimethoxyethane.
  • a 9-(acylamino)-6-demethyl-6-deoxytetracycline, 5a prepared by the procedures described in U.S. Pat. No. 3,239,499, or a 9-(sulfonylamino)-6-demethyl-6-deoxytetracycline, 5b, prepared by the procedures described in this invention, is treated with a halogenation agent such a bromine, N-bromoacetamide, N-bromosuccinimide, iodine monochloride, benzyltrimethylammonium chloride iodine monochloride complex or N-iodosuccinimide to give the corresponding 9-(acyl or sulfonylamino)-7-halo-6-demethyl-6-deoxytetracycline, 6.
  • a halogenation agent such as bromine, N-bromoacetamide, N-bromosuccinimide, iodine monochloride, benzyltrimethylam
  • compound 5a or 5b can be treated with:
  • 9-(acyl or sulfonyl amino)-7-nitro-6-demethyl-6-deoxytetracycline, 7, is selectively N-alkylated with aldehydes or ketones in the presence of acid and hydrogen to the corresponding 7,9-di(substituted amino)-6-demethyl-6-deoxytetracycline, 8, by methodology known to those skilled in the art (U.S. Pat. Nos. 3,226,436 and 3,518,306).
  • Compounds 4,6,7 or 8 are selectively N-alkylated in the presence of formaldehyde and either a primary amine such as methylamine, ethylamine, benzylamine, methyl glycinate, (L or D)lysine, (L or D)alanine or their substituted congeners; or a secondary amine such morpholine, pyrrolidine, piperidine or their substituted congeners to give the corresponding Mannich base adduct, 9,10,11 or 12, or the desired intermediate or of the biologically active 7-(substituted)-9-(substituted amino)-6-demethyl-6-deoxytetracyclines.
  • Contemplated equivalents include those substituted morpholine, pyrrolidine or piperidine moieties wherein the substituents are chosen to provide the requisite increase in solubility without adversely affecting antibacterial activity.
  • the 7-(substituted)-9-(substituted amino)-6-demethyl-6-deoxytetracyclines may be obtained as metal complexes such as aluminum, calcium, iron, magnesium, manganese and complex salts; inorganic and organic salts and corresponding Mannich base adducts using methods known to those skilled in the art (Richard C. Larock, Comprehensive Organic Transformations, VCH Publishers, 411-415, 1989).
  • the 7-(substituted)-9-(substituted amino)-6-demethyl-6-deoxytetracyclines are obtained as inorganic salts such as hydrochloric, hydrobromic, hydroiodic, phosphoric, nitric or sulfate; or organic salts such as acetate, benzoate, citrate, cysteine or other amino acids, fumarate, glycolate, maleate, succinate, tartrate alkylsulfonate or arylsulfonate. In all cases, the salt formation occurs with the C(4)-dimethylamino group.
  • the salts are preferred for oral and parenteral administration.
  • test organisms comprise genetically defined strains that are sensitive to tetracycline and resistant strains that are insensitive to tetracycline, either by preventing the antibiotic from interacting with bacterial ribosomes (tetM) or by a tetK encoded membrane protein which confers tetracycline resistance by energy-dependent efflux of the antibiotic from the cell.
  • tetM bacterial ribosomes
  • tetK encoded membrane protein which confers tetracycline resistance by energy-dependent efflux of the antibiotic from the cell.
  • the antibiotics are added to exponentially growing cultures of tetracycline-susceptible E. coli at growth inhibitory concentrations. After 30 minutes, excess antibiotic is removed from the bacteria by centrifugation and the organism is resuspended in fresh growth medium. The ability of bacteria to resume growth is monitored. Washing of inhibited cells alleviates growth inhibition due to chlortetracycline, but not that caused by polymyxin. This reflects the different binding characteristics of the drugs. Chlortetracycline binds reversibly to bacterial ribosomes, while polymyxin remains tightly associated with its target, the cytoplasmic membrane, and continues to prevent bacterial growth even when excess antibiotic is removed.
  • mice Female mice, strain CD-1 (Charles River Laboratories), 20 ⁇ 2 grams, are challenged by an intraperitoneal injection of sufficient bacteria (suspended in broth or hog mucin) to kill non-treated controls within 24-48 hours.
  • Antibacterial agents contained in 0.5 ml of 0.2% aqueous agar, are administered subcutaneously or orally 30 minutes after infection.
  • animals When an oral dosing schedule is used, animals are deprived of food for 5 hours before and 2 hours after infection. Five mice are treated at each dose level. The 7 day survival ratios from 3 separate tests are pooled for calculation of median effective dose (ED 50 ).
  • each 10 ⁇ l reaction contains S30 extract (a whole extract) made from either tetracycline sensitive cells or an isogenic tetracycline resistant (tetM) strain, low molecular weight components necessary for transcription and translation (i.e. ATP and GTP), a mix of 19 amino acids (no methionine), 35 S labeled methionine, DNA template (either pBR322 or pUC119), and either DMSO (control) or the novel tetracycline compound to be tested (“Novel Tc”) dissolved in DMSO.
  • the reactions are incubated for 20 minutes at 37° C. Timing is initiated with the addition of the S30 extract, the lase component to be added. After 30 minutes, 2.5 ⁇ l of the reaction is removed and mixed with 0.5 ml of 1N NaOH to destroy RNA and tRNA. Two ml of 25% trichloroacetic acid is added and the mixture incubated at room temperature for 15 minutes. The trichloracetic acid precipitated material is collected on Whatman GF/C filters and washed with a solution of 10% trichloroacetic acid. The filters are dried and the retained radioactivity, representing incorporation of 35 S-methionine into polypeptides, is counted using standard liquid scintillation methods.
  • the claimed compounds exhibit antibacterial activity against a spectrum of tetracycline sensitive and resistant Gram-positive and Gram-negative bacteria, especially, strains of E. coli, S. aureus and E. faecalis, containing the tetM resistance determinants (Table I). Notable is 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline, as shown in Tables I and IV, which has good in vitro activity against tetracycline resistant strains containing the tetM resistance determinant (such as S. aureus UBMS 88-5, S. aureus UBMS 90-1 and 90-2, E. coli UBMS 89-1 and 90-4) and is equally as effective as minocycline against susceptible strains.
  • the tetM resistance determinant such as S. aureus UBMS 88-5, S. aureus UBMS 90-1 and 90-2, E. coli UBMS 89-1 and
  • 7-(Dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline demonstrates effective activity against minocycline susceptible strains including a variety of recently isolated bacteria from clinical sources (Table V). With the exception of some Proteus spp., 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline's activity is superior to that of minocycline against other isolates.
  • Protein synthesis directed by cell-free extracts from the tetracycline susceptible strain MRE-600, are inhibited by tetracycline, minocycline and the 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline of this invention (Table 6).
  • Protein synthesis, directed by cell-free extracts from strain MRE 600 (tetM) is resistant to tetracycline and minocycline, since 50% inhibition of protein synthesis required addition of approximately 5-fold more antibiotic than in extracts prepared from strain MRE 600 (Table VI).
  • 7-(Dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline binds reversibly to its target (the ribosome) since bacterial growth resumed when the compound was removed from the cultures by washing of the organism. Therefore, the ability of 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline to inhibit bacterial growth appears to be a direct consequence of its ability to inhibit protein synthesis at the ribosome level.
  • compounds of the invention may be used to prevent or control important veterinary diseases such as mastitis, diarrhea, urinary tract infections, skin infections, ear infections, wound infections and the like.
  • aureus UBMS 90-2 0.03 ND 0.12 0.12 2 0.5 0.5 0.5 16 S. aureus UBMS 90-3 (Sensitive) ⁇ 0.015 ND 0.03 0.06 0.5 0.12 0.03 0.12 4 S. aureus UBMS 88-7 (tetK) 2 4 0.25 2 4 2 16 16 16 16 S. aureus IVES 2943 (meth. 4 64 1 4 8 2 32 32 ND resistant) S. aureus IVES 1983 (meth. 8 ND 1 4 16 4 32 32 32 32 resistant) S. aureus ATCC 29213 (Sensitive) ⁇ 0.015 0.12 ⁇ 0.015 ⁇ 0.015 ⁇ 0.015 ⁇ 0.015 ND 0.22 1 S.
  • aureus Smith (Sensitive) ⁇ 0.015 0.12 0.03 0.03 0.5 0.12 0.03 0.12 8 S. haemolyticus AVAH 88-3 0.03 ND 0.12 ND 8 2 0.06 2 0.5 E. faecalis 12201 0.12 0.5 0.5 1 16 4 16 2 16 E. faecalis ATCC 29212 ⁇ 0.015 0.12 0.06 0.12 2.0 0.25 0.25 0.25 8 E. coli UBMS 88-1 (tetB) 32 >128 16 >32 >32 >32 >32 >128 >32 E. coli UBMS 88-2 (Sensitive) 0.12 2 0.25 0.5 >32 32 1 >128 32 E.
  • aureus UBMS 90-1 (tetM) 4 0.25 8 2 >32 4 1 0.25 S. aureus UBMS 90-2 (tetM) 2 0.06 2 0.5 32 2 0.25 0.06 S. aureus UBMS 90-3 (Sensitive) 0.5 0.03 1 0.5 1 ⁇ 0.015 0.03 0.06 S. aureus UBMS 88-7 (tetK) 2 32 >32 >32 8 0.06 0.5 0.06 S. aureus IVES 2943 (meth. 4 32 >32 >32 32 1 2 1 resistant) S. aureus IVES 1983 (meth. 4 32 >32 >32 >32 1 2 1 resistant) S.
  • aureus ATCC 29213 (Sensitive) 0.06 ⁇ 0.015 0.5 0.5 0.25 ⁇ 0.015 ⁇ 0.015 0.03
  • S. aureus Smith (Sensitive) 0.5 ⁇ 0.015 0.5 1 2 ⁇ 0.015 0.03 0.12
  • S. haemolyticus AVAH 88-3 4 0.5 16 1 4 0.03 0.25 0.25
  • coli UBMS 88-2 (Sensitive) >32 4 >32 2 >32 0.5 ND ND E. coli UBMS 89-1 (tetM) >32 1 >32 2 >32 16 4 0.12
  • E. coli UBMS 89-2 (Sensitive) >32 8 >32 2 >32 0.5 4 0.25 E. coli ATCC 25922 32 4 32 2 32 0.25 2 0.12
  • aureus UBMS 90-2 (tetM) 4 8 2 1 2 1 1 8 8 8 4 2 S. aureus UBMS 90-3 (Sensitive) 1 4 1 1 2 0.5 0.5 8 1 2 2 ⁇ 0.015 S. aureus UBMS 88-7 (tetK) 8 16 4 8 4 1 4 16 8 >32 32 0.06 S. aureus IVES 2943 (meth. resistant) 16 8 4 8 4 1 4 8 >32 >32 32 4 S. aureus IVES 1983 (meth. resistant) 8 16 8 4 4 1 8 8 >32 >32 32 4 S. aureus ATCC 29213 (Sensitive) 0.25 1 0.12 0.5 1 0.5 0.25 2 0.5 0.5 0.5 ⁇ 0.015 S.
  • aureus Smith (Sensitive) 1 4 1 1 4 1 0.5 4 1 2 2 ⁇ 0.015 S. haemolyticus AVAH 88-3 4 8 8 4 4 1 4 16 8 >32 8 0.03
  • E. coli UBMS 88-2 (Sensitive) >32 >32 >32 >32 >32 >32 >32 >32 >32 >32 >32 0.5 E.
  • E. coli UBMS 89-1 (tetM) ND ND ND ND ND >32 >32 >32 >32 16
  • E. coli UBMS 89-2 (Sensitive) >32 >32 >32 >32 >32 >32 >32 >32 0.5
  • E. coli ATCC 25922 >32 >32 >32 >32 >32 >32 ⁇ 32 >32 >32 >32 >32 0.25
  • aureus UBMS 90-2 (tetM) 0.12 0.5 0.06 0.25 0.12 0.06 4 1 S. aureus UBMS 90-3 (Sensitive) 0.06 0.12 4 0.25 0.12 0.12 2 ⁇ 0.015 S. aureus UBMS 88-7 (tetK) 2 4 4 2 1 8 32 0.06 S. aureus IVES 2943 (meth. resistant) 4 4 4 4 0.5 16 >32 2 S. aureus IVES 1983 (meth. resistant) 8 8 4 4 1 16 32 1 S. aureus ATCC 29213 (Sensitive) 0.12 0.06 ⁇ 0.015 0.03 0.03 0.03 0.5 ⁇ 0.015 S.
  • hemolyticus AVHAH 88-3 0.25 0.12 0.12 1 32 1 0.25 2 0.5 0.25 Enterococcus 12201 0.12 0.12 0.06 0.25 2 0.25 0.12 0.5 0.12 0.12 E. faecalis ATCC 29212 0.12 0.06 0.06 0.25 2 0.25 0.12 0.25 0.12 0.12 TT UU VV WW XX YY ZZ AAA BBB CCC DDD E. coli UBMS 88-1 TetB 0.5 0.5 >32 0.25 0.5 0.5 >32 0.5 0.5 1 0.5 E. coli J3272 Tet sens. 0.5 0.5 >32 0.25 0.5 0.5 NT NT NT NT E. coli MC4100 Tet sens.
  • aureus UBMS 88-5 TetM 0.25 0.25 32 0.25 0.25 0.5 8 0.25 0.5 0.5 0.5 0.5 S. aureus UBMS 88-7 TetK 2 0.25 32 1 1 4 16 0.5 2 1 2 S. aureus UBMS 90-1 TetM 0.25 0.25 32 0.12 0.25 0.25 8 0.5 0.25 1 1 S. aureus UBMS 90-3 0.12 0.12 4 0.12 0.25 0.12 2 0.25 0.06 0.25 0.5 S. aureus UBMS 90-2 TetM 0.25 0.12 16 0.25 0.25 0.25 4 0.25 0.25 0.25 0.5 S. aureus IVES 2943 2 0.25 >32 2 1 8 >32 0.5 4 1 4 S.
  • aureus ROSE (MP) 2 0.5 >32 2 1 8 >32 2 16 2 4 S. aureus SMITH (MP) 0.12 0.12 4 0.12 0.25 0.25 2 0.25 0.12 0.5 0.25 S. aureus IVES 1983 2 0.5 >32 2 1 4 >32 0.5 4 1 4 S. aureus ATCC 29213 0.25 0.12 8 0.25 0.25 0.5 2 0.25 0.25 0.5 1 S. hemolyticus AVHAH 88-3 0.5 0.12 >32 0.25 0.5 0.5 8 0.5 0.5 0.5 0.5 0.5 Enterococcus 12201 0.25 0.12 4 0.12 0.12 0.25 8 0.12 0.25 0.25 0.25 E.
  • aureus UBMS 88-4 0.25 0.12 0.12 0.25 0.5 8 32 0.25 0.25 S. aureus UBMS 88-5 TetM 0.5 0.12 0.12 0.25 1 8 >32 0.25 0.25 S. aureus UBMS 88-7 TetK 2 1 1 0.5 2 16 >32 2 4 S. aureus UBMS 90-1 TetM 0.5 0.12 0.25 0.25 1 16 >32 0.25 0.5 S. aureus UBMS 90-3 0.25 0.12 0.12 0.12 0.5 2 16 0.12 0.12 S. aureus UBMS 90-2 TetM 0.25 0.12 0.12 0.12 0.5 8 32 0.25 0.25 S. aureus IVES 2943 2 2 2 2 4 32 >32 2 4 S.
  • aureus ROSE MP
  • aureus SMITH MP
  • 0.25 0.12 0.12 0.12 0.5 4 16 0.25 0.25 S. aureus IVES 1983 2 2 2 2 4 32 >32 2 4 S. aureus ATCC 29213 0.5 0.12 0.25 0.25 0.5 4 32 0.25 0.25 S. hemolyticus AVHAH 88-3 2 0.25 0.5 0.5 2 16 >32 0.25 0.24 Enterococcus 12201 0.25 0.12 0.12 0.12 1 16 >32 0.25 0.24
  • gonorrhoeae IL 611 (Sensitive) 0.06 0.5 ND N. gonorrhoeae 6418 (tetM) 1 >32 >32 E. faecalis UBMS 90-6 (tetM) 0.12 8 32 E. faecalis UBMS 90-7 (tetM) 0.5 8 32
  • aureus SMITH Intraveneous 0.61 0.68 0.25-0.5 1-2 — 1-2 1-2
  • S. aureus SMITH (sens) Subcutaneous 0.66 — — — — — — Escherichia coli Intraveneous — 2.49 — — — — — UBMS 90-4 (Tet-M) Route of Antibiotic Organism Administration BBB WW XX YY AAA DDD EEE O S. aureus SMITH (sens) Oral 4-8 >16 8-16 >16 >16 8-16 8-16 0.74 S. aureus SMITH (sens) Intraveneous 1.8 0.82 0.5-1 0.5-1 — — 0.37 S.
  • aureus SMITH (sens) Subcutaneous — — — — — — — — — — Escherichia coli Intraveneous — — — — — — — >32 UBMS 90-4 (Tet-M) + Median effective dose protecting 50% of the infected mice, single subcutaneous dosing.
  • the compounds When the compounds are employed as antibacterials, they can be combined with one or more pharmaceutically acceptable carriers, for example, solvents, diluents and the like, and may be administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from about 20 to 50% ethanol, and the like, or parenterally in the form of sterile injectable solutions or suspensions containing from about 0.05 to 5% suspending agent in an isotonic medium.
  • Such pharmaceutical preparations may contain, for example, from about 25 to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and 60% by weight.
  • An effective amount of compound from 2.0 mg/kg of body weight to 100.0 mg/kg of body weight should be administered one to five times per day via any typical route of administration including but not limited to oral, parenteral, (including subcutaneous, intravenous, intramuscular, intrasternal injection or infusion techniques), topical or rectal, in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
  • active compounds may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes.
  • Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired.
  • Adjuvants customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA.
  • compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral administration of the compounds is preferred.
  • active compounds may also be administered parenterally or intraperitoneally.
  • Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose.
  • Dispersions can also be prepared in glycerol, liquid, polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacterial and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oil.
  • a mixture of 2.0 g of product from Example 1 in 20 ml of 2-methoxyethanol is stirred for 10 minutes and filtered.
  • the filtrate is shaken, in a pressure bottle, with 1.0 g of 10% palladium-on-carbon and 5 ml of 2N sulfuric acid, under 30 lbs. of hydrogen pressure, for 1 hour.
  • the reaction mixture is filtered and the filtrate concentrated in vacuo to half volume.
  • the solution is poured into 100 ml of diethyl ether, the solid collected, washed with diethyl ether and dried to give 1.6 g of the desired product as a solid.
  • a mixture of 0.20 g of product from Example 2 and 3.0 ml of trifluoroacetic anhydride is stirred at room temperature for 6 hours.
  • the reaction liquid is decanted from the solid residue.
  • the solid is dried, dissolved in 10 ml of methyl alcohol, stirred for 20 minutes and the mixture is poured into 100 ml of diethyl ether.
  • the solid is collected and dried to give 0.16 g of the desired product.
  • a solution of 0.2 g of product from Example 10 in 10 ml of water is treated with sodium acetate to achieve pH 5-6.
  • the mixture is extracted with chloroform.
  • the organic extracts are dried with sodium acetate, concentrated in vacuo and the solid triturated with diethyl ether/hexane to give 0.11 g of the desired product.
  • a solution of 0.25 g of product from Example 11 in ml of water is treated with sodium acetate to achieve pH 6.
  • the mixture is extracted with chloroform.
  • the organic extracts are dried with sodium acetate, concentrated in vacuo and the solid triturated with diethyl ether/hexane to give 0.090 g of the desired product.
  • Example 8 The title compound is prepared by the procedure of Example 8, using 0.460 g of product from Example 14, 15 ml of sulfuric acid and 0.101 g of sodium nitrate to give 0.5 g of the desired product.
  • the title compound is prepared by the procedure of Example 2, using 1.0 g of product from Example 15, 20 ml of 2-methoxyethanol, 1.0 g of 10% palladium-on-carbon and 5 ml of 2N sulfuric acid to give 0.8 g of the desired product.
  • Example 3 The title compound is prepared by the procedure of Example 3, using 1.5 g of product from Example 16, 0.235 g of anhydrous sodium acetate, 25 ml of 98% formic acid and 3.7 ml of acetic anhydride to give 1.35 g of the desired product.
  • reaction is stirred for 20 minutes, 0.5 ml of ammonium hydroxide is added and stirred for 5 minutes. Two and one half ml of sulfuric acid is added, the reaction is extracted twice with n-butyl alcohol, the combined organic layers are washed with water and concentrated in vacuo. The residue is dissolved in methyl alcohol and added dropwise to 500 ml of diethyl ether. The solid is collected and dried to give 2.3 g of the desired product.
  • Example 23 The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g-of sodium bicarbonate, 1.0 ml N-methylpyrrolidone, 0.010 g of cyclopropanecarbonyl chloride and 0.5 ml of acetonitrile to give 0.030 g of the desired product.
  • Example 23 The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1 ml of N-methylpyrrolidone, 0.013 g of chloroacetyl chloride and 0.5 ml of acetonitrile to give 0.035 g of the desired product.
  • Example 23 The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1 ml of N-methylpyrrolidone, 0.025 g of 4-bromobutyryl chloride and 0.5 ml of acetonitrile to give 0.050 g of the desired product.
  • Example 23 The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1.0 ml N-methylpyrrolidone, 0.011 g of acryloyl chloride and 0.5 ml of acetonitrile to give 0.040 g of the desired product.
  • Example 23 The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1.0 ml of N-methylpyrrolidone, 0.013 g of acetoxyacetyl chloride and 0.5 ml of acetonitrile to give 0.040 g of the desired product.
  • Example 23 The title compound is prepared by the procedure of Example 23, using 0.110 g of product from Example 2, 0.40 g of sodium bicarbonate, 4.0 ml of N-methylpyrrolidone, 0.035 g of phenylthioacetyl chloride and 0.5 ml of acetonitrile to give 0.075 g of the desired product.
  • Example 23 The title compound is prepared by the procedure of Example 23, using 0.110 g of product from Example 2, 0.40 g of sodium bicarbonate, 1.0 ml of N-methylpyrrolidone, 0.018 g of pyruvyl chloride and 0.5 ml of acetonitrile to give 0.060 g of the desired product.
  • Example 23 The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1.0 ml of N-methylpyrrolidone, 0.013 g of ethyl malonyl chloride and 0.5 ml of acetonitrile to give 0.035 g of the desired product.
  • Example 23 The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1.0 ml of N-methylpyrrolidone, 0.018 g of 4-bromophenylacetyl chloride and 0.5 ml of acetonitrile to give 0.040 g of the desired product.
  • the catalyst is removed by filtration and the filtrate is concentrated in vacuo and codistilled with benzene.
  • the oily residue is dissolved in 0.5 ml of 2-methoxyethanol, precipitated with diethyl ether and the solid collected to give 0.018 g of the desired product.
  • the catalyst is removed by filtration and the filtrate is concentrated in vacuo and codistilled with heptane.
  • the oily residue is dissolved in 1.0 ml of 2-methoxyethanol, precipitated with diethyl ether to give 0.085 g of the desired product as the sulfate salt.
  • the sulfate salt is dissolved in 0.5 ml of water and 6 ml of tetrahydrofuran followed by the addition of 0.10 g of sodium acetate.
  • the organic layer is washed with saturated sodium chloride, dried and concentrated in vacuo.
  • the residue is triturated with ethyl acetate/heptane to give 0.035 g of the desired product as the free base.
  • the catalyst is removed by filtration and the filtrate is concentrated in vacuo and codistilled with benzene.
  • the oily residue is dissolved in 0.5 ml of 2-methoxyethanol, precipitated with diethyl ether and the precipitate collected to give 0.025 g of the desired product.
  • a mixture of 0.30 g of product from Example 2, 0.40 g of sodium acetate in 10 ml of tetrahydrofuran and 1.5 ml of water is stirred for 10 minutes under argon.
  • the organic layer is separated, dried over anhydrous sodium sulfate and treated with 0.125 ml of benzenesulfonyl chloride and 0.60 g of sodium bicarbonate.
  • the reaction is stirred vigorously for 1.5 hours.
  • the organic layer is decanted and codistilled with heptane.
  • the residue is dissolved in ethyl acetate, dried and concentrated in vacuo.
  • the residue is chromatographed on diatomaceous earth using hexane:ethyl acetate:2-methoxyethanol:water (35:65:15:5) to give 0.036 g of the desired product as a yellow solid.
  • a mixture of 0.30 g of product from Example 2, 0.40 g of sodium acetate in 10 ml of tetrahydrofuran and 1.5 ml of water is stirred for 10 minutes at room temperature under argon.
  • the organic layer is separated, dried over sodium sulfate, filtered and treated with 0.10 ml of methanesulfonyl chloride and 0.60 g of sodium bicarbonate.
  • the reaction is stirred vigorously for 1.5 hours.
  • the organic layer is decanted and codistilled with heptane.
  • the residue is dissolved in ethyl acetate, dried and concentrated in vacuo.
  • the crude product is chromatographed on diatomaceous earth using hexane:ethyl acetate:2-methoxyethanol:water (35:65:15:5) to give 0.016 g of the desired product as a yellow solid.
  • Example 23 The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1.0 ml of N-methylpyrrolidine, 0.018 g of benzyloxyacetyl chloride and 0.5 ml of acetonitrile to give 0.060 g of the desired product.
  • the title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1.0 ml of N-methylpyrrolidone, 0.015 g of ethyl oxalyl chloride and 0.5 ml of acetonitrile to give 0.030 g of the desired product.
  • Example 62 The title compound is prepared by the procedure of Example 62, using 0.443 g of product from Example 2, 2 ml of 1-methyl-2-pyrrolidone, 0.165 g of ⁇ -diethylaminoethyl chlorocarbonate hydrochloride and 0.443 g of sodium bicarbonate to give 0.350 g of the desired product.
  • Example 62 The title compound is prepared by the procedure of Example 62, using 0.189 g of product from Example 2, 1 ml of 1-methyl-2-pyrrolidone, 0.75 ml of acetonitrile, 0.20 g of sodium bicarbonate and 0.037 g of vinyl chloroformate to give 0.133 g of the desired product.
  • Example 62 The title compound is prepared by the procedure of Example 62, using 0.213 g of product from Example 2, 1 ml of 1-methyl-2-pyrrolidone, 0.75 ml of acetonitrile, 0.20 g of sodium bicarbonate and 0.054 g of allyl chloroformate to give 0.143 g of the desired product.
  • Example 72 uses the appropriate anhydride rather than the acid chloride.
  • Example 46 The title compound is prepared by the procedure of Example 46, using 0.030 g of product from Example 45, 0.020 g of 10% palladium-on-carbon, 2.5 equivalents of acetaldehyde, 1.5 ml of 2-methoxyethanol and 0.175 ml of 2N sulfuric acid to give the desired product as a solid.
  • the reaction is stirred for 30 minutes, filtered, and the filtrate added dropwise to 100 ml of diethyl ether, containing 1 ml of 1M hydrochloric acid in diethyl ether.
  • the resulting solid is collected and dried to give 0.340 g of the desired product.
  • the title compound is prepared by the procedure of Example 98, using 0.668 g of 9-amino-4,7-bis(dimethylamino)- 6-demethyl-6-deoxytetracycline sulfate, 6 ml of DMPU, 2 ml of acetonitrile, 0.636 g of sodium carbonate and 0.215 g of bromoacetyl chloride. Seven tenths of a gram of the desired product is obtained.
  • the title compound is prepared by the procedure of Example 98, using 1.00 g of 9-amino-4,7-bis(dimethylamino)- 6-demethyl-6-deoxytetracycline, 1.0 g of sodium carbonate and 0.648 g of 2-bromopropionyl bromide to give 0.981 g of the desired product.
  • the title compound is prepared by the procedure of Example 98, using 1.34 g of 9-amino-4,7-bis(dimethylamino)- 6-demethyl-6-deoxytetracycline sulfate, 1.3 g of sodium carbonate, 24 ml of DMPU, 8 ml of acetonitrile and 0.389 g of 4-bromobutyryl chloride to give 1.45 g of the desired product.
  • Example 105 Substantially following the methods described in detail herein above in Example 105, the compounds of this invention listed below in Examples 106-125 are prepared.
  • a mixture of 0.5 g of product from Example 117, 3 ml of t-butyl alcohol, 0.55 ml of 37% formaldehyde, and 0.55 ml of pyrrolidine, morpholine or piperidine is stirred at room temperature for 30 minutes followed by heating at 100° C. for 15 minutes.
  • the reaction mixture is cooled to room temperature and triturated with diethyl ether and hexane. The solid is collected, washed with diethyl ether and hexane, and dried to give the desired product.
  • Example 105 The title compound is prepared by the procedure of Example 105 using 0.20 g of product form Example 99, 0.50 g of azetidine and 5 ml of DMPU to give 0.126 g of the desired product.

Abstract

The disclosure is drawn to a method of using novel 7-substituted-9-(substituted amino)-6-demethyl-6-deoxytetracycline compounds to treat infections caused by a wide spectrum of bacterial organisms, including those which are resistant to tetracycline.

Description

This is a divisional of application Ser. No. 08/286,096 filed on Aug. 4, 1994 which is a continuation of Ser. No. 07/926,091 filed Aug. 13, 1992 now abandoned which is a continuation in part of Ser. No. 07/771,576, filed on Oct. 4, 1991 now abandoned for NOVEL 7-SUBSTITUTED-9-SUBSTITUTED AMINO-6-DEMETHYL-6-DEOXYTETRACYCLINES.This application is a reissue of 08/455,446, filed May 31, 1995, now Pat. No. 5,529,990, which is a divisional of application Ser. No. 08/286,096, filed on Aug. 4, 1994, now Pat. No. 5,494,903, which is a continuation of Ser. No. 07/926,091, filed Aug. 13, 1992, now abandoned, which is a continuation-in-part of Ser. No. 07/771,576, filed on Oct. 4, 1991, now abandoned for NOVEL 7-SUBSTITUTED-9-SUBSTITUTED AMINO-6-DEMETHYL-6-DEOXYTETRACYCLINES.
BACKGROUND OF THE INVENTION
1. Field of the Invention
The invention relates to novel [4S-(4,12aα)]-4-(dimethylamino)-7-(substituted)-9-(substituted amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamides hereinafter called 7-(substituted)-9-(substituted amino)-6-demethyl-6-deoxytetracyclines, which exhibit antibiotic activity against a wide spectrum of organisms including organisms which are resistant to tetracyclines and are useful as antibiotic agents. The invention also relates to novel 7-(substituted)-9-(substituted amino)-6-demethyl-6-deoxytetracycline intermediates useful for making the novel compounds of the present invention and to novel methods for producing the novel compounds and intermediate compounds.
DESCRIPTION OF THE PRIOR ART
A variety of tetracycline antibiotics have been synthesized and described for the treatment of infectious diseases in man and animals since 1947. Tetracyclines inhibit protein synthesis by binding to the 30S subunit of the bacterial ribosome preventing binding of aminoacyl RNA (Chopra, Handbook of Experimental Pharmacology, Vol. 78, 317-392, Springer-Verlag, 1985). Resistance to tetracyclines has emerged among many clinically important microorganisms which limit the utility of these antibiotics. There are two major mechanisms of bacterial resistance to tetracyclines: a) energy-dependent efflux of the antibiotic mediated by proteins located in the cytoplasmic membrane which prevents intracellular accumulation of tetracycline (S. B. Levy, et al., Antimicrob. Agents Chemotherapy 33, 1373-1374 (1989); and b) ribosomal protection mediated by a cytoplasmic protein which interacts with the ribosome such that tetracycline no longer binds or inhibits protein synthesis (A. A. Salyers, B. S. Speers and N. B. Shoemaker, Mol. Microbiol, 4:151-156, 1990). The efflux mechanism of resistance is encoded by resistance determinants designated tetA-tetL. They are common in many Gram-negative bacteria (resistance genes Class A-E), such as Enterbacteriaceae, Pseudomonas, Haemophilus and Aeromonas, and in Gram-positive bacteria (resistance genes Class K and L), such as Staphylococcus, Bacillus and Streptococcus. The ribosomal protection mechanism of resistance is encoded by resistance determinants designated TetM, N and O and is common in Staphylococcus, Streptococcus, Campylobacter, Gardnerella, Haemophilus and Mycoplasma (A. A. Salyers, B. S. Speers and N. B. Shoemaker, Mol. Microbiol, 4:151-156 1990).
A particularly useful tetracycline compound is 7-(dimethylamino)-6-demethyl-6-deoxytetracycline, known as minocycline (see U.S. Pat. Nos. 3,148,212, Re. 26,253 and 3,226,436 discussed below). However, strains harboring the tetB (efflux in gram-negative bacteria) mechanism, but not tetK (efflux in Staphylococcus) are resistant to minocycline. Also, strains carrying tetM (ribosomal protection) are resistant to minocycline. This invention describes the synthesis of novel tetracycline compounds which demonstrate significant in vitro and in vivo activity vs. tetracycline and minocycline susceptible strains and some tetracycline and minocycline resistant strains, that is, those harboring the tetM (ribosomal protection) resistance determinants.
Duggar, U.S. Pat. No. 2,482,055, discloses the preparation of Aureomycin®(I) by fermentation which have antibacterial activity. Growich et al., U.S. Pat. No. 3,007,965, disclose improvements to the fermentation preparation of I. Neither of these patents teaches of suggests the 6-demethyl-6-deoxy-tetracyclines.
Figure USRE040086-20080219-C00001
Beereboom et al., U.S. Pat. No. 3,043,875 discloses tetracycline derivatives of the formulae (II) and (III) where R is H or CH3; R1 is H and when R is CH3, OH; R2 is H and N(CH3)2; X and Y are halogen; Z is H and halogen and B is bromo, chloro and iodo, which have anti-bacterial activity. This patent does not teach or suggest the inclusion of both di(lower alkyl) amino or mono(lower alkyl)amino substitutents (at Y or Z) and an amino function (at B).
Figure USRE040086-20080219-C00002
Boothe et al., U.S. Pat. No. 3,148,212, reissued as Re. 26,253, and Petisi et al., U.S. Pat. No. 3,226,436, discloses tetracycline derivatives of the formula (IV) wherein R is hydrogen or methyl and R1 and R2 is hydrogen, mono(lower alkyl)amino or di(lower alkyl)amino with the proviso that R1 and R2 cannot both be hydrogen, which are useful for treating bacterial infections. This patent does not teach or suggest the inclusion of a 9-amino functionality (at R2).
Figure USRE040086-20080219-C00003
Blackwood et al., U.S. Pat. No. 3,200,149 discloses tetracycline derivatives of the formulae (V) and (VI) and reduction products thereof wherein Y may be hydrogen or hydroxyl, X may be hydrogen, chloro, iodo, or bromo, X1 may be hydrogen, amino, and lower alkanoyl-amino, X2 may be hydrogen or nitro and Z is chloro or fluoro which possess microbiological activity. This patent does not teach or suggest the inclusion of both a di(lower alkyl)amino group (at X) and another nitrogen functionality (at X1) on the 6-demethyl-6-deoxy-tetracycline nucleus.
Figure USRE040086-20080219-C00004
Petisi et al., U.S. Pat. No. 3,338,963 discloses tetracycline compounds of the formula (VII) wherein R1 and R2 are hydrogen, nitro, amino, formylamino, acetyl-amino, p-(di-hydroxyboryl)benzoylamino, p-(aminobenzene-sulfonyl)amino, chlorine, bromine or diazonium with the proviso that R1 and R2 may not both be hydrogen and with the further proviso that when R1 is chlorine or bromine, R2 may not be hydrogen and vice versa, R3 is hydrogen or methyl and R4 is hydrogen or hydroxy, which have broad-spectrum antibacterial activity. This patent does not teach or suggest the inclusion of both di(lower alkyl)amino or mono(lower alkyl)amino substituents (at R1) and amino substituents (at R2).
Figure USRE040086-20080219-C00005
Bitha et al., U.S. Pat. No. 3,341,585 discloses tetracycline compounds of the formula (VIII) wherein R5 is hydrogen, α-hydroxy or β-hydroxy, R6 is α-methyl or β-methyl, and R7 and R9 are each hydrogen, mono(lower alkyl)amino or di(lower alkyl)amino with the proviso that R7 and R9 cannot both be hydrogen and with the further proviso that when R5 is hydrogen then R6 is α-methyl. A preferred embodiment of the general formula (VIII) is when R5 is α-hydroxy or β-hydroxy, R6 is α-methyl or β-methyl, R7 is di(lower alkyl)amino and R9 is hydrogen, which have broad-spectrum antibacterial activity. This patent does not teach or suggest the inclusion of both di(lower alkyl)amino or mono(lower alkyl)amino substituents (at R7) and amino substituents (at R9).
Figure USRE040086-20080219-C00006
Shu, U.S. Pat. No. 3,360,557 discloses 9-hydroxy-tetracyclines of the formula (IX) wherein R1 is hydrogen or hydroxy, R2 is hydrogen or hydroxy, R3 is hydrogen or methyl, R2 and R3 taken together is methylene, and R4 is hydrogen, halogen, nitro, amino, mono(lower alkyl)amino or di(lower alkyl)amino, which have been found to possess antibacterial activity. This patent is restricted to 9-hydroxytetracyclines and does not teach or suggest the presently claimed compounds.
Figure USRE040086-20080219-C00007
Zambrano, U.S. Pat. No. 3,360,561 discloses a process for preparing 9-nitrotetracyclines of the formula (X) wherein R5 is hydrogen or hydroxy, R1 is hydrogen or hydroxy, R6 is hydrogen or methyl, R1 and R6 taken together is methylene, R7 is hydrogen, chloro or nitro and R9 is hydrogen or nitro with the proviso that R7 and R9 cannot both be hydrogen. This patent does not teach or suggest the inclusion of both a di(lower alkyl)amino or mono(lower alkyl)amino substituent (at R7) and an amino functionality (at R9).
Figure USRE040086-20080219-C00008
Martell et al., U.S. Pat. No. 3,518,306 discloses 7-and/or 9-(N-nitrosoalkylamino)-6-demethyl-6-deoxy-tetracyclines of the formula (XI) which possess in vivo antibacterial activity. This patent does not teach or suggest the inclusion of both a di(lower alkyl)amino or mono(lower alkyl)amino substituent at (C-7) and an amino functionality (at C-9).
Figure USRE040086-20080219-C00009
In U.S. Pat. No. 5,021,407, a method of overcoming the resistance of tetracycline resistant bacteria is disclosed. The method involves utilizing a blocking agent compound in conjunction with a tetracycline type antibiotic. This patent does not disclose novel tetracycline compounds which themselves have activity against resistant organisms.
In summary, none of the above patents teach or suggest the novel compounds of this application. In addition, none of the above patents teach or suggest novel tetracycline compounds having activity against tetracycline and minocycline resistant strains as well as strains which are normally susceptible to tetracyclines.
SUMMARY OF THE INVENTION
This invention is concerned with novel 7-(substituted)-9-(substituted amino)-6-demethyl-6-deoxytetracyclines, represented by formula I and II, which have antibacterial activity; with method of treating infectious diseases in warm blooded animals employing these new compound; with methods of treating or controlling veterinary diseases; with pharmaceutical preparations containing these compounds; with novel intermediate compounds and processes for the production of these compounds. More particularly, this invention is concerned with compounds of formula I and II which have enhanced in vitro and in vivo antibiotic activity against tetracycline resistant strains as well as a high level of activity against strains which are normally susceptible to tetracyclines.
Figure USRE040086-20080219-C00010
In formula I and II, X is selected from amino, NR1R2 or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine;
and when X=NR1R2 and R1=hydrogen,
    • R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;
      and when R1=methyl or ethyl,
    • R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
      and when R1=n-propyl,
    • R2=n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
      and when R1=1-methylethyl,
    • R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
      and when R1=n-butyl,
    • R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
      and when R1=1-methylpropyl,
    • R2=2-methylpropyl;
R is selected from R4(CH2)nCO— or R4′(CH2)nSO2—;
and when R=R4(CH2)nCO— and n=0,
    • R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; α-amino-(C1-C4)alkyl group selected from aminomethyl, α-amino-ethyl, α-aminopropyl or α-aminobutyl; carboxy(C2-C4)alkylamino group selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and their optical isomers; (C7-C9)aralkylamino group such as phenylglycyl; (C1-C4)alkoxycarbonylamino substituted (C1-C4)alkyl group, substitution selected from phenyl or p-hydroxyphenyl; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; α-mercapto(C1-C3)alkyl group selected from mercaptomethyl, α-mercaptoethyl, α-mercapto-1-methylethyl or α-mercaptopropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00011
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl,
    • or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00012
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00013
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; acyl or haloacyl group or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl such as cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, (2,3-dimethylcyclopropyl)carbonyl, (1,2-dimethylcyclopropyl)carbonyl, (2-ethylcyclopropyl)carbonyl, (2-methylcyclopentyl)carbonyl or (3-ethylcyclobutyl)carbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00014
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl,
    • or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00015
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00016
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl propoxycarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinylgroup [substituted selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substituted selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00017
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl]; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl or RaRb is (C2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)—alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)—alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S;
      and when R=R4(CH2)nCO— and n=1-4,
    • R4 is selected from hydrogen; amino; straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; acyloxy or haloacyloxy group, selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00018
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00019
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00020
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C8)aralkylthio group such as benzylthio, 1-phenylethylthio or 2-phenylethylthio; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00021
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00022
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00023
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; hydroxy group; mercapto group; mono- or di-straight or branched chain (C1-C6)alkylamino group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, n-pentyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 3-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropylamino; (C2-C5)azacycloalkyl group such as aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or 2-methylpyrrolidinyl; carboxy(C2-C4)alkylamino group selected from aminoacetic acid, α-aminopropionic acid, α-aminobutyric acid and their optional isomers; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)-aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl, 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00024
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl; or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00025
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00026
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; RaRbamino (C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W—(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S;
      and when R—R(CH2)nSO2— and n=0,
    • R4′ is selected from amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloroethyl, 2,2-dichloroethyl, 2,2,2-trichloroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00027
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00028
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00029
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or RaRb is (C2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)—alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W—(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; and when R=R4 (CH2)nSO2— and n=1-4,
    • R4′ is selected from hydrogen; amino; straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C1-C4)carboxyalkyl group; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; RaRbamino (C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; (C1-C3)alkylthio group selected from methylthio, ethylthio or n-propylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C8)aralkylthio group such as benzylthio, 1-phenylethylthio or 2-phenylethylthio; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00030
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00031
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00032
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; hydroxy group; mercapto group; mono- or di-straight or branched (C1-C6)alkylamino group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl amino; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-chloroethyl, 2,2-dichloroethyl, 2,2,2-trichloroethyl, 2-bromoethyl or 2-iodoethyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkycarbonyl, (C6-C10)-aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00033
    •  such as pyrrolyl, N-methyl indolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00034
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00035
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl;
    • R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00036
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00037
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00038
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or —(CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl, or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl β-naphthyl; R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00039
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00040
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00041
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; or —(CH2)nCOOR7 where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl, or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen; or R5 and R6 taken together are —(CH2)2W(CH2)2—, wherein W is selected from (CH2)n and n=0-1, —NH, —N(C1-C3)alkyl [straight or branched], —N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.
Preferred compounds are compounds according to the above formula I and II in which X is selected from amino, NR1R2, or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine;
and when X=NR1R2 and R1=hydrogen,
    • R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; and when R1=methyl or ethyl,
    • R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
R is selected from R4(CH2)nCO— or R4′(CH2)nSO2—;
and when R=R4(CH2)nCO— and n=0,
    • R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); α-amino-(C1-C4)alkyl group selected from aminomethyl, α-aminoethyl, α-aminopropyl or α-aminobutyl; carboxy(C2-C4)alkylamino group selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and their optical isomers; (C7-C9)aralkylamino group such as phenylglycyl; (C1-C4)alkoxycarbonylamino substituted (C1-C4)alkyl group, substitution selected from phenyl or p-hydroxyphenyl; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00042
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00043
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00044
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl such as cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, (2,3-dimethylcyclopropyl)carbonyl, (1,2-dimethylcyclopropyl)carbonyl, (2-ethylcyclopropyl)carbonyl, (2-methylcyclopentyl)carbonyl or (3-ethylcyclobutyl)carbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-methyltoluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00045
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00046
      such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00047
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl) such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substituted selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substituted selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00048
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl]; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (C2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaR3 is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W—(CH2)2— wherein W is selected from —N(C1-C3)—alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S;
      and when R=R4(CH2)nCO— and n=1-4,
    • R4 is selected from hydrogen; (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); acyloxy or haloacyloxy group, selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl, 4-(1-methylethyl)benzoyl or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00049
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00050
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00051
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; RaRb amino (C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (C2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)—alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)—alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo,(C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00052
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00053
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00054
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; hydroxy group; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl, or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00055
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00056
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00057
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 3-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonylamino group selected from tertbutoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino;
      and when R=R4′ (CH2)nSO2— and n=0,
    • R4′ is selected from the amino; monosubstituted amino selected from as straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, triahlo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocyclic group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00058
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolidinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00059
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00060
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three, N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl;
      and when R=R4′ (CH2)nSO2— and n=1-4,
    • R4′ is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy, iso-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; (C1-C4)carboxyalkyl group;
    • R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocyclic group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00061
    •  such as pyrrolyl, N-methylindolyl, indolyl-2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl,benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00062
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended heteroatom:
      Figure USRE040086-20080219-C00063
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three, N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholino; or —(CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl;
    • R6 is selected from hydrogen; straight or branched (C1-C2)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocyclic group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00064
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolidinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00065
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended heteroatom:
      Figure USRE040086-20080219-C00066
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three, N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or (CH2)nCOOR7 where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, β-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen; or R5 and R6 taken together are —(CH2)2W(CH2)2—, wherein W is selected from (CH2)n and n=0-1, —NH, —N(C1-C3)alkyl [straight or branched], —N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.
Particularly preferred compounds are compounds according to the above formula I and II in which X is selected from amino, NR1R2 or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine;
and when X=NR1R2 and R1=hydrogen,
    • R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;
      and when R1=methyl or ethyl,
    • R2—methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
    • R is selected from R4(CH2)nCO— or R4′(CH2)nSO2—;
      and when R=R4(CH2)nCO— and n=0,
    • R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); α-amino—(C1-C4)alkyl group selected from aminomethyl, α-aminoethyl, α-aminopropyl or α-aminobutyl; carboxy(C2-C4)alkylamino group selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and their optical isomers; (C7-C9)aralkylamino group such as phenylglycyl; (C1-C4)alkoxycarbonylamino substituted (C1-C4)alkyl group, substitution selected from phenyl or p-hydroxyphenyl; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl,chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00067
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five-membered aromatic ring with two N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused therein:
      Figure USRE040086-20080219-C00068
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00069
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)alkoxycarbonyl such as cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, (2,3-dimethylcyclopropyl)carbonyl, (1,2-dimethylcyclopropyl)carbonyl, (2-ethylcyclopropyl)carbonyl, (2-methylcyclopentyl)carbonyl or (3-ethylcyclobutyl)carbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-methylbenzoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00070
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolidinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00071
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00072
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonylamino group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorometyyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00073
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolidinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl]; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy,n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O is S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; and when R=R4(CH2)nCO— and n=1-4,
    • R4 is selected from hydrogen; (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10) aryl group (substitution selected from halo,(C1-C4)alkoxy, triahlo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); acyloxy or haloacyloxy group, selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-tolyl, 2-toluoyl, 4-(1-methylethyl)benzoyl or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00074
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolidinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00075
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00076
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three, N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O is S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl (substitution selected from halo, (C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00077
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolidinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00078
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00079
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; hydroxy group; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromophenylcarbonyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as from 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one, N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00080
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolidinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00081
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00082
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino;
      and when R=R4′ (CH2)nSO2— and n=0,
    • R4′ is selected from the amino; monosubstituted amino selected from as straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocyclic group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00083
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00084
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00085
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl;
      and when R=R4′ (CH2)nSO2— and n=1-4,
    • R4′ is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O is S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2) 2W(CH2)2— wherein W is selected from —N(C1-C3)-alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S;
    • R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00086
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00087
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00088
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl; 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or —(CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl;
    • R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00089
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00090
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00091
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4) alkoxy, trihalo (C1-C3) alkyl, nitro, amino, cyano, (C1-C4) alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl )
    • such as γ--butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; or (CH2)nCOOR7′ where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen; or R5 and R6 taken together as —(CH2)2W(CH2)2—, wherein W is selected from (CH2)n and n=0-1, —NH, —N(C1-C3)alkyl [straight or branched], —N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.
Most particularly preferred compounds are compounds according to the above formula I and II in which X is selected from amino, NR1R2, or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine;
and when X=NR1R2 and R1=hydrogen,
    • R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;
      and when R1=methyl or ethyl,
    • R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
    • R is selected from R4(CH2)nCO— or R4′ (CH2)nSO2—; and when R=R4(CH2)nCO— and n=0,
    • R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C2)alkyl group selected from methyl or ethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); carboxy(C2-C6)alkylamino group selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and their optical isomers; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00092
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00093
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00094
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonylamino group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00095
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl]; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkylxoy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethoxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O is S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; and when R=R4(CH2)nCO— and n=1-4,
    • R4 is selected from hydrogen; (C1-C2)alkyl group selected from methyl or ethyl; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted(C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); acyloxy or haloacyloxy group, selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl, 4-(1-methylethyl)benzoyl or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto;
      Figure USRE040086-20080219-C00096
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00097
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00098
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to two N, N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C6)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methoxypropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl; (C1-C4)alkoxycarbonylamino group selected from tertbutoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino;
      and when R=R4′(CH2)nSO2— and n=0,
    • R4′ is selected from amino; monosubstituted amino selected from as straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, triahlo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocyclic group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto: ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl or ethyl; C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4) alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00099
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolidinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00100
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom;
      Figure USRE040086-20080219-C00101
    •  
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl;
      and when R=R4′ (CH2)nSO2— and n=1-4,
    • R4′ is selected from hydrogen; straight or branched (C1-C2)alkyl group selected from methyl or ethyl; R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00102
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00103
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00104
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxo-thiomorpholino; or —(CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl, or β-naphthyl; (C7-C10)aralkyl group such as benzyl,1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto;
      Figure USRE040086-20080219-C00105
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00106
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00107
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or (C2)nCOOR7′ where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen:
    • or R5 and R6 taken together are —(CH2)2W(CH2)2—, wherein W is selected from (CH2)n and n=0-1, —NH, —N(C1-C3)alkyl [straight or branched], —N(C1-C5)alkoxy, oxygen, sulfur or unsubstituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.
Compounds of special interest are compounds according to the above formula I and II in which X is selected from amino, NR1R2 or halogen; the halogen is selected from bromine chlorine, fluorine or iodine;
and when X=NR1R2 and R1=methyl or ethyl;
    • R2=methyl or ethyl, R is selected from R4(CH2)nCO— or R4′ (CH2)nSO2—;
      and when R=R4 (CH2)nCO— and n=0,
    • R4 is selected from hydrogen; straight or branched (C1-C2)alkyl group selected from methyl or ethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, or S heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00108
 such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
Figure USRE040086-20080219-C00109
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00110
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl )
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C2)alkyl group, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, (C1-C6)alkoxycarbonyl), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C2)alkyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl;
      and when R=R4(CH2)nCO— and n=1-4,
    • R4 is selected from hydrogen; (C1-C2)alkyl group selected from methyl, ethyl; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, or 1-(1,2,3-triazolyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted(C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, nitro, amino, (C1-C4)alkoxycarbonyl); acryloxy or haloacyloxy group selected from acetyl, propionyl or chloroacetyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methoxypropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W—(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino;
      and when R=R4′ (CH2)nSO2— and n=0,
    • R4′ is selected from straight or branched (C1-C2)alkyl group selected from methyl or ethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, nitro, (C1-C4)alkoxycarbonyl); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O or S heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00111
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00112
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl;
      and when R=R4′ (CH2)nSO2— and n=1-4,
    • R4′ is selected from hydrogen; straight or branched (C1-C2)alkyl group selected from methyl or ethyl;
    • R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl;
    • R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; with the proviso that R5 and R6 cannot both be hydrogen;
    • or R5 and R6 taken together are —(CH2)2W(CH2)2—, wherein W is selected from (CH2)n and n=0-1, —NH, —N(C1-C3)alkyl [straight or branched], —N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.
Also included in the present invention are compounds useful as intermediate for producing the above compounds of formula I and II. Such intermediate compounds include those having the formula:
Figure USRE040086-20080219-C00113
wherein formula III and IV, Y is NO2;
    • R is selected from R4(CH2)nCO— or R4, (CH2)nSO2—;
      and when R=R4(CH2)nCO— and n=0,
    • R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; α-amino(C1-C4)alkyl group selected from aminomethyl, α-aminoethyl, α-aminopropyl or α-aminobutyl; carboxy(C2-C4)alkylamino group selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and their optical isomers; (C7-C9)aralkylamino group such as phenylglycyl; (C1-C4)alkoxycarbonylamino substituted (C1-C4)alkyl group, substitution selected from phenyl or p-hydroxyphenyl; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; α-mercapto(C1-C3)alkyl group selected from mercaptomethyl, α-mercaptoethyl, α-mercapto-1-methylethyl or α-mercaptopropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00114
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00115
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00116
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)alkoxycarbonyl such as cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, (2,3-dimethylcyclopropyl)carbonyl, (1,2-dimethylcyclopropyl)carbonyl, (2-ethylcyclopropyl)carbonyl, (2-methylcyclopentyl)carbonyl or (3-ethylcyclobutyl)carbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzyl, (C1-C4)alkylbenzoyl such as 4-toluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00117
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl,
    • or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00118
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, inidazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazolyl[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two, N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00119
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, triahlo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorometyyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00120
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl];
    • (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substituted selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O is S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyll, O or S;
      and when R=R4(CH2)nCO— and n=1-4,
    • R4 is selected from hydrogen; amino; straight or branched (C1-C6)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted(C6-C10)aryl group (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; acyloxy or haloacyloxy group, selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00121
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00122
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00123
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy,n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C8)aralkylthio group such as benzylthio, 1-phenylethylthio or 2-phenylethylthio; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00124
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolidinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00125
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00126
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; hydroxy group; mercapto group; mono- or di-straight or branched chain (C1-C6)alkylamino group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl amino; (C2-C5)azacycloalkyl group such as aziridinyl, azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or 2-methylpyrrolidinyl; carboxy(C2-C4) alkylamino group selected from aminoacetic acid, α-aminopropionic acid, α-aminobutyric acid and their optical isomers; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)-aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl, 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00127
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl,benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00128
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended heteroatom:
      Figure USRE040086-20080219-C00129
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such a γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W —(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S;
      and when R=R4, (CH2)nSO2— and n=0,
    • R4′ is selected from amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloroethyl, 2,2-dichloroethyl, 2,2,2-trichloroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00130
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00131
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00132
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4) alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W —(CH2)2— wherein W is selected from—N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S;
      and when R=R4(CH2)nSO2— and n=1-4,
    • R4′ is selected from hydrogen; amino; straight or branched (C1-C4)alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C1-C4)carboxyalkyl group; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; (C1-C3)alkylthio group selected from methylthio, ethylthio or n-propylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C8)aralkylthio group such as benzylthio, 1-phenylethylthio or 2-phenylethylthio; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00133
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00134
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00135
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl, C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; hydroxy group, mercapto group; mono- or di- straight or branched (C1-C6)alkylamino group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl amino; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloroethyl, 2,2-dichloroethyl, 2,2,2-trichloroethyl, 2-bromoethyl or 2-iodoethyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00136
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00137
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended heteroatom:
      Figure USRE040086-20080219-C00138
    •  (A is selected from hydrogen; straight or branched (C1-C4) alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl;
    • R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00139
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00140
    •  such a imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00141
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3) alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or —(CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl; R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, β-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00142
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00143
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00144
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxo-thiomorpholinyl; or —(CH2)nCOOR7′ where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen;
    • or R5 and R6 taken together are —(CH2)2W(CH2)2—, wherein W is selected from (CH2)n and n=0-1, —NH, —N(C1-C3)alkyl [straight or branched], —N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.
Preferred compounds are compounds according to the above formula III and IV in which Y is NO2;
R is selected from R4(CH2)nCO— or R4′ (CH2)nSO2—; and when R=R4(CH2)nCO— and n=0,
    • R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); α-amino(C1-C4)alkyl group selected from aminomethyl, α-aminoethyl, α-aminopropyl or α-aminobutyl; carboxy(C2-C4)alkylamino group selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and their optical isomers; (C7-C9)aralkylamino group such as phenylglycyl; (C1-C4)alkoxycarbonylamino substituted (C1-C4)alkyl group, substitution selected from phenyl or p-hydroxyphenyl; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00145
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolidinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00146
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00147
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl such as cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, (2,3-dimethylcyclopropyl)carbonyl, (1,2-dimethylcyclopropyl)carbonyl, (2-ethylcyclopropyl)carbonyl, (2-methylcyclopentyl)carbonyl or (3-ethylcyclobutyl)carbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-methyltoluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00148
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00149
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00150
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, β-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00151
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl]; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy,n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W —(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S;
      and when R=R4(CH2)nCO— and n=−4,
    • R4 is selected from hydrogen; (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); acyloxy or haloacyloxy group, selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl,4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl, 4-(1-methylethyl)benzoyl or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00152
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00153
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00154
    •  (A is selected from hydrogen; straight or branched (C1-C4) alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4) alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy,n-butoxy or tert-butoxy; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W —(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00155
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00156
    •  such as imidazolyl; pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00157
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; hydroxy group; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl, or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00158
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00159
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00160
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)-alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkyloxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino;
      and when R=R4′ (CH2)nSO2— and n=0,
    • R4′ is selected from amino; monosubstituted amino selected from as straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00161
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl,
    • or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00162
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00163
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidazinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl;
      and when R=R4′ (CH2)nSO2— and n=1-4,
    • R4′ is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy, iso-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; (C1-C4)carboxyalkyl group;
    • R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00164
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl,benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00165
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00166
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or —(CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl;
    • R6 is selected from hydrogen; straight or branched (C1-C3-alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00167
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00168
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00169
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidazinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxo-thiomorpholinyl; or CCH2)nCOOR7′ where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen;
    • or R5 and R6 taken together are —(CH2)2W(CH2)2—, wherein W is selected from (CH2)n and n=0-1, —NH, —N(C1-C3)alkyl [straight or branched], —N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.
Particularly preferred compounds are compounds according to the above formula III and IV in which Y is NO2;
R is selected from R4(CH2)nCO— or R4′ (CH2)nSO2—; and when R=R4(CH2)nCO— and n=0,
    • R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C3-C6)cycloalkyl group selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; substituted (C3-C6)cycloalkyl group (substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); α-amino-(C1-C4)alkyl group selected from aminomethyl, α-aminoethyl, α-aminopropyl or α-aminobutyl; carboxy(C2-C4)alkylamino group selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and their optical isomers; (C7-C9)aralkylamino group such as phenylglycyl; (C1-C4)alkoxycarbonylamino substituted (C1-C4)alkyl group, substitution selected from phenyl or p-hydroxyphenyl; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00170
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00171
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00172
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclo-propyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl such as cyclopropylcarbonyl, cyclobutylcarbonyl, cyclopentylcarbonyl, cyclohexylcarbonyl, (2,3-dimethylcyclopropyl)carbonyl, (1,2-dimethylcyclopropyl)carbonyl, (2-ethylcyclopropyl)carbonyl, (2-methylcyclopentyl)carbonyl or (3-ethylcyclobutyl)carbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-methylbenzoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00173
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00174
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended heteroatom:
      Figure USRE040086-20080219-C00175
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3) alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00176
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl]; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy,n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S;
      and when R=R4(CH2)nCO— and n=1-4,
    • R4 is selected from hydrogen; (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10) aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); acyloxy or haloacyloxy group, selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl, 4-(1-methylethyl)benzoyl or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00177
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00178
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00179
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W —(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00180
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00181
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended heteroatom:
      Figure USRE040086-20080219-C00182
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as-pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; hydroxy group; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromophenylcarbonyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as from 4-toluoyl, 2-toluoyl or 4-(1-methylethyl)benzoyl, or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00183
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00184
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom;
      Figure USRE040086-20080219-C00185
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino;
  • and when R=R4′ (CH2)nSO2— and n=0,
    • R4′ is selected from amino; monosubstituted amino selected from as straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00186
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00187
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom;
      Figure USRE040086-20080219-C00188
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl;
  • and when R=R4′ (CH2)nSO2— and n=1-4,
    • R4′ is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (C2)n, n=2-6, or —(CH2)2W —(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W —(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S;
    • R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00189
    •  such as pyrrolyl, N-methyl indolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00190
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom;
      Figure USRE040086-20080219-C00191
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or —(CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl;
    • R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00192
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00193
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom;
      Figure USRE040086-20080219-C00194
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or (CH2)nCOOR7′ where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C2)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen;
    • or R5 and R6 taken together are —(CH2)2W(CH2)2—, wherein W is selected from (CH2)n and n=0-1, —NH, —N(C1-C3)alkyl [straight or branched], —N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.
Most particularly preferred compounds are compounds according to the above formula III and IV in which Y is NO2;
    • R is selected from R4(CH2)nCO— or R4′ (CH2)nSO2—;
  • and when R=R4(CH2)nCO— and n=0,
    • R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrollyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C2)alkyl group selected from methyl or ethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); carboxy(C2-C4)alkylamino group selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and their optical isomers; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00195
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00196
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom;
      Figure USRE040086-20080219-C00197
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C3)alkyl group, halogen, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy,trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00198
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl]; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C3-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W —(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S;
  • and when R=R4 (CH2)nCO— and n=1-4,
    • R4 is selected from hydrogen; (C1-C2)alkyl group selected from methyl or ethyl; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted(C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); acyloxy or haloacyloxy group, selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl such as pentafluorobenzoyl, 4-chlorobenzoyl, 3-bromobenzoyl or 3,4-difluorobenzoyl, (C1-C4)alkylbenzoyl such as 4-toluoyl, 2-toluoyl, 4-(1-methylethyl)benzoyl or (heterocycle)carbonyl, the heterocycle selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00199
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00200
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom;
      Figure USRE040086-20080219-C00201
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; α-hydroxy(C1-C3)alkyl group selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino;
  • and when R=R4′ (CH2)nSO2— and n=0,
    • R4′ is selected from amino; monosubstituted amino selected from as straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C2)alkyl group selected from methyl or ethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00202
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00203
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom;
      Figure USRE040086-20080219-C00204
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl or 2-dioxothiomorpholinyl;
  • and when R=R4′ (CH2)nSO2— and n=1-4,
    • R4′ is selected from hydrogen; straight or branched (C1-C2)alkyl group selected from methyl or ethyl; R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00205
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00206
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom;
      Figure USRE040086-20080219-C00207
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or —(CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl;
    • R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)aralkyl group such as benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00208
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O, S or Se heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00209
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended heteroatom;
      Figure USRE040086-20080219-C00210
    •  (A is selected from hydrogen; straight or branched (C1-C4)alkyl; C6-aryl; substituted C6-aryl (substitution selected from halo,(C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy); (C7-C9)aralkyl group selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, or a six membered aromatic ring with one to three N, O, S or Se heteroatoms such as pyridyl, pyridazinyl, pyrazinyl, sym-triazinyl, unsym-triazinyl, pyrimidinyl or (C1-C3)alkylthiopyridazinyl, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom such as 2,3-dioxo-1-piperazinyl, 4-ethyl-2,3-dioxo-1-piperazinyl, 4-methyl-2,3-dioxo-1-piperazinyl, 4-cyclopropyl-2-dioxo-1-piperazinyl, 2-dioxomorpholinyl, 2-dioxothiomorpholinyl; or (CH2)nCOOR7′ where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, β-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen;
    • or R5 and R6 taken together are —(CH2)2W(CH2)2—, wherein W is selected from (CH2)n and n=0-1, —NH, —N(C1-C3)alkyl [straight or branched], —N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.
Compounds of special interest are compounds according to the above formula III and IV in which Y is NO2;
    • R is selected from R4(CH2)nCO— or R4′ (CH2)nSO2—; and when R=R4(CH2)nCO— and n=0,
    • R4 is selected from hydrogen; straight or branched (C1-C2)alkyl group selected from methyl or ethyl; a heterocycle group selected from a five membered aromatic or saturated ring with one N, O, or S heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00211
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O or S heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00212
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl, or a five membered saturated ring with one or two N, O or S heteroatoms and an adjacent appended O heteroatom:
      Figure USRE040086-20080219-C00213
    •  (A is selected from hydrogen; straight or branched (C1-C2)alkyl; C6-aryl)
    • such as γ-butyrolactam, γ-butyrolactone, imidazolidinone or N-aminoimidazolidinone, (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or substituted vinyl group [substitution selected from (C1-C2)alkyl group, (C6-C10)aryl group selected from phenyl, α-naphthyl, β-naphthyl, substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, (C1-C4)alkoxycarbonyl), halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-bromoethyl or 2-iodoethyl, (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; C6-aryloxy group selected from phenoxy or substituted phenoxy (substitution selected from halo, (C1-C4)alkyl); (C7-C10)aralkyloxy group such as benzyloxy, 1-phenylethyloxy or 2-phenylethyloxy; vinyloxy or substituted vinyloxy group (substitution selected from (C1-C2)alkyl); RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl;
  • and when R=R4(CH2)nCO— and n=1-4,
    • R4 is selected from hydrogen; (C1-C2)alkyl group selected from methyl or ethyl; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, or 1-(1,2,3-triazolyl); (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted(C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, nitro, amino, (C1-C4)alkoxycarbonyl); acyloxy or haloacyloxy group selected from acetyl, propionyl or chloroacetyl; (C1-C4)alkoxy group such as allyloxy, methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (3)alkyl], O or S; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)n, n=2-6, or —(CH2)2W —(CH2)2— wherein W is selected from —N(C1-C3)alkyl [straight or branched], —NH, —NOB [B is selected from hydrogen or (C1-C3)alkyl], O or S; halo(C1-C3)alkyl group such as bromomethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoromethyl, 2-bromoethyl or 2-iodoethyl; (C1-C4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino;
  • and when R=R4′ (CH2)nSO2— and n=0,
    • R4′ is selected from straight or branched (C1-C2)alkyl group selected from methyl or ethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; substituted (C6-C10)aryl group (substitution selected from halo, (C1-C4)alkoxy, nitro, (C1-C4)alkoxycarbonyl); a heterocycle group selected from a five membered aromatic or saturated ring with one N, O or S heteroatom optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00214
    •  such as pyrrolyl, N-methylindolyl, indolyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 2-pyrrolinyl, tetrahydrofuranyl, furanyl, benzofuranyl, tetrahydrothienyl, thienyl, benzothienyl or selenazolyl, or a five membered aromatic ring with two N, O or S heteroatoms optionally having a benzo or pyrido ring fused thereto:
      Figure USRE040086-20080219-C00215
    •  such as imidazolyl, pyrazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, indazolyl, thiazolyl, benzothiazolyl, 3-alkyl-3H-imidazo[4,5-b]pyridyl or pyridylimidazolyl;
  • and when R=R4′ (CH2)nSO2— and n=1-4,
    • R4′ is selected from hydrogen; straight or branched (C1-C2)alkyl group selected from methyl or ethyl; R5 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl;
    • R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; with the proviso that R5 and R6 cannot both be hydrogen;
    • or R5 and R6 taken together are —(CH2)2W (CH2)2—, wherein W is selected from (CH2)n and n=0-1, —NH, —N(C1-C3)alkyl [straight or branched], —N(C1-C4)alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine;and the pharmacologically acceptable organic and inorganic salts or metal complexes.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
The novel compounds of the present invention may be readily prepared in accordance with the following schemes.
The starting 7-(substituted amino)-6-de-methyl-6-deoxytetracyclines described in formula 1, wherein X=NR1NR2 and R1=R2 (1a) and X═NHR1 (1b) or the salts thereof are prepared by procedures known to those skilled in the art including those described in U.S. Pat. Nos. 3,226,436 and 3,518,306.
Figure USRE040086-20080219-C00216
The starting 7-(substituted amino)-6-de-methyl-6-deoxytetracyclines described in formula 1 wherein X=NR1R2 and R1=R2 (1c) are prepared according to Scheme 1.
Figure USRE040086-20080219-C00217
In accordance with Scheme 1, a 7-(monoalkylamino)-6-demethyl-6-deoxytetracycline, 1b in which X=NHR1, is reductively alkylated with an aldehyde to give an unsymmetrical dialkylamino, 1c.
Figure USRE040086-20080219-C00218
In accordance with Scheme II, a 7-(substituted amino)-6-demethyl-6-deoxytetracycline or its salts, 1a or 1c, is treated with
    • a) a metal nitrate salt; such as calcium, potassium or sodium; and a strong acid; such as sulfuric acid, trifluoroacetic acid, methanesulfonic acid or perchloric acid or
    • b) nitric acid and a strong acid; such as sulfuric acid, trifluoroacetic acid, methanesulfonic acid or perchloric acid; to form the corresponding 7-(substituted amino)-9-nitro-6-demethyl-6-deoxytetracycline 2.
To produce the 9-(amino)-7-(substituted amino)-6-demethyl-6-deoxytetracyclines, 3, compound 2 or its salts is treated with hydrogen in an acidic alcohol solvent, in the presence of a suitable catalyst such as, for example:
    • a) any supported catalyst; such as 0.5-23% palladium-on-carbon, 0.5-25% palladium-on-barium, 0.5-25% platinum-on-carbon or 0.5-25% rhodium-on-carbon;
    • b) any reducible supported catalyst; such as Raney nickle or platinum oxide; or
    • c) a homogeneous hydrogenation catalyst; such as tris(triphenylphosphine)rhodium (I) chloride; to obtain the 9-amino-7-(substituted amino)-6-demethyl-6-deoxytetracycline, 3.
Alternatively, the 9-(amino)-7-(substituted amino)-6-demethyl-6-deoxytetracyclines, 3, are obtained by treating with:
    • a) stannous chloride dihydrate as described by R. B. Woodward, Org. Syn., Coll. Vol. 3, 453 (1955);
    • b) a soluble metal sulfide, preferably sodium sulfide, in alcoholic solvents as described by G. R. Robertson, Org. Syn., Coll. Vol. 1, 52 (1941);
    • c) an active metal in mineral acid; such as iron, tin or zinc in dilute hydrochloric acid;
    • d) active metal couples; such as copper-zinc, tin-mercury or aluminum amalgam in dilute acid; or
    • e) transfer hydrogenation using triethylammonium formate and a supported catalyst as described by I. D. Entwistle et al., J. Chem. Soc., Perkin 1, 443 (1977).
Preferably, the 9-(amino)-7-(substituted amino)-6-demethyl-6-deoxytetracyclines, 3, are obtained as inorganic salts such as hydrochloric, hydrobromic, hydroiodic, phosphoric, nitric or sulfate.
Figure USRE040086-20080219-C00219
SCHEME III
In accordance with Scheme III, a 9-(amino)-7-(substituted amino)-6-demethyl-6-deoxytetracycline or its salts, 3, is treated with an acyl chloride, acyl anhydride, mixed acyl anhydride, sulfonyl chloride or sulfonyl anhydride in the presence of a suitable acid scavenger in a variety of solvents to form the corresponding 9-(acyl or sulfonyl amino)-7-(substituted amino)-6-demethyl-6-deoxytetracycline, 4. The acid scavenger is selected from sodium bicarbonate, sodium acetate, pyridine, triethylamine, N,O-bis(trimethylsilyl)acetamide, N,O-bis(trimethylsilyl)trifluoroacetamide or a basic ion-exchange resin. The solvents are selected from water-tetrahydrofuran, N-methylpyrrolidone, 1,3-dimethyl-2-imidazolidone, hexamethylphosphoramide, 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone or 1,2-dimethoxyethane.
Alternatively, in accordance with Scheme III, a 9-(acylamino)-6-demethyl-6-deoxytetracycline, 5a, prepared by the procedures described in U.S. Pat. No. 3,239,499, or a 9-(sulfonylamino)-6-demethyl-6-deoxytetracycline, 5b, prepared by the procedures described in this invention, is treated with a halogenation agent such a bromine, N-bromoacetamide, N-bromosuccinimide, iodine monochloride, benzyltrimethylammonium chloride iodine monochloride complex or N-iodosuccinimide to give the corresponding 9-(acyl or sulfonylamino)-7-halo-6-demethyl-6-deoxytetracycline, 6.
Similarly, compound 5a or 5b can be treated with:
    • a) a metal nitrate such as calcium, potassium or sodium; and a strong acid such as sulfuric, trifluoroacetic, methanesulfonic acid or trifluoromethanesulfonic; or
    • b) nitric acid and a strong acid such as sulfuric, trifluoroacetic, methanesulfonic, trifluoromethanesulfonic or perchloric acid to give the corresponding 9-(acyl or sulfonyl amino)-7-nitro-6-demethyl-6-deoxytetracycline, 7.
      Figure USRE040086-20080219-C00220
In accordance with Scheme IV, 9-(acyl or sulfonyl amino)-7-nitro-6-demethyl-6-deoxytetracycline, 7, is selectively N-alkylated with aldehydes or ketones in the presence of acid and hydrogen to the corresponding 7,9-di(substituted amino)-6-demethyl-6-deoxytetracycline, 8, by methodology known to those skilled in the art (U.S. Pat. Nos. 3,226,436 and 3,518,306).
Figure USRE040086-20080219-C00221
    • 4 X=NR1R2(R1=R2 or R1≠R2)
    • 6 X=halogen
    • 7 Y=NO2
    • 8 X=NHR3(R3=R1 or R2)
In accordance with Scheme V, Compounds 4,6,7 or 8 are selectively N-alkylated in the presence of formaldehyde and either a primary amine such as methylamine, ethylamine, benzylamine, methyl glycinate, (L or D)lysine, (L or D)alanine or their substituted congeners; or a secondary amine such morpholine, pyrrolidine, piperidine or their substituted congeners to give the corresponding Mannich base adduct, 9,10,11 or 12, or the desired intermediate or of the biologically active 7-(substituted)-9-(substituted amino)-6-demethyl-6-deoxytetracyclines. Contemplated equivalents include those substituted morpholine, pyrrolidine or piperidine moieties wherein the substituents are chosen to provide the requisite increase in solubility without adversely affecting antibacterial activity.
The 7-(substituted)-9-(substituted amino)-6-demethyl-6-deoxytetracyclines may be obtained as metal complexes such as aluminum, calcium, iron, magnesium, manganese and complex salts; inorganic and organic salts and corresponding Mannich base adducts using methods known to those skilled in the art (Richard C. Larock, Comprehensive Organic Transformations, VCH Publishers, 411-415, 1989). Preferably, the 7-(substituted)-9-(substituted amino)-6-demethyl-6-deoxytetracyclines are obtained as inorganic salts such as hydrochloric, hydrobromic, hydroiodic, phosphoric, nitric or sulfate; or organic salts such as acetate, benzoate, citrate, cysteine or other amino acids, fumarate, glycolate, maleate, succinate, tartrate alkylsulfonate or arylsulfonate. In all cases, the salt formation occurs with the C(4)-dimethylamino group. The salts are preferred for oral and parenteral administration.
BIOLOGICAL ACTIVITY
Methods for in Vitro antibacterial evaluation (Tables I-V)
The minimum inhibitory concentration (MIC), the lowest concentration of the antibiotic which inhibits growth of the test organism, is determined by the agar dilution method using 0.1 ml Muller-Hinton II agar (Baltimore Biological Laboratories) per well. An inoculum level of 1-5×105 CFU/ml, and a range of antibiotic concentrations (32-0.004 μg/ml) is used. MIC is determined after the plates are incubated for 18 hours at 35° C. in a forced air incubator. The test organisms comprise genetically defined strains that are sensitive to tetracycline and resistant strains that are insensitive to tetracycline, either by preventing the antibiotic from interacting with bacterial ribosomes (tetM) or by a tetK encoded membrane protein which confers tetracycline resistance by energy-dependent efflux of the antibiotic from the cell.
E. coli in Vitro Protein translation System (Table VI)
An in vitro, cell free, protein translation system using extracts from E. coli strain MRE 600 (tetracycline-sensitive) and a derivative of MRE 600 containing the tetM determinant has been developed based on literature methods. [J. M. Prutt, Coupled Transcription-translation in Prokaryotic Cell-free Systems, Transcription and Translation, a Practical Approach, (B. D. Hames and S. J. Higgins, eds.) p. 179-209, IRL Press, Oxford-Washington, 1984]
The antibiotics are added to exponentially growing cultures of tetracycline-susceptible E. coli at growth inhibitory concentrations. After 30 minutes, excess antibiotic is removed from the bacteria by centrifugation and the organism is resuspended in fresh growth medium. The ability of bacteria to resume growth is monitored. Washing of inhibited cells alleviates growth inhibition due to chlortetracycline, but not that caused by polymyxin. This reflects the different binding characteristics of the drugs. Chlortetracycline binds reversibly to bacterial ribosomes, while polymyxin remains tightly associated with its target, the cytoplasmic membrane, and continues to prevent bacterial growth even when excess antibiotic is removed.
In Vivo Antibacterial Evaluation (Table VII)
The therapeutic effects of tetracyclines are determined against acute lethal infections with various staphylococcal and E. coli strains. Female mice, strain CD-1 (Charles River Laboratories), 20±2 grams, are challenged by an intraperitoneal injection of sufficient bacteria (suspended in broth or hog mucin) to kill non-treated controls within 24-48 hours. Antibacterial agents, contained in 0.5 ml of 0.2% aqueous agar, are administered subcutaneously or orally 30 minutes after infection. When an oral dosing schedule is used, animals are deprived of food for 5 hours before and 2 hours after infection. Five mice are treated at each dose level. The 7 day survival ratios from 3 separate tests are pooled for calculation of median effective dose (ED50).
E. coli in Vitro Protein Translation System(Table VIII)
An in vitro, cell free, protein translation system using extracts from E. coli strain MRE600 (tetracycline sensitive) and a derivative of MRE600 containing the tetM determinant has been developed based on literature methods [J. M. Pratt, Coupled Transcription-translation in Prokaryotic Cell-free Systems, Transcription and Translation, a Practical Approach, (B. D. Hames and S. J. Higgins, eds) p. 179-209, IRL Press, Oxford-Washington, 1984].
Using the systems described above, the novel tetracycline compounds of the present invention are tested for their ability to inhibit protein synthesis in vitro. Briefly, each 10 μl reaction contains S30 extract (a whole extract) made from either tetracycline sensitive cells or an isogenic tetracycline resistant (tetM) strain, low molecular weight components necessary for transcription and translation (i.e. ATP and GTP), a mix of 19 amino acids (no methionine), 35S labeled methionine, DNA template (either pBR322 or pUC119), and either DMSO (control) or the novel tetracycline compound to be tested (“Novel Tc”) dissolved in DMSO.
The reactions are incubated for 20 minutes at 37° C. Timing is initiated with the addition of the S30 extract, the lase component to be added. After 30 minutes, 2.5 μl of the reaction is removed and mixed with 0.5 ml of 1N NaOH to destroy RNA and tRNA. Two ml of 25% trichloroacetic acid is added and the mixture incubated at room temperature for 15 minutes. The trichloracetic acid precipitated material is collected on Whatman GF/C filters and washed with a solution of 10% trichloroacetic acid. The filters are dried and the retained radioactivity, representing incorporation of 35S-methionine into polypeptides, is counted using standard liquid scintillation methods.
The percent inhibition (P.I.) of protein synthesis is determined to be: P.I. = 100 - [ Retained  radioactivity  of  Novel  TC  containing  sample Retained  radioactivity  of  the  DMSO  control  reaction ] × 100
Testing Results
The claimed compounds exhibit antibacterial activity against a spectrum of tetracycline sensitive and resistant Gram-positive and Gram-negative bacteria, especially, strains of E. coli, S. aureus and E. faecalis, containing the tetM resistance determinants (Table I). Notable is 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline, as shown in Tables I and IV, which has good in vitro activity against tetracycline resistant strains containing the tetM resistance determinant (such as S. aureus UBMS 88-5, S. aureus UBMS 90-1 and 90-2, E. coli UBMS 89-1 and 90-4) and is equally as effective as minocycline against susceptible strains.
7-(Dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline demonstrates effective activity against minocycline susceptible strains including a variety of recently isolated bacteria from clinical sources (Table V). With the exception of some Proteus spp., 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline's activity is superior to that of minocycline against other isolates.
Protein synthesis, directed by cell-free extracts from the tetracycline susceptible strain MRE-600, are inhibited by tetracycline, minocycline and the 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline of this invention (Table 6). Protein synthesis, directed by cell-free extracts from strain MRE 600 (tetM), is resistant to tetracycline and minocycline, since 50% inhibition of protein synthesis required addition of approximately 5-fold more antibiotic than in extracts prepared from strain MRE 600 (Table VI). However, in contrast, 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline effectively inhibited protein synthesis in extracts prepared from either MRE 600 or MRE 600 (tetM) (Table VI). The evidence presented indicates that 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxy-tetracycline is an inhibitor of protein synthesis at the ribosome level. The ability of 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline to inhibit bacterial growth almost certainly reflects directed inhibition of bacterial synthesis. If so, then it is expected, like other tetracyclines, to exhibit a bacteriostatic effect against susceptible bacteria.
7-(Dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline binds reversibly to its target (the ribosome) since bacterial growth resumed when the compound was removed from the cultures by washing of the organism. Therefore, the ability of 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline to inhibit bacterial growth appears to be a direct consequence of its ability to inhibit protein synthesis at the ribosome level.
The enhanced activity (Table VII) of 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline against tetracycline susceptible and resistant organisms (tetM) is also demonstrated in vivo in animals infected with S. aureus UBMS 90-1 and 90-2. The ED50's (Table VII) obtained for 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline are lower than those of minocycline.
The improved efficacy of 7-(dimethylamino)-9-(formylamino)-6-demethyl-6-deoxytetracycline is demonstrated by the in-vitro activity against isogenic strains into which the resistance determinants, such as tetM, were cloned (Tables I-IV); the inhibition of protein synthesis by tetM ribosomes (Table VI); and the in vivo activity against experimental infections caused by strains resistant to the tetracyclines, due to the presence of resistance determinants, such as tetM (Table VII).
As can be seen from Tables I-V, compounds of the invention may be used to prevent or control important veterinary diseases such as mastitis, diarrhea, urinary tract infections, skin infections, ear infections, wound infections and the like.
LEGEND FOR COMPOUNDS
LETTER NAME
A 7-(Dimethylamino)-9-(formylamino)-6-demethyl-6-de-
oxytetracycline
B 9-(Acetylamino)-7-(dimethylamino)-6-demethyl-6-de-
oxytetracycline
C 7-(Dimethylamino)-9-(dimethylamino)-6-demethyl-6-de-
oxytetracycline
D 7-(Diethylamino)-9-(formylamino)-6-demethyl-6-de-
oxytetracycline disulfate
E 9-(Acetylamino)-7-(diethylamino)-6-demethyl-6-de-
oxytetracycline disulfate
F 9-(Acetylamino)-7-(diethylamino)-6-demethyl-6-de-
oxytetracycline
G 9-(Formylamino)-7-iodo-6-demethyl-6-deoxytetracy-
cline sulfate
H 9-(Acetylamino)-7-iodo-6-demethyl-6-deoxytetracy-
cline sulfate
I 7-(Dimethylamino)-9-((trifluoroacetyl)amino]-g-de-
methyl-6-deoxytetracycline sulfate
J 7-(Dimethylamino)-9-([(phenylmethoxy)acetyl)-
amino]-6-demethyl-6-deoxytetracycline
K 9-[[(Acetyloxy)acetyl]amino)-7-(dimethylamino)-6-
demethyl-6-deoxytetracycline
L 7-(Dimethylamino)-9-[(hydroxyacetyl)amino]-6-de-
methyl-6-deoxytetracycline
M 9-[(Aminoacetyl)amino]-7-(dimethylamino)-6-demeth-
yl-6-deoxytetracycline mono(trifluoroacetate)
N [7S-(7α,10aα) ]-C(9-(Aminocarbonyl)-7-(dimethyl-
amino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-
tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]-
oxoacetic acid ethyl ester
O 7-(Dimethylamino)-6-demethyl-6-deoxytetracycline
hydrochloride (minocycline hydrochloride)
P 9-(Benzoylamino)-7-(dimethylamino)-6-demethyl-6-
deoxytetracycline
Q 7-(Dimethylamino)-9-[(4-methoxybenzoyl)amino)-6-
demethyl-6-deoxytetracycline
R 7-(Dimethylamino)-9-((2-methylbenzoyl)amino]-6-de-
methyl-6-deoxytetracycline
S 7-(Dimethylamino)-9-[(2-fluorobenzoyl)amino]-6-de-
methyl-6-deoxytetracycline
T 7-(Dimethylamino)-9-((pentafluorobenzoyl)amino]-6-
demethyl-6-deoxytetracycline
U 7-(Dimethylamino)-9-[[3-(trifluoromethyl)benzoyl)-
amino]-6-demethyl-6-deoxytetracycline
V 7-(Dimethylamino)-9-[(4-nitrobenzoyl)amino]-6-de-
methyl-6-deoxytetracycline
W 7-(Dimethylamino)-9-[[(4-dimethylamino)benzoyl)-
amino)-6-demethyl-6-deoxytetracycline
X 9-[(4-Aminobenzoyl)amino)-7-(dimethylamino)-6-de-
methyl-6-deoxytetracycline sulfate
Y 7-(Dimethylamino)-9-((2-furanylcarbonyl)amino)-6-
demethyl-6-deoxytetracycline
Z 7-(Dimethylamino)-9-[(2-thienylcarbonyl)amino]-6-
demethyl-6-deoxytetracycline
AA 7-(Dimethylamino)-9-[[(4-nitrophenyl)sulfonyl]-
amino]-6-demethyl-6-deoxytetracycline
BB 7-(Dimethylamino)-9-[(3-nitrophenyl)sulfonyl)-
amino]-6-demethyl-6-deoxytetracycline
CC 7-(Dimethylamino)-9-[(phenylsulfonyl)amino]-6-de-
methyl-6-deoxytetracycline
DD 7-(Dimethylamino)-9-[(2-thienylsulfonyl)amino)-6-
demethyl-6-deoxytetracycline
EE 9-[[(4-Chlorophenyl)sulfonyl]amino)-7-(dimethyl-
amino)-6-demethyl-6-deoxytetracycline
FF 7-(Dimethylamino)-9-[(methylsulfonyl)amino]-6-de-
methyl-6-deoxytetracycline
GG 9-[[[(2-Acetylamino)-4-methyl-5-thiazolyl]sul-
fonyl]amino]-7-(dimethylamino)-6-demethyl-6-deoxy-
tetracycline
HH [7S-(7α,10aα)]-[9-(Aminocarbonyl)-4,7-bis(dimeth-
ylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,-
11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]car-
bamic acid methyl ester
II 7-(Dimethylamino)-9-[[(dimethylamino)acetyl]-
amino]-6-demethyl-6-deoxytetracycline sulfate
TC Tetracycline hydrochloride
JJ [4S-(4alpha,12aalpha))-4,7-Bis(dimethylamino)-9-
([(dimethylamino)acetyl)amino]-1,4,4a,5,5a,6,11,-
12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-
2-naphthacenecarboxamide disulfate
KK [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-
[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,-
12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-di-
oxo-2-naphthacenecarboxamide dihydrochloride
LL [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-
[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,-
12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-
2-naphthacenecarboxamide
MM [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,
4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetra-
hydroxy-9-[[(methylamino)acetyl]amino]-1,11-dioxo-
2-naphthacenecarboxamide dihydrochloride
NN [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-
bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octa-
hydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naph-
thacenyl)-4-morpholineacetamide dihydrochloride
OO [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-
CC(ethylamino)acetyl)amino]-1,4,4a,5,5a,6,11,12a-
octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-
2-naphthacenecarboxamide dihydrochloride
PP [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-
[[(butylamino)acetyl]amino)-1,4,4a,5,5a,6,11,12a-
octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-
naphthacenecarboxamide dihydrochloride
QQ [4S-(4alpha,12aalpha))-9[[(Cyclopropylamino)acet-
yl)amino]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,-
12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-
2-naphthacenecarboxamide dihydrochloride
RR [4S-(4alpha,12aalpha))-9-([(Diethylamino)acetyl)-
amino]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,-
12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-
2-naphthacenecarboxamide dihydrochloride
SS [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-
bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-
1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacen-
yl]-1-pyrrolidineacetamide dihydrochloride
TT [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,
4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahy-
droxy-9-[[[(2-methylpropyl)amino]acetyl]amino)-1,11-
dioxo-2-naphthacenecarboxamide dihydrochloride
UU [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-
bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octa-
hydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphtha-
cenyl)-1-piperidineacetamide dihydrochloride
VV [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-
bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octa-
hydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naph-
thacenyl]-1H-imidazole-1-acetamide dihydrochloride
WW [4S-(4alpha,12aalpha)]-4,7-bis(dimethylamino)-1,4,
4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetra-hydroxy-
1,11-dioxo-9-[[(propylamino)acetyl]amino]-2-
naphthacenecarboxamide dihydrochloride
XX [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino(-9-
[[2-(dimethylamino)-1-oxopropyl]amino]-1,4,4a,5,
5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,
11-dioxo-2-naphthacenecarboxamide dihydrochloride
YY [4S-(4alpha,12aalpha))-4,7-Bis(dimethylamino)-1,4,
4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahy-
droxy-9-[[2-(methylamino)-1-oxopropyl]amino]-1,11-
dioxo-2-naphthacenecarboxamide dihydrochloride
ZZ [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-
[[4-(dimethylamino)-1-oxobutyl]amino]-1,4,4a,5,
5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,
11-dioxo-2-naphthacenecarboxamide dihydrochloride
AAA [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-
bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahy-
dro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naph-
thacenyl)-alpha-methyl-1-pyrrolidineacetamide
dihydrochloride
BBB [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-
[[(hexylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-
octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-
naphthacenecarboxamide dihydrochloride
CCC [4S-(4alpha,12aalpha)]-9-[[(Butylmethylamino)-
acetyl]amino]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,
6,11,12a-octahydro-3,10-12,12a-tetrahydroxy-1,11-
dioxo-2-naphthacenecarboxamide dihydrochloride
DDD [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4
4a,5,5a,6,11,12a-octahydro-3,10-12,12a-tetrahy-
droxy-1,11-dioxo-9-[[(pentylamino)acetyl]amino)-2-
naphthacenecarboxamide dihydrochloride
EEE [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,
4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahy-
droxy-1,11-dioxo-9-[[[(phenylmethyl)amino]acetyl]-
amino]-2-naphthacenecarboxamide dihydrochloride
FFF [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-
[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,
12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-
N-(1-pyrrolidinylmethyl)-2-naphthacenecarboxamide
GGG [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-
[[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,
12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-
N-(4-morpholinylmethyl)-2-naphthacenecarboxamide
HHH [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-
([(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,
12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-
N-(1-piperadinylmethyl)-2-naphthacenecarboxamide
III [4S-(4alpha,12aalpha)]-9-[(Bromoacetyl)amino)-4,7-
bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahy-
dro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naph-
thacenecarboxamide dihydrochloride
JJJ [4S-(4alpha,12aalpha)]-9-[(2-Bromo-1-oxopropyl)-
amino-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,
12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-
2-naphthacenecarboxamide hydrobromide
KKK [7S-(7alpha,10aalpha]-N-[2-[[9-(Aminocarbonyl)-4,7-
bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahy-
dro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphtha-
cenyl)amino]-2-oxoethyl]glycine
LLL (7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-
bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahy-
dro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphtha-
cenyl]-1-azetidineacetamide
MMM [4S-(4alpha,12aalpha)]-g-[[(Cyclobutylamino)acet-
yl]amino]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,
12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-
2-naphthacenecarboxamide
TABLE I
ANTIBACTERIAL ACTIVITY OF 9-(ACYLAMINO)-7-(SUBSTITUTED)-6-DEMETHYL-6-
DEOXYTETRACYCLINES
MIC (μg/ml)
COMPOUND
ORGANISM A B C D E F G H I
S. aureus UBMS 88-5 (tetM) 0.06 0.12 0.12 0.25 4 0.5 1 1 16
S. aureus UBMS 88-4 (Sensitive) 0.015 ≦0.06 0.03 0.12 0.5 0.25 <0.015 0.25 8
S. aureus UBMS 90-1 (tetM) 0.06 ND 0.5 0.5 8 2 4 1 16
S. aureus UBMS 90-2 (tetM) 0.03 ND 0.12 0.12 2 0.5 0.5 0.5 16
S. aureus UBMS 90-3 (Sensitive) ≦0.015 ND 0.03 0.06 0.5 0.12 0.03 0.12 4
S. aureus UBMS 88-7 (tetK) 2 4 0.25 2 4 2 16 16 16
S. aureus IVES 2943 (meth. 4 64 1 4 8 2 32 32 ND
resistant)
S. aureus IVES 1983 (meth. 8 ND 1 4 16 4 32 32 32
resistant)
S. aureus ATCC 29213 (Sensitive) ≦0.015 0.12 ≦0.015 ≦0.015 ≦0.015 ≦0.015 ND 0.22 1
S. aureus Smith (Sensitive) ≦0.015 0.12 0.03 0.03 0.5 0.12 0.03 0.12 8
S. haemolyticus AVAH 88-3 0.03 ND 0.12 ND 8 2 0.06 2 0.5
E. faecalis 12201 0.12 0.5 0.5 1 16 4 16 2 16
E. faecalis ATCC 29212 ≦0.015 0.12 0.06 0.12 2.0 0.25 0.25 0.25 8
E. coli UBMS 88-1 (tetB) 32 >128 16 >32 >32 >32 >32 >128 >32
E. coli UBMS 88-2 (Sensitive) 0.12 2 0.25 0.5 >32 32 1 >128 32
E. coli UBMS 89-1 (tetM) 0.12 ND 1 ND 32 4 1 128 32
E. coli UBMS 89-2 (Sensitive) 0.12 ND 0.5 0.5 >32 32 1 16 32
E. coli ATCC 25922 0.06 2 0.25 0.5 32 4 0.5 16 32
MIC (μg/ml)
COMPOUND
ORGGANISM J K L M N O HH II
S. aureus UBMS 88-5 (tetM) 4 0.25 4 1 32 2 0.25 0.12
S. aureus UBMS 88-4 (Sensitive) 2 0.12 4 1 2 ≦0.015 0.03 0.06
S. aureus UBMS 90-1 (tetM) 4 0.25 8 2 >32 4 1 0.25
S. aureus UBMS 90-2 (tetM) 2 0.06 2 0.5 32 2 0.25 0.06
S. aureus UBMS 90-3 (Sensitive) 0.5 0.03 1 0.5 1 ≦0.015 0.03 0.06
S. aureus UBMS 88-7 (tetK) 2 32 >32 >32 8 0.06 0.5 0.06
S. aureus IVES 2943 (meth. 4 32 >32 >32 32 1 2 1
resistant)
S. aureus IVES 1983 (meth. 4 32 >32 >32 >32 1 2 1
resistant)
S. aureus ATCC 29213 (Sensitive) 0.06 ≦0.015 0.5 0.5 0.25 ≦0.015 ≦0.015 0.03
S. aureus Smith (Sensitive) 0.5 ≦0.015 0.5 1 2 ≦0.015 0.03 0.12
S. haemolyticus AVAH 88-3 4 0.5 16 1 4 0.03 0.25 0.25
E. faecalis 12201 2 0.25 4 0.25 32 4 2 0.12
E. faecalis ATCC 29212 4 0.06 2 0.25 32 0.5 0.25 0.03
E. coli UBMS 88-1 (tetB) >32 16 >32 2 >32 8 16 0.25
E. coli UBMS 88-2 (Sensitive) >32 4 >32 2 >32 0.5 ND ND
E. coli UBMS 89-1 (tetM) >32 1 >32 2 >32 16 4 0.12
E. coli UBMS 89-2 (Sensitive) >32 8 >32 2 >32 0.5 4 0.25
E. coli ATCC 25922 32 4 32 2 32 0.25 2 0.12
TABLE II
ANTIBACTERIAL ACTIVITY OF 9-(AROYLAMINO) AND 9-(HETEROYLAMINO)-7-
(SUBSTITUTED)-6-DEMETHYL-6-DEOXYTETRACYCLINES
MIC (μg/ml)
COMPOUND
ORGANISM P Q R S T U V W X Y Z O
S. aureus UBMS 88-5 (tetM) 4 8 4 2 4 1 2 32 8 16 8 2
S. aureus UBMS 88-4 (Sensitive) 4 8 2 2 4 0.5 2 8 1 4 8 ≧0.015
S. aureus UBMS 90-1 (tetM) 4 8 8 4 4 1 2 16 16 32 4 4
S. aureus UBMS 90-2 (tetM) 4 8 2 1 2 1 1 8 8 8 4 2
S. aureus UBMS 90-3 (Sensitive) 1 4 1 1 2 0.5 0.5 8 1 2 2 ≦0.015
S. aureus UBMS 88-7 (tetK) 8 16 4 8 4 1 4 16 8 >32 32 0.06
S. aureus IVES 2943 (meth. resistant) 16 8 4 8 4 1 4 8 >32 >32 32 4
S. aureus IVES 1983 (meth. resistant) 8 16 8 4 4 1 8 8 >32 >32 32 4
S. aureus ATCC 29213 (Sensitive) 0.25 1 0.12 0.5 1 0.5 0.25 2 0.5 0.5 0.5 ≦0.015
S. aureus Smith (Sensitive) 1 4 1 1 4 1 0.5 4 1 2 2 ≦0.015
S. haemolyticus AVAH 88-3 4 8 8 4 4 1 4 16 8 >32 8 0.03
E. faecalis 12201 8 8 8 4 4 1 4 16 32 32 8 4
E. faecalis ATCC 29212 4 8 2 4 4 1 4 8 8 8 8 0.5
E. coli UBMS 88-1 (tetB) >32 >32 2 >32 >32 >32 >32 >32 >32 >32 >32 8
E. coli UBMS 88-2 (Sensitive) >32 >32 >32 >32 >32 >32 >32 >32 >32 >32 >32 0.5
E. coli UBMS 89-1 (tetM) ND ND ND ND ND >32 >32 >32 >32 >32 >32 16
E. coli UBMS 89-2 (Sensitive) >32 >32 >32 >32 >32 ≧32 >32 >32 >32 >32 >32 0.5
E. coli ATCC 25922 >32 >32 >32 >32 >32 ≧32 >32 >32 >32 >32 32 0.25
TABLE III
ANTIBACTERIAL ACTIVITY OF 9-(SULFONYLAMINO)-7-(SUBSTITUTED)-
6-DEMETHYL-6-DEOXYTETRACYCLINES
MIC (μg/ml)
COMPOUND
ORGANISM AA BB CC DD EE FF GG O
S. aureus UBMS 88-5 (tetM) 0.12 ND 4 0.5 0.12 0.25 16 4
S. aureus UBMS 88-4 (Sensitive) 0.12 1 0.03 0.5 0.12 0.25 4 0.03
S. aureus UBMS 90-1 (tetM) 0.5 2 4 1 0.25 0.25 32 2
S. aureus UBMS 90-2 (tetM) 0.12 0.5 0.06 0.25 0.12 0.06 4 1
S. aureus UBMS 90-3 (Sensitive) 0.06 0.12 4 0.25 0.12 0.12 2 ≦0.015
S. aureus UBMS 88-7 (tetK) 2 4 4 2 1 8 32 0.06
S. aureus IVES 2943 (meth. resistant) 4 4 4 4 0.5 16 >32 2
S. aureus IVES 1983 (meth. resistant) 8 8 4 4 1 16 32 1
S. aureus ATCC 29213 (Sensitive) 0.12 0.06 ≦0.015 0.03 0.03 0.03 0.5 ≦0.015
S. aureus Smith (Sensitive) 0.12 0.25 4 0.03 0.12 0.12 2 ≦0.015
S. haemolyticus AVAH 88-3 2 4 4 2 ND ND ND 0.06
E. faecalis 12201 ND ND ND ND ND ND ND 8
E. faecalis ATCC 29212 0.12 0.12 0.06 0.25 0.06 0.06 1 0.5
E. coli UBMS 88-1 (tetB) 16 >32 16 32 >32 8 >32 16
E. coli UBMS 88-2 (Sensitive) 8 4 8 8 >32 2 >32 0.5
E. coli UBMS 89-1 (tetM) 4 ND ND ND ND ND 32 16
E. coli UBMS 89-2 (Sensitive) 16 16 16 16 >32 2 >32 0.5
E. coli ATCC 25922 4 2 2 4 >32 2 >32 0.5
TABLE IA
ANTIBACTERIAL ACTIVITY OF 9-(ACYLAMINO)-7-(SUBSTITUTED)-
6-DEMETHYL-6-DEOXYTETRACYCLINES
JJ KK LL MM NN OO PP QQ RR SS
E. coli UBMS 88-1 TetB 0.25 0.25 0.25 1 >32 1 0.5 4 1 0.25
E. coli J3272 Tet sens. 0.25 0.12 0.12 1 >32 1 0.5 2 1 0.25
E. coli MC4100 Tet sens. NT NT NT NT NT NT NT NT NT NT
E. coli MC4100 TetB 0.25 0.25 0.25 1 >32 1 0.5 2 1 0.25
E. coli PRP1 TetA 2 1 1 16 >32 2 1 32 2 0.5
E. coli J3272 TetC 1 1 0.5 8 >32 2 0.5 8 1 0.25
E. coli UBMS 89-1 TetM 0.25 0.12 0.12 1 32 1 0.25 1 0.25 0.12
E. coli UBMS 89-2 Tet Sens. 0.25 0.25 0.12 1 >32 1 0.5 2 1 0.25
E. coli J2175 0.25 0.25 0.12 1 >32 1 0.25 2 1 0.25
E. coli BAJ9003 0.03 0.03 NG 0.25 0.5 0.12 0.12 0.25 0.06 ≦0.015
E. coli UBMS 90-4 TetM 0.25 0.25 0.25 CONT CONT 0.5 0.25 2 0.5 0.25
E. coli UBMS 90-5 0.25 0.25 0.12 1 >32 1 0.5 2 1 0.25
E. coli #311 (MP) 0.25 0.25 0.12 1 >32 1 0.25 2 0.5 0.12
E. coli ATCC 25922 0.25 0.25 0.12 1 >32 1 0.25 2 0.5 0.25
E. coli J3272 TetD 0.12 0.12 0.06 0.05 32 0.5 0.25 2 0.25 0.12
S. mariescens FDOR 8733 4 2 2 16 >32 8 2 >32 4 2
X. maltophilia NEMC 87210 0.5 0.25 0.25 8 32 2 0.5 2 0.25 0.5
Ps. acruginosa ATCC 27853 8 4 4 16 >32 16 16 >32 32 16
S. aureus NEMC 8769/89-4 0.06 0.06 ≦0.015 0.5 0.5 0.5 0.12 0.12 0.06 0.03
S. aureus UBMS 88-4 0.25 0.12 0.06 0.5 2 1 0.25 0.5 0.25 0.12
S. aureus UBMS 88-5 TetM 0.25 0.25 0.12 0.5 4 1 0.5 0.5 0.25
S. aureus UBMS 88-7 TetK 1 0.25 0.5 16 32 8 2 4 0.5 0.5
S. aureus UBMS 90-1 TetM 0.25 0.25 0.12 1 4 1 0.5 0.5 0.25 0.12
S. aureus UBMS 90-3 0.12 0.03 0.06 0.5 2 0.5 0.25 0.5 0.25 0.12
S. aureus UBMS 90-2 TetM 0.25 0.12 0.12 0.5 2 0.5 0.5 0.5 0.25 0.12
S. aureus IVES 2943 2 1 1 32 >32 8 2 16 1 1
S. aureus ROSE (MP) 2 1 1 32 >32 8 2 16 1 1
S. aureus SMITH (MP) 0.12 0.06 0.06 0.5 2 0.5 0.12 0.25 0.25 0.12
S. aureus IVES 1983 2 1 1 16 >32 8 2 8 0.25 0.5
S. aureus ATCC 29213 0.03 ≦0.015 0.06 1 2 1 0.25 0.5 0.12 0.12
S. hemolyticus AVHAH 88-3 0.25 0.12 0.12 1 32 1 0.25 2 0.5 0.25
Enterococcus 12201 0.12 0.12 0.06 0.25 2 0.25 0.12 0.5 0.12 0.12
E. faecalis ATCC 29212 0.12 0.06 0.06 0.25 2 0.25 0.12 0.25 0.12 0.12
TT UU VV WW XX YY ZZ AAA BBB CCC DDD
E. coli UBMS 88-1 TetB 0.5 0.5 >32 0.25 0.5 0.5 >32 0.5 0.5 1 0.5
E. coli J3272 Tet sens. 0.5 0.5 >32 0.25 0.5 0.5 NT NT NT NT NT
E. coli MC4100 Tet sens. NT NT NT NT NT NT 2 0.12 0.25 0.25 0.12
E. coli MC4100 TetB 0.5 0.5 >32 0.25 1 0.5 >32 0.5 0.5 2 0.5
E. coli PRP1 TetA 2 1 >32 1 1 2 >32 0.5 0.5 2 1
E. coli J3272 TetC 0.5 0.5 >32 0.25 1 1 32 0.5 0.5 1 0.5
E. coli UBMS 89-1 TetM 0.25 0.12 >32 0.25 0.12 0.5 32 0.12 0.25 0.25 0.25
E. coli UBMS 89-2 Tet Sens. 0.5 0.5 >32 0.25 0.5 0.5 16 0.5 0.25 2 0.5
E. coli J2175 0.5 0.5 >32 0.25 0.5 0.5 16 0.5 0.25 2 0.5
E. coli BAJ9003 0.06 0.06 1 0.06 0.06 0.06 1 0.06 0.06 0.12 0.12
E. coli UBMS 90-4 TetM 0.5 0.5 >32 0.25 0.5 0.5 16 0.5 0.25 1 0.5
E. coli UBMS 90-5 0.5 0.5 >32 0.25 0.5 0.5 16 0.5 0.25 2 0.5
E. coli #311 (MP) 0.5 0.25 >32 0.25 0.5 0.5 16 0.25 0.5 1 0.5
E. coli ATCC 25922 0.5 0.25 >32 0.25 0.5 0.5 8 0.25 0.12 1 0.5
E. coli J3272 TetD 0.12 0.25 >32 0.12 0.25 0.25 4 0.12 0.12 0.5 0.25
S. mariescens FDOR 8733 4 4 >32 2 4 8 >32 4 4 16 8
X. maltophilia NEMC 87210 0.5 0.12 >32 0.5 0.5 4 32 0.5 4 0.25 0.5
Ps. acruginosa ATCC 27853 16 32 >32 8 32 16 >32 >32 16 >32 32
S. aureus NEMC 8769/89-4 0.03 0.06 4 0.06 0.12 0.12 1 0.12 0.06 0.12 0.25
S. aureus UBMS 88-4 0.25 0.25 8 0.25 0.25 0.5 2 0.25 0.25 0.5 0.5
S. aureus UBMS 88-5 TetM 0.25 0.25 32 0.25 0.25 0.5 8 0.25 0.5 0.5 0.5
S. aureus UBMS 88-7 TetK 2 0.25 32 1 1 4 16 0.5 2 1 2
S. aureus UBMS 90-1 TetM 0.25 0.25 32 0.12 0.25 0.25 8 0.5 0.25 1 1
S. aureus UBMS 90-3 0.12 0.12 4 0.12 0.25 0.12 2 0.25 0.06 0.25 0.5
S. aureus UBMS 90-2 TetM 0.25 0.12 16 0.25 0.25 0.25 4 0.25 0.25 0.25 0.5
S. aureus IVES 2943 2 0.25 >32 2 1 8 >32 0.5 4 1 4
S. aureus ROSE (MP) 2 0.5 >32 2 1 8 >32 2 16 2 4
S. aureus SMITH (MP) 0.12 0.12 4 0.12 0.25 0.25 2 0.25 0.12 0.5 0.25
S. aureus IVES 1983 2 0.5 >32 2 1 4 >32 0.5 4 1 4
S. aureus ATCC 29213 0.25 0.12 8 0.25 0.25 0.5 2 0.25 0.25 0.5 1
S. hemolyticus AVHAH 88-3 0.5 0.12 >32 0.25 0.5 0.5 8 0.5 0.5 0.5 0.5
Enterococcus 12201 0.25 0.12 4 0.12 0.12 0.25 8 0.12 0.25 0.25 0.25
E. faecalis ATCC 29212 0.25 0.06 4 0.25 0.12 0.12 4 0.12 0.12 0.12 0.25
EEE FFF GGG HHH III JJJ KKK LLL MMM
E. coli UBMS 88-1 TetB 2 0.25 0.25 0.25 >32 >32 >32 0.5 0.5
E. coli J3272 Tet sens. NT NT NT NT 16 >32 >32 0.25 0.06
E. coli MC4100 Tet sens. 0.5 0.06 0.06 0.12 NT NT 32 NT NT
E. coli MC4100 TetB 4 0.25 0.25 0.25 >32 >32 >32 0.5 0.25
E. coli PRP1 TetA 4 2 1 2 >32 >32 >32 1 4
E. coli J3272 TetC 2 1 1 0.5 >32 >32 >32 0.5 0.5
E. coli UBMS 89-1 TetM 0.5 0.12 0.12 0.25 4 32 >32 0.25 0.25
E. coli UBMS 89-2 Tet Sens. 4 0.25 0.25 0.25 32 >32 >32 0.5 0.5
E. coli J2175 4 0.25 0.25 0.25 32 >32 >32 0.25 0.25
E. coli BAJ9003 0.25 ≧0.015 0.03 0.03 0.25 4 16 0.06 0.03
E. coli UBMS 90-4 TetM 0.5 0.12 0.25 0.25 — >32 >32 0.25 0.25
E. coli UBMS 90-5 0.5 0.25 0.25 0.25 16 >32 >32 0.25 0.5
E. coli #311 (MP) 0.5 0.25 0.25 0.25 8 >32 >32 0.25 0.25
E. coli ATCC 25922 0.5 0.12 0.12 0.25 16 >32 >32 0.25 0.25
E. coli J3272 TetD 0.5 0.12 0.12 0.12 32 >32 >32 0.12 0.12
S. mariescens FDOR 8733 4 4 4 4 >32 >32 >32 2 8
X. maltophilia NEMC 87210 1 0.25 0.5 0.5 4 16 >32 1 0.5
Ps. acruginosa ATCC 27853 32 8 8 8 >32 >32 >32 8 32
S. aureus NEMC 8769/89-4 0.12 0.25 0.25 0.25 0.12 4 32 0.12 0.5
S. aureus UBMS 88-4 0.25 0.12 0.12 0.25 0.5 8 32 0.25 0.25
S. aureus UBMS 88-5 TetM 0.5 0.12 0.12 0.25 1 8 >32 0.25 0.25
S. aureus UBMS 88-7 TetK 2 1 1 0.5 2 16 >32 2 4
S. aureus UBMS 90-1 TetM 0.5 0.12 0.25 0.25 1 16 >32 0.25 0.5
S. aureus UBMS 90-3 0.25 0.12 0.12 0.12 0.5 2 16 0.12 0.12
S. aureus UBMS 90-2 TetM 0.25 0.12 0.12 0.12 0.5 8 32 0.25 0.25
S. aureus IVES 2943 2 2 2 2 4 32 >32 2 4
S. aureus ROSE (MP) 8 2 2 2 8 >32 >32 2 8
S. aureus SMITH (MP) 0.25 0.12 0.12 0.12 0.5 4 16 0.25 0.25
S. aureus IVES 1983 2 2 2 2 4 32 >32 2 4
S. aureus ATCC 29213 0.5 0.12 0.25 0.25 0.5 4 32 0.25 0.25
S. hemolyticus AVHAH 88-3 2 0.25 0.5 0.5 2 16 >32 0.25 0.24
Enterococcus 12201 0.25 0.12 0.12 0.12 1 16 >32 0.25 0.24
E. faecalis ATCC 29212 0.25 0.06 0.06 0.06 0.5 16 16 0.25 0.25
NG = No Growth
CONT = Contaminated
NT = Not Tested
TABLE IV
Susceptibility of Sensitive and Resistant (tetM)
Organisms to Tetracyclines
MIC (μg/ml)
Organisms A O TC
E. coli UBMS 88-2 (Sensitive) 0.12 0.5 ND
E. coli UBMS 90-4 (tetM) 1 64 64
S. aureus UBMS 88-4 (Sensitive) <0.015 0.03 0.12
S. aureus UBMS 88-5 (tetM) 0.03 2 32
S. aureus UBMS 90-3 (Sensitive) <0.015 0.03 0.12
S. aureus UBMS 90-1 (tetM) 0.12 4 32
N. gonorrhoeae IL 611 (Sensitive) 0.06 0.5 ND
N. gonorrhoeae 6418 (tetM) 1 >32 >32
E. faecalis UBMS 90-6 (tetM) 0.12 8 32
E. faecalis UBMS 90-7 (tetM) 0.5 8 32
TABLE V
In vitro Activity of Compounds A and O Against Clinical Isolates
MIC (μg/ml)+
No. Anti-
Organism Tested biotic Range MIC50 MIC90
Neisseria  (9) A   0.015-1.00 0.03 1.00
gonorrhoeae O   0.03->32.00 0.25 >32.00
Haemophilus (18) A <0.008-0.06 0.06 0.06
influenzae O   0.06-0.25 0.12 0.25
Enterococcus (14) A <0.015-2.00 0.12 1.00
faecalis O <0.015-16.00 4.00 16.00
Enterococcus (11) A <0.015-2.00 0.06 2.00
faecium O <0.015-16.00 8.00 16.00
Escherichia coli (10) A   0.06->32.00 0.25 >32.00
O   0.12-32.00 0.25 16.00
Klebsiella (10) A   0.25->32.00 0.50 0.50
pneumoniae O   1.00->32.00 1.00 4.00
Proteus spp.  (9) A   0.50->32.00 2.00 >32.00
indole+ O   1.00->32.00 16.00 >32.00
Bacteroides spp. (15) A >0.15-4.00   0.25 2.00
O >0.15-16.00 1.00 4.00
In Vitro Activity of KK and Comparative
Antibiotics vs Recent Clinical and Agricultural Isolates
MIC (μg/ml)
[No.
Organism Tested] KK O TC
Staphylococcus aureus, [15] 0.12-2   0.06-4 0.25->64
methicillin-resistant
Staphylococcus aureus, [15] 0.12-0.25   0.03-0.12 0.12-1
methicillin-susceptible
Staphylococcus [16] 0.12-8   0.03-1 0.12->64
Coagulase-negative,
methicillin-susceptible
Enterococcus faecalis [10] 0.015-0.12   0.03-16 0.12-64
Enterococcus faecium [10] 0.03-0.12   0.03-16 0.12-64
Enterococcus spp.  [8] 0.015-0.06   0.03-16 0.12->64
Vancomycin-resistant
Streptococcus pyogenes [10] 0.06-0.12   0.03-2 0.12-16
Streptococcus agalactiae [10] 0.06-0.25   0.12-16 0.25-64
Streptococcus [10] 0.03-0.25   0.06-0.5 0.12-2
pneumoniae
Listeria monocytogenes  [8] 0.06-0.12   0.015-0.03 0.12-0.5
Escherichia coli [30] 0.12-4   0.25-32 0.5->64
(Clinical)
Escherichia coli [15] 0.12-4   1-16 2->64
(Agricultural)
Shigella spp. [14] 0.06-0.5   0.25-8 0.25->64
Kiebsiella pneumoniae [10] 0.25-8   0.5-8 0.5->64
Klebsiella oxytoca [10] 0.5-1   0.5-4 0.5-1
Citrobacter freundii [10] 0.25-8   0.03-32 0.5-16
Citrobacter diversus [10] 0.25-1   0.25-4 0.5-4
Salmonella spp. [11] 0.25-0.5   0.5-16 0.5->64
(Clinical)
Salmonella cholerasuis [15] 0.5-16   2->64 1->64
(Agricultural)
Serratia mercescens [10] 2-8   1-8 8->64
Enterobacter cloacae [10] 0.5-1   0.25-4 0.5-2
Enterobacter aerogenes [10] 0.5-1   0.5-1 0.5-1
Providencia spp. [13] 2-8   4->64 1->64
Proteus mirabilis [26] 1-32   1-32 0.5-64
Proteus vulgaris [18] 0.5-4   0.5-16 0.25-64
Morganella morganii [16] 0.5-4   0.25-32 0.25->64
Pseudomonas aeruginosa [10] 1-16   1-16 2-32
Xanthomonas maltophilia [10] 0.5-2   0.12-1 8-16
Moraxella catarrhalis [18] 0.06-0.12   0.03-0.12 0.06-0.5
Neisseria gonorrhoeae [14] 0.25-1   0.5-64 1->64
Haemophilus influenzae [15] 0.5-2   0.5-2 1-32
Pasturella multocida [17] 0.03-0.25   0.015-4 0.06-16
(Agricultural & Clinical)
Bordetella [10] 0.12   0.06-0.12 0.12-0.25
bronchiseptica
(Agricultural)
Bacteroides fragilis [11] 0.06-0.2 <0.008-16 0.25->64
Bacertoides fragilis [10] 0.06-2 <0.008-4 0.25-32
group
Bacteroides spp.  [9] 0.03-1   0.03-16 0.25->64
Clostridium difficile [12] 0.03   0.015-16 0.12-32
Clostridium perfringens [16] 0.03-1 >0.008-16 0.015-16
Clostridium spp.  [9] 0.015-0.12 <0.008-16 0.015-64
Anaerobic Gram (+) [15] 0.015-0.06   0.05-8 4->64
Cocci
+MIC50 = minimum concentration required to inhibit 50% of strains tested.
MIC90 = minimum concentration required to inhibit 90% of strains tested
TABLE VI
Inhibition of Protein Synthesis Directed by E. coli Cell-free
Ribosomes with Tetracyclines
IC50 (μg/ml)+
Antibiotic TC Sensitive Host Tet M Host
Tetracycline 0.6 2.0
Compound O 0.4 2.0
Compound A <0.3 0.4
+Concentration of antibiotic required to inhibit protein synthesis by 50% compared to a drug-free control
TABLE VII
In vivo Protective Activity of Compounds A and O in Mice
Infected with Staphylococci Containing the tetM Determinant
Organism Compound ED50 (mg/kg)+
S. aureus UBMS 90-1 A 0.22
O 1.7
S. aureus UBMS 90-2 A 0.49
O 3.0
In Vitro Protective Activity in Mice
Compounds (ED50 (mg/kg)
Route of
Antibiotic
Organism Administration JJ KK LL PP RR SS TT
S. aureus SMITH (sens) Oral 9.6  8-16 4-8 >16 8-16 8-16 8-16
S. aureus SMITH (sens) Intraveneous 0.61 0.68 0.25-0.5  1-2 — 1-2  1-2 
S. aureus SMITH (sens) Subcutaneous 0.66 — — — — — —
Escherichia coli Intraveneous — 2.49 — — — — —
UBMS 90-4 (Tet-M)
Route of
Antibiotic
Organism Administration BBB WW XX YY AAA DDD EEE O
S. aureus SMITH (sens) Oral 4-8 >16 8-16 >16 >16 8-16 8-16 0.74
S. aureus SMITH (sens) Intraveneous 1.8 0.82 0.5-1   0.5-1 — — — 0.37
S. aureus SMITH (sens) Subcutaneous — — — — — — — —
Escherichia coli Intraveneous — — — — — — — >32
UBMS 90-4 (Tet-M)
+Median effective dose protecting 50% of the infected mice, single subcutaneous dosing.
TABLE VIII
InVitro Transcription and Protein Translation
Sensitivity to Tetracycline Compounds
COMPOUND % INHIBITION
Organism Concentration Wild Type S30 TetM S30
KK 1.0 mg/ml 92 95
0.5 mg/ml 90 96
0.25 mg/ml 89 93
0.12 mg/ml 84 93
0.06 mg/ml 82 89
0.03 mg/ml 81 75
MM 1.0 mg/ml 99 99
0.2 mg/ml 98 97
0.06 mg/ml 95 92
OO 1.0 mg/ml 99 99
0.2 mg/ml 97 95
0.06 mg/ml 94 87
QQ 1.0 mg/ml 99 99
0.2 mg/ml 97 95
0.06 mg/ml 92 85
RR 1.0 mg/ml 99 99
0.2 mg/ml 97 97
0.06 mg/ml 93 90
VV 1.0 mg/ml 99 98
0.2 mg/ml 93 92
0.06 mg/ml 91 79
WW 1.0 mg/ml 99 98
0.2 mg/ml 99 97
0.06 mg/ml 93 88
XX 1.0 mg/ml 98 97
0.2 mg/ml 96 89
0.06 mg/ml 85 78
Minocycline 1.0 mg/ml 98 68
0.2 mg/ml 89 43
0.06 mg/ml 78  0
When the compounds are employed as antibacterials, they can be combined with one or more pharmaceutically acceptable carriers, for example, solvents, diluents and the like, and may be administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from about 20 to 50% ethanol, and the like, or parenterally in the form of sterile injectable solutions or suspensions containing from about 0.05 to 5% suspending agent in an isotonic medium. Such pharmaceutical preparations may contain, for example, from about 25 to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and 60% by weight.
An effective amount of compound from 2.0 mg/kg of body weight to 100.0 mg/kg of body weight should be administered one to five times per day via any typical route of administration including but not limited to oral, parenteral, (including subcutaneous, intravenous, intramuscular, intrasternal injection or infusion techniques), topical or rectal, in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
These active compounds may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes. Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired. Adjuvants customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA.
The preferred pharmaceutical compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral administration of the compounds is preferred.
These active compounds may also be administered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid, polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacterial and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oil.
The invention will be more fully described in conjunction with the following specific examples which are not to be construed as limiting the scope of the invention.
EXAMPLE 1 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1)
To a stirred ice bath cooled solution of 0.444 g of [4S-(4α,12aα)]-4,7-bis(dimethylamino)-1,4,4a,5,5a,-6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride, prepared by the procedure described in U.S. Pat. No. 3,226,436, dissolved in 15 ml of sulfuric acid is added 0.101 g of sodium nitrate. The mixture is stirred in the cold for 45 minutes followed by the dropwise addition to 500 ml of diethyl ether. The resulting solid is collected, washed with diethyl ether and dried to give 0.6 g of the desired product as a solid.
MS(FAB): m/z 503(M+H) and 601(M+H2SO4+H).
EXAMPLE 2 [4S-(4α,12aα)]-9-Amino-4,7-bis(dimethylamino)-1,4a,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:1)
A mixture of 2.0 g of product from Example 1 in 20 ml of 2-methoxyethanol is stirred for 10 minutes and filtered. The filtrate is shaken, in a pressure bottle, with 1.0 g of 10% palladium-on-carbon and 5 ml of 2N sulfuric acid, under 30 lbs. of hydrogen pressure, for 1 hour. The reaction mixture is filtered and the filtrate concentrated in vacuo to half volume. The solution is poured into 100 ml of diethyl ether, the solid collected, washed with diethyl ether and dried to give 1.6 g of the desired product as a solid.
MS(FAB): m/z 473 (M+H).
EXAMPLE 3 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetra-hydroxy-1,11-dioxo-2-naphthacenecarboxamide
To a stirring 0° C. solution of 3.0 g of product from Example 2, 0.451 g of anhydrous sodium acetate and ml of 98% formic acid is added, dropwise, 7.4 ml of acetic anhydride. The reaction is stirred at 0° C. for 10 minutes followed by stirring at room temperature for 1 hour. The mixture is poured into 500 ml of diethyl ether and the precipitate collected. The solid is washed with diethyl ether and dried to give 2.9 g of the desired product.
MS(FAB): m/z 501 (M+H).
EXAMPLE 4 [4S-(4α,12aα)],4,7-Bis(dimethylamino)-9-(formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetra-hydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate
To a solution of 3.5 g of product from Example 3 in 150 ml of distilled water is added sufficient 0.75N sulfuric acid to bring the reaction solution of pH 3.6. The solution is lyophilized to give 3.6 g of the desired salt.
MS(FAB): m/z 501 (M+H).
EXAMPLE 5 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide mono-hydrochloride
To a solution of 3.5 g of product from Example 3 in 150 ml of distilled water is added sufficient 0.75N hydrochloric acid to bring the reaction solution of pH 3.6. The solution is lyophilized to give 3.6 g of the desired salt.
MS(FAB): m/z 501 (M+H).
EXAMPLE 6 [4S-(4α,12aα)]-9-(Acetylamino)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetra-hydroxy-1,11-dioxo-2-naphthacenecarboxamide
To a stirring solution of 0.468 g of product from Example 2 in 5 ml of water is added 0.50 g of sodium acetate and 0.2 ml of acetic anhydride. The reaction is stirred at room temperature for 10 minutes followed by the addition of 0.2 ml of concentrated ammonium hydroxide. After stirring 5 hours at room temperature, the reaction is treated with 0.5 ml of concentrated sulfuric acid. The reaction solution is extracted with 4 portions of n-butyl alcohol and the aqueous layer is concentrated in vacuo to dryness. The residue is triturated with 20 ml of methyl alcohol, filtered and the organic layer is concentrated in vacuo to give 0.35 g of the desired product.
MS(FAB): m/z 515 (M+H).
EXAMPLE 7 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetra-hydroxy-1,11-dioxo-9-[(trifluoroacetyl)amino]-2-naphthacenecarboxamide sulfate
A mixture of 0.20 g of product from Example 2 and 3.0 ml of trifluoroacetic anhydride is stirred at room temperature for 6 hours. The reaction liquid is decanted from the solid residue. The solid is dried, dissolved in 10 ml of methyl alcohol, stirred for 20 minutes and the mixture is poured into 100 ml of diethyl ether. The solid is collected and dried to give 0.16 g of the desired product.
MS(FAB): m/z 569 (M+H).
EXAMPLE 8 [4S-(4α,12aα)]-7-(Diethylamino)-4-(dimethylamino)-1,4o4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy- 9-nitro-1,11-dioxo-2-naphthacene-carboxamide sulfate (1:2)
To a stirred ice cooled solution of 0.660 g of [4S-(4α,12aα)]-7-(diethylamino)-4-(dimethylamino)-1,4a,-5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,-11-dioxo-2-naphthacenecarboxamide hydrochloride, prepared by the procedure described in U.S. Pat. No. 3,226,436, dissolved in 15 ml of sulfuric acid is added 0.151 g of sodium nitrate. The mixture is stirred in the cold followed by dropwise addition to 500 ml of diethyl ether. The resulting solid is collected, washed with diethyl ether and dried to give 0.8 g of the desired product as a solid.
MS(FAB): m/z 531(M+H) and 629(M+H2SO4+H).
EXAMPLE 9 [4S-(4α,12aα)]-9-Amino-7-(diethylamino)-4-(dimethylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12 a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:2)
The title compound is prepared by the procedure of Example 2, using 0.82 g of product from Example 8, to give 0.65 g of the desired product as a solid. 1H NMR (CD3SOCD3): δ 4.25(s,1H,4-H) and 7.27(s,1H,8-H).
MS(FAB): m/z 501(M+H) and 599 (M+H2SO4+H).
EXAMPLE 10 [4S-(4α,12aα)]-7-(Diethylamino)-4-(dimethylamino)-9-(formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (1:2)
To a solution of 0.238 g of product from Example 9 in 6 ml of formic acid is added 0.035 g of sodium acetate and 0.75 ml of acetic anhydride. The reaction mixture is stirred at room temperature for 1.5 hours then poured into 200 ml of diethyl ether. The solid is collected and dried at 50° C. to give 0.125 g of the desired product.
MS(FAB): m/z 529 (M+H) and 627 (M+H2SO4+H).
EXAMPLE 11 [4S-(4α,12aα)]-9-(Acetylamino)-7-(diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide sulfate (1:2)
To a solution of 0.16 g of product from Example 9 in 0.6 ml of water is added 0.125 g of sodium acetate. After stirring for 5 minutes, 0.05 ml of acetic anhydride is added. The reaction is stirred for 15 minutes, 0.025 ml of ammonium hydroxide is added and the stirring continued for an additional 5 minutes. The mixture is acidified with 0.125 ml of sulfuric acid, extracted with n-butyl alcohol and concentrated in vacuo. The residue is dissolved in methyl alcohol and added to diethyl ether. The solid is collected and dried to give 0.10 g of the desired product.
MS(FAB): m/z 543 (M+H) and 641 (M+H2SO4+H).
EXAMPLE 12 [4S-(4α,12aα)]-7-(Diethylamino)-4-(dimethylamino)-9-(formylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene carboxamide
A solution of 0.2 g of product from Example 10 in 10 ml of water is treated with sodium acetate to achieve pH 5-6. The mixture is extracted with chloroform. The organic extracts are dried with sodium acetate, concentrated in vacuo and the solid triturated with diethyl ether/hexane to give 0.11 g of the desired product.
MS (FAB): m/z 529 (M+H).
EXAMPLE 13 [4S-(4α,12aα)]-9-(Acetylamino)-7-(diethylamino)-4-(dimethylamino)- 1,4,4a,5,5a,6,11 , 12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide
A solution of 0.25 g of product from Example 11 in ml of water is treated with sodium acetate to achieve pH 6. The mixture is extracted with chloroform. The organic extracts are dried with sodium acetate, concentrated in vacuo and the solid triturated with diethyl ether/hexane to give 0.090 g of the desired product.
MS (FAB): m/z 543 (M+H).
EXAMPLE 14 [4S-(4α,12aα)]-4-(Dimethylamino)-7-(ethylmethylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy- 1,11-dioxo-2-naphthacene-carboxamide hydrochloride
A solution of 0.460 g of [4S-(4α,12aα)]-4-(dimethylamino)- 7-(ethylamino)-1,4,4a,5,5a,6,11,12 a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride, prepared by the procedure described in U.S. Pat. No. 3,226,436, in 0.5 ml of 97% formic acid and 0.75 ml of 40% aqueous formaldehyde is heated at reflux temperature for 2 hours, concentrated to ½ volume and poured into diethyl ether. The resulting solid is collected, washed with diethyl ether and dried to give 0.30 g of the desired product.
EXAMPLE 15 [4S-(4α,12aα)]-4-(Dimethylamino)-7-(ethylmethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-nitro-1,11-dioxo-2-naphthacene-carboxamide sulfate
The title compound is prepared by the procedure of Example 8, using 0.460 g of product from Example 14, 15 ml of sulfuric acid and 0.101 g of sodium nitrate to give 0.5 g of the desired product.
EXAMPLE 16 [4S-(4α,12aα)]-9-Amino-4-(dimethylamino)-7-(ethylmethylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide sulfate
The title compound is prepared by the procedure of Example 2, using 1.0 g of product from Example 15, 20 ml of 2-methoxyethanol, 1.0 g of 10% palladium-on-carbon and 5 ml of 2N sulfuric acid to give 0.8 g of the desired product.
EXAMPLE 17 [4S-(4α,12aα)]-4-(Dimethylamino)-7-(ethylmethylamino)-9-(formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate
The title compound is prepared by the procedure of Example 3, using 1.5 g of product from Example 16, 0.235 g of anhydrous sodium acetate, 25 ml of 98% formic acid and 3.7 ml of acetic anhydride to give 1.35 g of the desired product.
EXAMPLE 18 [4S-(4α,12aα)]-9-(Acetylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate
To a solution of 3.2 g of [4S-(4α,12aα)]-9-amino- 4-dimethylamino-1, 2,3,4,4a,5,5a,6,11,11a,12,12 a-dodecahydro-10,12aα-dihydroxy-1, 3,11,12-tetraoxo-2-naphthacenecarboxamide, prepared by the procedure described in U.S. Pat. No. 3,239,499, in 50 ml of water is added a solution of 2.5 g of sodium acetate in 12 ml of water. The mixture is cooled to 0° C. and 1 ml of acetic anhydride is added with stirring. The reaction is stirred for 20 minutes, 0.5 ml of ammonium hydroxide is added and stirred for 5 minutes. Two and one half ml of sulfuric acid is added, the reaction is extracted twice with n-butyl alcohol, the combined organic layers are washed with water and concentrated in vacuo. The residue is dissolved in methyl alcohol and added dropwise to 500 ml of diethyl ether. The solid is collected and dried to give 2.3 g of the desired product.
MS(FAB): m/z 472 (M+H) and 570 (M+H2SO4H).
EXAMPLE 19 [4S-(4α,12aα)]-4-(Dimethylamino)-9-(formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide monohydrochloride
To a 0° C. solution of 1.06 g of [4S-(4α,12aα)]-9-amino-4-dimethylamino-1, 2,3,4,5a, 6,11,11a,12,12a-dodecahydro-10,12aα-dihydroxy-1,3,11,12 -tetraoxo-2-naphthacenecarboxamide, prepared by the procedures described in U.S. Pat. No. 3,239,499, in 50 ml of formic acid is added 2.4 ml of acetic anhydride. After stirring for 5 minutes, the cooling bath is removed and the reaction is stirred for 55 minutes. The mixture is added to 400 ml of diethyl ether. The resulting solid is collected, washed with diethyl ether and dried to give 1.1 g of the desired product.
MS(FAB): m/z 458 (M+H).
This procedure is a modification of U.S. Pat. No. 3,239,499.
EXAMPLE 20 [4S-(4α,12aα)]-4-(Dimethylamino)-9-(formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-2-naphthacenecarboxamide sulfate
To a well stirred 0° C. solution of 0.278 g of product from Example 19 in 10 ml of sulfuric acid is added, in portions, 0.1344 g of N-iodosuccinimide. The reaction is stirred at 0° C. for 20 minutes then poured into 500 ml of diethyl ether. The resulting solid is collected, washed with diethyl ether and dried to give 0.251 g of the desired product.
MS (FAB): m/z 584 (M+H).
EXAMPLE [4S-(4α,12aα)]-4-(Dimethylamino)-9-(formylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-nitro-1,11-dioxo-2-naphthacenecarboxamide sulfate
To a well stirred 0° C. solution of 0.278 g of product from Example 19 in 10 ml of sulfuric acid is added 0.3 ml of 10% nitric acid in sulfuric acid. The reaction is stirred at 0° C. for 20 minutes then poured into 500 ml of diethyl ether. The resulting solid is collected, washed with diethyl ether and dried to give 0.26 g of the desired product.
MS (FAB): m/z 503 (M+H).
EXAMPLE 22 [4S-(4α,12aα)]-4-(Dimethylamino)-9-(formylamino)-7-(1-methylethyl)amino-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide sulfate
A solution of 0.2 g of product from Example 21 (1:2 salt), 0.5 ml of acetone, 0.5 ml of 0.5N sulfuric acid and 10 ml of 2-methoxyethanol is shaken under 35 lbs. of hydrogen, in the presence of platinum oxide, for 2 hours. The catalyst is removed by filtration, the filtrate concentrated in vacuo to ½ volume and poured into diethyl ether. The resulting solid is collected and dried to give 0.135 g of the desired product.
EXAMPLE 23 [4S-(4α,12aα]-(4,7-Bis(dimethylamino)-1,4,4a,5,5a,-6,11,12 a-octahydro-3,10,12,12a-tetrahydroxy-9-[(methoxyacetyl)amino]-1,11-dioxo-2-naphthacenecarboxamide
To a well stirred solution of 0.055 g of product from Example 2, 0.200 g of sodium bicarbonate and 1 ml of N-methylpyrrolidone is added a solution of 0.011 g of methoxyacetyl chloride in 0.5 ml of acetonitrile. After 5 minutes, the suspension is filtered and the filtrate diluted with 50 ml of tert-butyl methyl ether. The resulting solid is collected and dried to give 0.040 g of the desired product.
MS (FAB): m/z 545 (M+H).
EXAMPLE 24 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(cyclopropylcarbonylamino)- 1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide
The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g-of sodium bicarbonate, 1.0 ml N-methylpyrrolidone, 0.010 g of cyclopropanecarbonyl chloride and 0.5 ml of acetonitrile to give 0.030 g of the desired product.
EXAMPLE 25 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(chloroacetylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1 ml of N-methylpyrrolidone, 0.013 g of chloroacetyl chloride and 0.5 ml of acetonitrile to give 0.035 g of the desired product.
EXAMPLE 26 [4S-(4α,12aα)]-9-[(4-Bromo-1-oxobutyl)amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide
The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1 ml of N-methylpyrrolidone, 0.025 g of 4-bromobutyryl chloride and 0.5 ml of acetonitrile to give 0.050 g of the desired product.
MS(FAB): m/z 622 (M+H).
EXAMPLE 27 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[(1-oxo-2-propenyl)amino]-2-naphthacenecarboxamide
The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1.0 ml N-methylpyrrolidone, 0.011 g of acryloyl chloride and 0.5 ml of acetonitrile to give 0.040 g of the desired product.
MS(FAB): 513 (M+H).
EXAMPLE 28 [4S-(4α,12aα)]-9-[[(Acetyloxy)acetyl]amino]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide
The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1.0 ml of N-methylpyrrolidone, 0.013 g of acetoxyacetyl chloride and 0.5 ml of acetonitrile to give 0.040 g of the desired product.
MS(FAB): m/z 573 (M+H).
EXAMPLE 29 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(phenylthio-acetylamino)-1,4,4a,5,5a,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
The title compound is prepared by the procedure of Example 23, using 0.110 g of product from Example 2, 0.40 g of sodium bicarbonate, 4.0 ml of N-methylpyrrolidone, 0.035 g of phenylthioacetyl chloride and 0.5 ml of acetonitrile to give 0.075 g of the desired product.
EXAMPLE 30 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(pyruvyl-amino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
The title compound is prepared by the procedure of Example 23, using 0.110 g of product from Example 2, 0.40 g of sodium bicarbonate, 1.0 ml of N-methylpyrrolidone, 0.018 g of pyruvyl chloride and 0.5 ml of acetonitrile to give 0.060 g of the desired product.
EXAMPLE 31 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(ethoxy-carbonylacetylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1.0 ml of N-methylpyrrolidone, 0.013 g of ethyl malonyl chloride and 0.5 ml of acetonitrile to give 0.035 g of the desired product.
EXAMPLE 32 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(4-bromo-phenylacetylamino)-1,4,4a,5,5a,6,11,12-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide
The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1.0 ml of N-methylpyrrolidone, 0.018 g of 4-bromophenylacetyl chloride and 0.5 ml of acetonitrile to give 0.040 g of the desired product.
EXAMPLE 33 [4S-(4α,12aα)]-9-(Benzoylamino)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
To a vigorously stirring solution of 0.066 g of product from Example 2, 0.085 g of sodium acetate and 3 ml of tetrahydrofuran is added 0.015 ml of benzoyl chloride and 0.25 ml of water. The reaction is stirred for 1 hour. The organic layer is decanted, washed with saturated sodium chloride, dried and concentrated in vacuo. The residue is chromatographed on acid-washed diatomaceous earth using a two phase system of hexane-ethyl acetate:2-methoxyethanol:water (50:50:17:6) to give in the second void volume 0.030 g of the desired product as an orange solid.
MS (FAB): m/z 577 (M+H). 1H NMR (d6-DMSO): δ 2.45 (s,6H,C(4)N(CH3)2), 2.57(s,6-H,C(7)N(CH3)2), 7.5-7.6(m, 3H, benzoyl), 7.86(s,1H,H-8), 7.96(d,J=7Hz,2H, benzoyl).
EXAMPLES 34-41
(Table I)
Substantially following the method described in detail hereinabove in Example 33 using [4S-(4α,12aα)]-9-amino-4,7-bis(dimethylamino)-1,4,4a, 5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (product from Example 2), the compounds of this invention listed below in Examples 34-41 are prepared.
TABLE I
Ex. Acid Chloride Product Spectra
34 4-Methoxybenzoyl [4S-(alpha,12aalpha))]-4,7- MS(FAB): m/z 607(M+H); 1H NMR
chloride Bis(dimethylamino)-1,4,4a,5 (d6-DMSO): delta 2.45(s, 6H,
5a,6,11,12a-octahydro-3,10, C(4)NMe2), 2.57(s, 6H, C(7)
12,12a-tetrahydroxy-9-[(4- NME2), 7.06(d, J=9Hz, 2H of 4-
methoxybenzoyl)amino]-1,11- methoxybenzoyl), 7.84(s, 1H,
dioxo-2-naphthacenecarbox- H-8), 7.97(d, J=9Hz, 2H of 4-
amide methoxybenzoyl)
35 2-Methylbenzoyl [4S-(4alpha,12aalpha))]-4,7- MS(FAB): m/z 591(M+H); 1H NMR
chloride Bid(dimethylamino)-1,4,4a,5 (d6-DMSO): delta 2.52(m, 12H,
5a,6,11,12a-octahydro-3,10, C(4)NMe2, & C(7)NMe2), 7.25-
12,12a-tetrahydroxy090[(2- 7.56(m, 4H from 2-methyl-
methylbenzoyl)amino]-1,11- benzoyl), 7.98(s, 1H, H-8)
dioxo-2-naphthacenecarbox-
amide
36 2-Fluorobenzoyl [4S-(4alpha,12aalpha))]-4,7- MS(FAB): m/z 595(M+H): 1H NMR
chloride Bis(dimethylamino)-9-[(2- (d6-DMSO): delta 2.47-2.51
fluorobenzoyl)amino]-1,4,4a, (m, 6H, C(4)NMe2), 2.57(bs, 6H,
5,5a,6,11,12a-octahydro-3,10, C(7)NMe2), 7.39(m, 2H from
12,12a-tetrahydroxy-1,11- 2-fluorobenzoyl), 7.63(m, 1H
dioxo-2-naphthacenecarbox- from 2-fluorobenzoyl), (m,
amide 1H from 2-fluorobenzoyl),
8.24(s, 1H, H-8)
37 Pentafluoro- [4S-(4alpha,12aalpha)]-4,7- MS(FAB): m/z 667(M+H); 1H NMR
benzoyl chloride Bis(dimethylamino)-1,4,4a, (d6-DMSO): delta 2.5(m, 12H,
5,5a,6,11,12a-octahydro-3,10, C(4)NMe2 & C(7)NMe2), 8.08
12,12a-tetrahydroxy-9- (s, 1H, H-8)
[(pentafluorobenzoyl)amino]-
1,11-dioxo-2-naphthacenecar-
boxamide
38 3-Trifluoro- [4S-(4alpha,12aalpha)]-4,7- MS(FAB): m/z 645(M+H); 1H NMR
methylbenzoyl Bis(dimethylamino)-1,4,4a,5, (d6-DMSO): delta 250(m, 6H,
chloride 5a,6,11,12a-octahydro-3,10, C(4)NMe2), 2.57(m, 6H, C(7)
12,12a-tetrahydroxy-1,11- NMe2), 7.85(m, 2H of 3-tri-
dixox-9-[[3-(trifluoro- fluoromethylbenzoly), 7.99
methyl)benzoyl]amino]-2- (m, 1H or 3-trifluoromethyl-
naphthacenecarboxamide benzoyl), 8.28(1H of 3-tri-
fluoromethylbenzoyl), 8.33
(s, 1H, H-8), 8.31-8.42(m, 2H)
39 2-Furoyl [4S-(alpha,12aalpha)]-4,7- MS(FAB): m/z 567(M+H); 1H NMR
chloride Bis(dimethylamino)-9-[(2- (d6-DMSO): delta 2.47(m, 6H,
furanylcarbonyl)amino]-1,4, C(4)NMe2), 2.56(s, 6H, C(7)
4a,5,5a,6,11,12a-octahydro- NMe2), 6.73(s, 1H of furanyl)
3,10,12,12a-tetrahydroxy- 7.31(s, 1H of furanyl), 7.95
1,11-dioxo-2-naphthacene- (s, 1H of furanyl(, 8.00(s,
carboxamide 1H, H-8)
40 2-Thiophene- [4S-(4alpha,12aalpha)]-4,7- MS(FAB): m/z 583(M+H); 1H NMR
carbonyl Bis(dimethylamino)-1,4,4a, (d6-DMSO): delta 2.49(m, 6H,
chloride 5,5a,6,11,12a-octahydro- C(4)NMe2), 2.56(s, 6H, C(7)
3,10,12,12a-tetrahydroxy- NMe2), 7.21(m, 1H of
1,11-dioxo-9-[(2-thienyl- thienyl), 7.70(s, 1H, H-8),
carbonyl)amino]-2-naphtha- 7.85(m, 1H of thienyl), 8.01
cenecarboxamide (m, 1H of thienyl)
41 4-Nitro- [4S-(4alpha,12aalpha)]-4,7- MS(FAB): m/z 622(M+H); 1H NMR
benzoyl Bis(dimethylamino)-1,4,4a, (d6-DMSO): delta 2.50(m, 6H,
chloride 5,5a,6,11,12a-octahydro- C(4)NMe2), 2.57(s, 6H, C(7)
3,10,12,12a-tetrahydroxy-9- NMe2), 7.76(s, 1H, H-8), 8.20
[(4-nitrobenzoyl)amino]- (d, J=9Hz, 2H of 4-nitro-
1,11-dixox-2-naphthacene- nitrobenzoyl), 8.36(d, J=9Hz, 2H of
carboxamide 4-nitrobenzoyl)
EXAMPLE 42 [4S-(4α,12aα)]-9-[(4-Aminobenzoyl)amino]-4,7-Bis-dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide sulfate
A mixture of 0.030 g of product from Example 41, 0.010 g of 10% palladium-carbon, 1.5 ml of 2-methoxyethanol and 0.175 ml of 2N sulfuric acid, in a pressure bottle, is shaken under 30 lbs. of hydrogen pressure for 40 minutes. The catalyst is removed by filtration and the filtrate is concentrated in vacuo and codistilled with benzene. The oily residue is dissolved in 0.5 ml of 2-methoxyethanol, precipitated with diethyl ether and the solid collected to give 0.018 g of the desired product.
MS(FAB): m/z 592 (M+H).
EXAMPLE 43 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-[[(4-dimethylamino)benzoyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
A mixture of 0.065 g of product from Example 41, 2.0 ml of 2-methoxyethanol, 0.025 g of 10% palladium-on-carbon, 0.4 ml of 2N sulfuric acid and 0.3 ml of 37% aqueous formaldehyde, in a pressure bottle, is shaken under 30 lbs. of hydrogen pressure for 50 minutes. The catalyst is removed by filtration and the filtrate is concentrated in vacuo and codistilled with heptane. The oily residue is dissolved in 1.0 ml of 2-methoxyethanol, precipitated with diethyl ether to give 0.085 g of the desired product as the sulfate salt. The sulfate salt is dissolved in 0.5 ml of water and 6 ml of tetrahydrofuran followed by the addition of 0.10 g of sodium acetate. The organic layer is washed with saturated sodium chloride, dried and concentrated in vacuo. The residue is triturated with ethyl acetate/heptane to give 0.035 g of the desired product as the free base.
MS (FAB): m/z 620 (M+H).
1H NMR (d6-DMSO): δ 2.50(m,6H,C(4)NMe2), 2.57(s, 6H, C(7) NMe2), 3.33 (s,6H, NMe2 of 4-dimethylaminobenzoyl), 7.76(s,1H,H-8), 8.20(d,J=9Hz,2H of 4-dimethylaminobenzoyl), 8.37(d,J=9Hz,2H of 4-dimethylaminobenzoyl).
EXAMPLE 44 [7S-(7α,10aα)]-[2-[[9-(Aminocarbonyl)-4,7-Bis-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-β-naphthacenyl]-amino]-2-oxoethyl]carbamic acid 1,1-dimethylethyl ester
A mixture of 0.850 g of product from Example 2 (as the disulfate), 0.680 g of sodium acetate in 25 ml of tetrahydrofuran and 5 ml of water is stirred at 25° C. for 5 minutes. The solution is treated with 0.359 g of (succinimyloxycarbonyl)methyl carbamic acid tert-butyl ester, stirred for 2 hours and extracted with chloroform. The organic layer is concentrated in vacuo to give 0.50 g of the desired product.
MS(FAB): m/z 630 (M+H).
EXAMPLE 45 [4S-(4α,12aα)]-9-[(Aminoacetyl)amino]-4,7-Bis-dimethylamino)-1,4,4a,5.,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide mono(trifluoroacetate).
A solution of 0.030 g of product from Example 44 and 1.0 ml of trifluoroacetic acid is maintained at 24° C. for 24 hours followed by concentrating in vacuo. The residue is triturated with methyl alcohol and the solid collected to give 0.024 g of the desired product.
MS (FAB): m/z 530 (M+H).
EXAMPLE 46 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide sulfate
A mixture of 0.030 g of product from Example 45, 0.020 g of 10% palladium-on-carbon, 0.5 ml of 37% formaldehyde, 1.5 ml of 2-methoxyethanol and 0.175 ml of 2N sulfuric acid, in a pressure bottle, is shaken under 30 lbs. of hydrogen pressure for 40 minutes. The catalyst is removed by filtration and the filtrate is concentrated in vacuo and codistilled with benzene. The oily residue is dissolved in 0.5 ml of 2-methoxyethanol, precipitated with diethyl ether and the precipitate collected to give 0.025 g of the desired product.
EXAMPLE 47 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[(phenylsulfonyl)amino]-2-naphthacenecarboxamide
A mixture of 0.30 g of product from Example 2, 0.40 g of sodium acetate in 10 ml of tetrahydrofuran and 1.5 ml of water is stirred for 10 minutes under argon. The organic layer is separated, dried over anhydrous sodium sulfate and treated with 0.125 ml of benzenesulfonyl chloride and 0.60 g of sodium bicarbonate. The reaction is stirred vigorously for 1.5 hours. The organic layer is decanted and codistilled with heptane. The residue is dissolved in ethyl acetate, dried and concentrated in vacuo. The residue is chromatographed on diatomaceous earth using hexane:ethyl acetate:2-methoxyethanol:water (35:65:15:5) to give 0.036 g of the desired product as a yellow solid.
MS(FAB): m/z 613 (M+H).
1H NMR (CDCl3): δ 2.44(bs,6H,C(4)NMe2), 2.55(s,6H, C(7)NMe2, 7.38-7.45(m,2H,m-H's from benzenesulfonyl), 7.52-7.56(m, 1H,p-H from benzenesulfonyl), 7.58(s,1H,H-8), 7.78(dj=7Hz,2H,o-H's from benzenesulfonyl).
EXAMPLES 48-53
(Table II)
Substantially following the method described in detail hereinabove in Example 47 using [4S-(4α,12aα)]-9-amino-4,7-bis(dimethylamino)-1,4,4a, 5,5a,6,11,12 a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate (product from Example 2) and the appropriate alkyl, aryl or heteroarylsulfonyl chloride, the compounds of this invention listed below in Examples 48-53 are prepared.
TABLE II
Ex. Sulfonyl Chloride Product Spectra
48 4-Chlorobenzene- [4S-(4alpha,12aalpha))]-9- MS(FAB): m/z 622(M+H); 1H NMR
sulfonyl chloride [[4-chlorophenyl)sulfonyl]- (d6-DMSO): delta 2.48(m, 12H,
amino]-4,7-bis(dimethyl- C(4)NMe2 & C(7)NMe2), 7.16
amino)-1,4,4a,5,5a,6,11,12a- (s, 1H, H-8), 7.62(d, J=9Hz, 2H
tetrahydroxy-1,11-dioxo-2- of 4-chlorobenzenesulfonyl),
naphthacenecarboxamide 7.75(d, J=9Hz, 2H of 4-chloro-
benzenesulfonyl)
49 3-Nitrobenzene- [4S-(4alpha,12aalpha))]-4,7- MS(FAB): m/z 658(M+H); 1H NMR
sulfonyl chloride Bis(dimethylamino)-1,4,4a,5 (d6-DMSO): delta 2.44-2.45
5a,6,11,12a-octahydro-3,10, (m, 12H, C(4)NMe2) & C(7)NMe2)
12,12a-tetrahydroxy-9-[(3- 7.51-7.62(m, 3H of 3-nitro-
nitrophenyl)sulfonyl]amino]- benzenesulfonyl), 7.74-7.78
1,11-dioxo-2-naphthacenecar- (m, 1H or 3-nitrobenzenesul-
boxamide fonyl), 7.75(s, 1H, H-8)
50 4-Nitrobenzene- [4S-(4alpha,12aalpha))]-4,7- MS(FAB): m/z 658(M+H); 1H NMR
sulfonyl chloride Bis(dimethylamino)-1,4,4a,5, (CDCl3): delta 2.46(s, 6H, C(4)
5a,6,11,12a-octahydro-3,10, NMe2), 2.58(s, 6H, C(7)NMe2),
12,12a-tetrahydroxy-9- 7.59(s, 1H, H-8), 7.96(d, J=
[[(4-nitrophenyl)sulfonyl] 9Hz, 2H of 4-nitrobenzene-
amino]-1,11-dioxo-2- sulfonyl), 8.25(d, J=9Hz,
naphthacenecarboxamide 2H of 4-nitrobenzene-
sulfonyl).
51 2-Thiophene [4S-(4alpha,12aalpha)]-4,7- MS(FAB): m/z 619(M+H); 1H NMR
sulfonyl Bis(dimethylamino)-1,4,4a,5, (d6-DMSO): delta, 2.50(m, 6H,
chloride 5a,6,11,12a-octahydro-3,10, C(4)NMe2), 2.54(s, 6H, C(7)
12,12a-tetrahydroxy-1,11- NMe2), 7.14(m, 1H or thienyl),
dioxo-9-[(2-thienylsulfonyl) 7.20(m, 1H or thienyl), 7.51
amino]-2-naphthacenecarbox- (s, 1H of thienyl), 7.91(s,
amide 1H, H-8)
52 2-Acetamido-4- [4S-(4alpha,12aalpha)]-9- MS(FAB): m/z 691(M+H); 1H NMR
methyl-5-thiazole [[(2-(Acetylamino)-4-methyl- (CDCl3) delta 2.21(s, 3H thia-
sulfonyl 5-thiazoyl]sulfonyl]amino]- zoyl H3CCONH), 2.40(s, 3H,
chloride 4,7-bis(dimethylamino)-1,4, thiazoyl H3C), 2.54(s, 6H, C(4)
4a,5,5a,6,11,12a-octahydro- NMe2), 2.57(s, 6H, C(7)NMe2),
3,10,12,12a-tetrahydroxy-1, 7.65(s, 6H, C(7)NMe2, 7.65(s,
11-dioxo-2-naphthacenecar- 1H, H-8)
boxamide
53 Ethane sulfonyl [4S-(4alpha,12aalpha)]-4,7- MS(FAB): m/z 565(M+H); 1H NMR
chloride Bis(dimethylamino)-9- (CDCl3): delta 0.88(t, 3H, CH 3
[(ethylsulfonyl)amino]-1,4, CH2SO2), 2,4-2.6(m, 12H, C(4)
4a,5,5a,6,11,12a-octahydro- NMe2 & C(7)NMe2), 3.34(q, 2H,
3,10,12,12a-tetracydroxy- CH3CH2SO2), 7.61(s, 1H, H-8)
1,11-dioxo-2-naphthacene-
carboxamide
EXAMPLE 54 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-(formylamino)-1,4,4a,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-N-(1-pyrrolidinylmethyl)-2-naphthacenecarboxamide
A solution of 0.30 g of product from Example 3 and 1.2 equivalents of 30% aqueous formaldehyde in 6.0 ml of 2-methoxyethanol is treated with 5.0 equivalents of pyrrolidine. The reaction is stirred vigorously at room temperature for 1.5 hours. The crystalline solid is collected and dried to give 0.25 g of the desired product.
MS (FAB): m/z 584 (M+H).
EXAMPLE 55 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,-6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[(methanesulfonyl)amino]-1,11-dioxo-2-naphthacene-carboxamide
A mixture of 0.30 g of product from Example 2, 0.40 g of sodium acetate in 10 ml of tetrahydrofuran and 1.5 ml of water is stirred for 10 minutes at room temperature under argon. The organic layer is separated, dried over sodium sulfate, filtered and treated with 0.10 ml of methanesulfonyl chloride and 0.60 g of sodium bicarbonate. The reaction is stirred vigorously for 1.5 hours. The organic layer is decanted and codistilled with heptane. The residue is dissolved in ethyl acetate, dried and concentrated in vacuo. The crude product is chromatographed on diatomaceous earth using hexane:ethyl acetate:2-methoxyethanol:water (35:65:15:5) to give 0.016 g of the desired product as a yellow solid.
MS (FAB): m/z 551 (M+H).
EXAMPLE 56 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-[(methanesulfonyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-N-(pyrrolidinylmethyl)-2-naphthacenecarboxamide
A solution of 0.30 g of product from Example 55 and 1.2 equivalents of 30% aqueous formaldehyde in 6.0 ml of 2-methoxyethanol is treated with 5.0 equivalents of pyrrolidine. The reaction is stirred vigorously at room temperature for 1.5 hours. The crystalline solid is collected and dried to give 0.250 g of the desired product.
MS (FAB): m/z 634 (M+H).
EXAMPLE 57 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[[(phenylmethoxy)acetyl]amino]-2-naphthacenecarboxamide
The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1.0 ml of N-methylpyrrolidine, 0.018 g of benzyloxyacetyl chloride and 0.5 ml of acetonitrile to give 0.060 g of the desired product.
MS(FAB): m/z 622 (M+H).
EXAMPLE 58 [7S-(7α,10aα)]-[[9-(Aminocarbonyl)-4,7-Bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]oxoacetic acid ethyl ester
The title compound is prepared by the procedure of Example 23, using 0.055 g of product from Example 2, 0.20 g of sodium bicarbonate, 1.0 ml of N-methylpyrrolidone, 0.015 g of ethyl oxalyl chloride and 0.5 ml of acetonitrile to give 0.030 g of the desired product.
MS (FAB): m/z 574 (M+H).
EXAMPLE 59 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[(hydroxyacetyl)amino]-1,11-dioxo-2-naphthacene-carboxamide
A mixture of 0.048 g of product from Example 28 and 0.6 ml of concentrated sulfuric acid is stirred at room temperature for 2 hours, poured into diethyl ether and the precipitated salt collected. The salt is dissolved in 10 ml of tetrahydrofuran, 0.250 g of sodium acetate is added and the mixture stirred for 1 hour. The reaction is filtered and the filtrate is concentrated in vacuo. The residue is chromatographed on a poly(styrene-vinyl benzene)copolymer column with water:acetonitrile (1:1) to give 0.018 g of the desired product as a light yellow solid.
MS (FAB): m/z 532 (M+H).
EXAMPLE 60 [4S-(4α,12aα)]-9-(Acetylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide sulfate
To a 0° C. solution of 1.06 g of [4S-(4α,12aα)]-9-amino-4-(dimethylamino)-1,2,3,4,4a,5,5a,6,11,11a,12,12a-dodecahydro-10,12aα-dihydroxy-1,3,11,12-tetraoxo-2-naphthacenecarboxamide, prepared by the procedures described in U.S. Pat. No. 3,239,499, in 50 ml of acetic acid is added 2.4 ml of acetic anhydride. After 5 minutes, the reaction is allowed to warn to room temperature. The reaction mixture is poured into 500 ml of diethyl ether and the resulting precipitate is collected. The precipitate is washed with diethyl ether and dried to give 1.1 g of the desired product.
MS(FAB): m/z 472 (M+H).
EXAMPLE 61 [4S-(4α,12aα)]-4-(Dimethylamino)-9-(acetylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-2-naphthacenecarboxamide sulfate
To a stirring 0° C. solutin of 0.278 g of product from Example 60 in 10 ml of sulfuric acid is added, portionwise, 0.1344 g of N-iodosuccinimide. After stirring at 0° C. for 20 minutes, the reaction mixture is poured into 400 ml of diethyl ether. The resultant precipitate is collected, washed with diethyl ether and dried to give 1.1 g of the desired product as a solid.
MS(FAB): m/z 598 (M+H) and 696 (M+H2SO4+H).
EXAMPLE 62 [7S-(7α,10aα)]-[9-(Aminocarbonyl)-4,7-Bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]carbamic acid methyl ester
To a room temperature mixture of 0.60 g of product from Example 2 in 2 ml of 1-methyl-2-pyrrolidinone is added 0.60 g of sodium bicarbonate. The mixture is stirred for 5 minutes followed by the addition of 0.12 ml of methyl chloroformate. The reaction is stirred at room temperature for 30 minutes and filtered into 200 ml of t-butyl methyl ether. The resulting solid is collected and dried to give 0.370 g of the desired product.
MS (FAB): m/z 531 (M+H).
1H NMR (d6DMSO): δ 2.6(s,12H,C(4)NMe2 and C(7)NMe2), 3.7(m,3H,o-CH3), 7.8(s,1H,H-3), 8.7(s,1H,aromatic NH), 9.1 (d,2H, CONH2).
EXAMPLE 63 [7S-(7α,10aα)]-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]carbamic acid (2-diethylamino)ethyl ester
The title compound is prepared by the procedure of Example 62, using 0.443 g of product from Example 2, 2 ml of 1-methyl-2-pyrrolidone, 0.165 g of β-diethylaminoethyl chlorocarbonate hydrochloride and 0.443 g of sodium bicarbonate to give 0.350 g of the desired product.
1H NMR (d6DMSO): δ 1.2(m,6H,—N(CH2CH 3)2), 2.5(s,6H, C(7)NMe2), 2.7(s,6H,C(4)NMe2), 3.4(m,2H, OCH2CH2N), 3.51(m,4H,—N(CH 2CH3)2), 4.0(m,2H,—OC H 2CH2N), 6.8(s,1H,H-3), 9.0(d,2H,CONH2).
EXAMPLE 64 [7S-(7α,10aα)]-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]carbamic acid ethenyl ester
The title compound is prepared by the procedure of Example 62, using 0.189 g of product from Example 2, 1 ml of 1-methyl-2-pyrrolidone, 0.75 ml of acetonitrile, 0.20 g of sodium bicarbonate and 0.037 g of vinyl chloroformate to give 0.133 g of the desired product.
MS (FAB): m/z 548 (M+H).
1H NMR (d6DMSO+TFA): δ 4.35(s,1H,H-7), 4.6(d,1H, CH═CH2cis), 4.9(d,1H,CH═CH2,trans), 7.2(m,2H, —O—CH═CH2), 8.1(s,1H,H-3), 9.6 & 9.1(s,2H,CONH2), 9.61(s,H,aromatic NH)
EXAMPLE 65 [7S-(7α,10aα)]-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]carbamic acid 2-propenyl ester
The title compound is prepared by the procedure of Example 62, using 0.213 g of product from Example 2, 1 ml of 1-methyl-2-pyrrolidone, 0.75 ml of acetonitrile, 0.20 g of sodium bicarbonate and 0.054 g of allyl chloroformate to give 0.143 g of the desired product.
1H NMR (d6DMSO+TFA): δ 4.65(d,2H,═CHCH 2), 5.25(d,1H,CH═CH 2cis), 5.4(d,1H,CH═CH 2trans), 6.0(m, 1H,CH2═CH—CH2), 8.1(s,1H,H-3), 9.1(s,1H,aromatic NH), 9.6 & 9.0(s,2H,CONH2).
Substantially following the methods described in detail hereinabove in Example 23, the compounds of this invention listed below in Examples 66-82 are prepared. Example 72 uses the appropriate anhydride rather than the acid chloride.
EXAMPLE 66 [4S-(4α,12aα)]-4-(Dimethylamino)-9-[[(4-fluorophenoxy)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12 a-tetrahydroxy-7-iodo-1,11-dioxo-2-naphthacenecarboxamide. EXAMPLE 67 [7S-(7α,10aα)]-N-[9-(Aminocarbonyl)-4,7-Bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-2-thiopheneacetamide. EXAMPLE 68 [4S-(4α,12aα)]-9-[[(Diethylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide. EXAMPLE 69 [4S-(4α,12aα)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-iodo-9-[[(methylthio)acetyl]amino]-1,11-dioxo-2-naphthacene-carboxamide. EXAMPLE 70 [4S-(4α,12aα)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[(1-methyl-ethyl)amino]-1,11-dioxo-9-[(3,3,3-trichloro-1-oxopropyl)amino]-2-naphthacenecarboxamide. EXAMPLE 71 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-[(1,3-dioxo-3-Phenylpropyl)amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,12-dioxo-2-naphthacenecarboxamide. EXAMPLE 72 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-[4-(dimethylamino)-1-oxobutyl]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide. EXAMPLE 73 [4S-(4α,12aα)]-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[[(phenylsulfonyl)acetyl]amino]-2-naphthacene-carboxamide. EXAMPLE 74 [7S-(7α,10aα)]-N-[9-(Aminocarbonyl)-7-(dimethylamino)-5,5a,6,6a,7,10,10a-octahydro-1,8,10a,11-tetrahydroxy-4-iodo-10,12-dioxo-2-naphthacenyl]-5-methyl-2-furanacetamide. EXAMPLE 75 [7S-(7α,10aα)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12 -dioxo-2-naphthacenyl]-2-thiazoleacetamide. EXAMPLE 76 [7S-(7α,10aα)]-2-[[[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]-carbonyl]benzoic acid. EXAMPLE 77 [7S-(7α,10aα)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-3-methyl-2-oxo-1-imidazolidineacetamide. EXAMPLE 78 [7S-(7α,10aα)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-5,6-dimethylpyrazinecarboxamdie. EXAMPLE 79 [7S-(7α,10aα)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-3-methyl-3H-imidazo[4,5-b]pyridine-2-acetamide. EXAMPLE 80 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-[[(pentafluorophenyl)acetyl]amino]-2-naphthacenecarboxamide. EXAMPLE 81 [7S-(7α,10aα)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-4-iodo-10,12-dioxo-2-naphthacenyl]-4-ethyl-2,3-dioxo-1-piperazinecarboxamide. EXAMPLE 82 [7S-(7α,10aα)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-4-ethyl-2,3-dioxo-1-piperazinecarboxamide. EXAMPLES 83-86
Substantially following the methods described in detail hereinabove in Example 44, the compounds of this invention listed below in Examples 83-86 are prepared.
EXAMPLE 83 [7S-(7α,10aα)]-[2-[[9-Aminocarbonyl-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-1,12 10,12-dioxo-2-naphthacenyl]amino]-2-oxoethyl]carbamic acid 1,1-dimethylethyl ester. EXAMPLE 84 [7S-[2(S*),(7α,10aα)]]-[2-[[9-(Aminocarbonyl)-4-(diethylamino)-7-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-amino]-1-methyl-2-oxoethyl]carbamic acid 1,1-dimethylethyl ester. EXAMPLE 85 [7S-[2(S*),(7α,10aα)]]-[2-[[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-amino]-2-oxo-1-phenylethyl]carbamic acid 1,1-dimethylethyl ester. EXAMPLE 86 [7S-[2(S*),(7α,10aα)]]-[4-[[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-amino]-3-[[(1,1-dimethylethoxy)carbonyl]amino]-4-oxobutanoic acid 1,1-dimethylethyl ester. EXAMPLES 87-91
Substantially following the methods described in detail hereinabove in Example 45, the compounds of this invention listed below in Examples 87-91 are prepared.
EXAMPLE 87 [4S-(4α,12aα)]-9-[(Aminoacetyl)amino]-7-(diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide. EXAMPLE 88 [4S-(4α,9(S*),12aα)]-9-[(2-Amino-1-oxopropyl)-amino]-7-(diethylamino)-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide. EXAMPLE 89 [4S-(4α,9(S*),12aα)]-9-[(Aminophenylacetyl)amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacence-carboxamide. EXAMPLE 90 [7S-[2(S*),7α,10aα)]]-3-Amino-4-[[9-(aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]-4-oxobutanoic acid. EXAMPLE 91 [7S-[2(S*),7α,10aα)]]-4-[[9-(Aminocarbonyl)-4,7-bis-(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10,10a-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-amino]-3-(dimethylamino)-4-oxobutanoic acid. EXAMPLES 92-94
Substantially following the methods described in detail hereinabove in Example 47, the compounds of this invention listed below in Examples 92-94 are prepared.
EXAMPLE 92 [4S-(4α,12aα)]-4-(Dimethylamino)-9-[[(2,2-dimethylpropyl)sulfonyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-[(1-methylethyl)amino]-1,11-dioxo-2-naphthacenecarboxamide. EXAMPLE 93 [7S-(7α,10aα)]-4-[[[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]amino]-sulfonyl]butanoic acid. EXAMPLE 94 [4S-(4α,12aα)]-4-(Dimethylamino)-9-[[(1,1-dimethylethyl)sulfonyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-7-iodo-1,11-dioxo-2-naphthacenecarboxamide. EXAMPLE 95 [4S-(4α,12aα)]-4,7-Bis(dimethylamino)-9-[[(diethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide sulfate
The title compound is prepared by the procedure of Example 46, using 0.030 g of product from Example 45, 0.020 g of 10% palladium-on-carbon, 2.5 equivalents of acetaldehyde, 1.5 ml of 2-methoxyethanol and 0.175 ml of 2N sulfuric acid to give the desired product as a solid.
EXAMPLE 96
Dimethylaminoacetyl chloride hydrochloride
A mixture of 15 g of N,N-dimethylglycine hydrochloride (pulverized and dried in a vacuum oven at 45°-50° C. for 24 hours) and 13.85 ml of thionyl chloride is heated, very slowly, in a sand bath to 78° C. and kept at this temperature for 1½ hours. Toluene is added to the mixture and the excess liquid is removed by pipette. This step is repeated several times. The solid is then transferred to a Buchner funnel, washed with methylene chloride and dried under vacuum at 50° C. for 24 hours to yield 14.2 g of the desired intermediate.
EXAMPLE 97 [4S-(4alpha,12alpha)]-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride
To a mixture of 6.68 g of 9-amino-4,7-bis(dimethylamino)- 6-demethyl-6-deoxytetracycline in 120 ml of DMPU and acetonitrile is added 6.57 g of sodium carbonate. The mixture is stirred for 5 minutes, followed by the addition of 2.83 g of product from Example 96. The reaction is stirred for 1 hour, filtered and the filtrate is added slowly to a mixture of methylene chloride/diethyl ether (1200 ml/400 ml). The solid is collected, dissolved in 250 ml methyl alcohol and added slowly to 1600 ml of methylene chloride. The precipitate is collected, washed with diethyl ether and dried to give 5.75 g of the desired product.
MS(FAB): m/z 558 (M+H).
EXAMPLE 98 [4S-(4alpha,12alpha)]-9-[(Chloroacetyl)amino]-4,7-bis-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,1-dioxo-2-naphthacene-carboxamide dihydrochloride
To a room temperature solution of 0.334 g of 9-amino-4,7-bis(dimethylamino)- 6-demethyl-6-deoxytetracycline sulfate, 6 ml of 1,3-dimethyl-3,4,5,6-tetrahydro- 2(1H)pyrimidinone, hereinafter called DMPU, and 2 ml of acetonitrile is added 0.318 g of sodium carbonate. The mixture is stirred for 5 minutes followed by the addition of 0.068 g of chloroacetyl chloride. The reaction is stirred for 30 minutes, filtered, and the filtrate added dropwise to 100 ml of diethyl ether, containing 1 ml of 1M hydrochloric acid in diethyl ether. The resulting solid is collected and dried to give 0.340 g of the desired product.
MS(FAB): m/z 549 (M+H).
EXAMPLE 99 [4S-(4alpha,12alpha)]-9-[(Bromoacetyl)amino]-4,7-bis-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide dihydrochloride
The title compound is prepared by the procedure of Example 98, using 0.668 g of 9-amino-4,7-bis(dimethylamino)- 6-demethyl-6-deoxytetracycline sulfate, 6 ml of DMPU, 2 ml of acetonitrile, 0.636 g of sodium carbonate and 0.215 g of bromoacetyl chloride. Seven tenths of a gram of the desired product is obtained.
MS (FAB): m/z 593 (M+H).
EXAMPLE 100 [4S-(4alpha,12alpha)]-9-[(Bromoacetyl)amino]-4,7-bis-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide (free base)
To 0.20 g of product from Example 99 in 3 ml of 1,3-dimethyl-2-imidazolidenone is added 0.30 g of sodium bicarbonate. The reaction is stirred at room temperature for 15 minutes and filtered. The filtrate is added to 15 ml of diethyl ether and the resulting precipitate is collected to give 0.150 g of the desired product as the free base.
EXAMPLE 101 [4S-(4alpha,12aalpha)]-9-[(Bromoacetyl)amino]-4,7-bis-(dimethylamino)-1,4,4a,5,5a,6,10,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacene-carboxamide monohydrobromide
To a solution of 5.01 g of 9-amino-4,7-bis-(dimethylamino)- 6 -demethyl-6-deoxytetracycline, 100 ml of DMPU and 25 ml of acetonitrile is added 5.0 g of sodium carbonate. The reaction is stirred, under argon, at room temperature for 5 minutes, followed by the addition of 3.03 g of bromoacetyl bromide. The stirring is continued for an additional hour. The solid is collected and the filtrate is added slowly to isopropyl alcohol/diethyl ether (200 ml/750 ml). The yellow solid is collected, washed with isopropanol and diethyl ether to give 5.77 g of the desired intermediate.
MS (FAB) :m/z 593 (M+H).
EXAMPLE 102 [4S-(4alpha,12aalpha)]-9-[(2-Bromo-1-oxopropyl)-amino-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrobromide
The title compound is prepared by the procedure of Example 98, using 1.00 g of 9-amino-4,7-bis(dimethylamino)- 6-demethyl-6-deoxytetracycline, 1.0 g of sodium carbonate and 0.648 g of 2-bromopropionyl bromide to give 0.981 g of the desired product.
MS(FAB): m/z 607 (M+H).
EXAMPLE 103 [4S-(4alpha,12aalpha)]-9-[(4-Bromo-1-oxobutyl)amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride
The title compound is prepared by the procedure of Example 98, using 1.34 g of 9-amino-4,7-bis(dimethylamino)- 6-demethyl-6-deoxytetracycline sulfate, 1.3 g of sodium carbonate, 24 ml of DMPU, 8 ml of acetonitrile and 0.389 g of 4-bromobutyryl chloride to give 1.45 g of the desired product.
EXAMPLE 104 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride
To a solution of 0.15 g of product from Example 99 in 4 ml of DMPU is added 0.85 g of dimethylamine (40% in water). The reaction is stirred for 20 minutes followed by concentration in vacuo to remove any excess dimethylamine. The mixture is filtered and the filtrate added, dropwise, to 70 ml of isopropyl alcohol/diethyl ether (1:1). To this solution is added 1 ml of 1M hydrochloric acid/diethyl ether. The resulting precipitate is collected, washed with isopropyl alcohol and diethyl ether, and dried to give 0.11 g of the desired product.
MS (FAB): m/z 558 (M+H).
EXAMPLE 105 [4S-(4alpha,12aalpha]]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[[(methylamino)acetyl]amino]-1,11-dioxo-2-naphthacenecarboxamide dihydrochloride (331,256)
A mixture of 0.1258 g of product from Example 99, 5 ml of 40% methylamine in water and 5 ml of methyl alcohol, under Argon, is stirred at room temperature for 30 minutes. The excess methylamine is removed in vacuo and the residue diluted with a small volume of methyl alcohol. The diluted reaction solution is added dropwise to 100 ml of diethyl ether containing 1 ml of 1M hydrochloric acid in diethyl ether and 10 ml of isopropyl alcohol. The resulting solid is collected and dried to give 0.106 g of the desired product.
MS (FAB): m/z 544 (M+H).
Substantially following the methods described in detail herein above in Example 105, the compounds of this invention listed below in Examples 106-125 are prepared.
Starting
Example Material Rx MS(FAB):
# Name Prod. of Exp. Reactant Time m/z
106 [7S-(7alpha,10aalpha)[-N-[(Aminocarbonyl)-4,7-bis(di- 99 Morpholine 0.5 hr. 600(M+H)
methylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-
tetrahydroxy-10,12-dioxo-2-naphthacenyl]-4-morpholineacet-
amide dihydrochloride.
107 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[(ethyl- 99 Ethylamine   2 hr. 558(M+H)
amino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,- (70% in water)
12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
dihydrochloride.
108 [4S-(4alpha,12aalpha)]-9-[[(Cyclopropylamino)acetyl]amino]- 99 Cyclopropylamine   2 hr. 570(M+H)
4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,-
12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide di-
hydrochloride.
109 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[(butyl- 99 Butylamine   2 hr. 586(M+H)
amino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,-
12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihy-
drochloride.
110 [4S-(4alpha,12aalpha)]-9-[[(Diethylamino)acetyl]amino]-4,7- 99 Diethylamine   2 hr. 586(M+H)
bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,12,12,-
12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide dihy-
drochloride.
111 [7S-(7alpha,10aalpha)-N-[9-(Aminocarbonyl)-4,7-bis(dimethyl 99 Pyrrolidine 0.5 hr. 584(M+H)
amino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahy-
droxy-10,12-dioxo-2-naphthacenyl]-1-pyrrolidineacetamide
dihydrochloride.
112 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a- 99 Isobutylamine   2 hr. 586(M+H)
6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-9-[[[(2-methyl-
propyl)amino]acetyl]amino]-1,11-dioxo-2-naphthacenecarbox-
amide dihydrochloride.
113 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-bis(di- 99 Piperdine   1 hr. 598(M+H)
methylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-
tetrahydroxy-10,12-dioxo-2-naphthacenyl]-1-piperidineacet-
amide dihydrochloride.
114 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-bis(di- 99 Imidazole   1 hr. 579(M+H)
methylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-
tetrahydroxy-10,12-dioxo-2-naphthacenyl]-1H-imidazole-1-
acetamide dihydrochloride.
115 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a- 99 Propylamine 0.75 hr.  570(M+H)
6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-
[[(propylamino)acetyl]amino]-2-naphthacenecarboxamide
dihydrochloride.
116 [4S-(4alpha,12aalpha)]-4,7-Bis)dimethylamino)-9-[[dimethyl- 99 Dimethylamine 0.5 hr. 558(M+H)
amino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,
12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
disulfate.
117 [4S-(4alpha,12aalpha)]-4,7-Bis(dimethylamino)-9-[[dimethyl- 99 Dimethylamine 0.5 hr. 558(M+H)
amino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,
12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide.
118 [4S-(4alpha,12aalpha)-4,7-Bis(dimethylamino)-9-[[(hexyl- 99 n-Hexylamine   2 hr. 614(M+H)
amino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,-
12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
dihydrochloride.
119 [4S-(4alpha,12aalpha)-4,7-Bis(dimethylamino)-9-[[(dimethyl- 102 Dimethylamine 2.5 hr. 572(M+H)
amino)-1-oxopropyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3, (40% in water)
10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
dihydrochloride.
120 [4S-(4alpha,12aalpha)-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11, 102 Methylamine   2 hr. 558(M+H)
12a-octahydro-3,10,12,12a-tetrahydroxy-9-[[2-methylamino)-1- (40% in water)
oxopropyl]amino]-1,11-dioxo-2-naphthacenecarboxamide
dihydrochloride.
121 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethyl- 102 Pyrrolidine   1 hr. 598(M+H)
amino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetra-
droxy-10,12-dioxo-2-naphthacenyl]-alpha-methyl-1-pyrrolidine-
acetamide dihydrochloride.
122 [4S-(4alpha,12aalpha)-4,7-Bis(dimethylamino)-9-[[4-dimethyl- 103 Dimethylamine   2 hr. 586(M+H)
amino)-1-oxobutyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10, (40% in water)
12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
dihydrochloride.
123 [4S-(4alpha,12aalpha)]-9-[[(Butylmethylamino)acetyl]amino]- 99 N-Methylbutyl-   2 hr. 600(M+H)
4,7-bis(dimethylamino)1,4,4a,5,5a,6,11,12a-octahydro-3,10,12, amine
12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
dihydrochloride
124 [4S-(4alpha,12aalpha)-4,7-Bis(dimethylamino)-1,4,4a,5,5a- 99 Amylamine   2 hr. 600(M+H)
6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-
[[[(pentylamino)acetyl]amino]-2-naphthacenecarboxamide
dihydrochloride.
125 [4S-(4alpha,12aalpha)-4,7-Bis(dimethylamino)-1,4,4a,5,5a- 99 Benzylamine   1 hr. 620(M+H)
6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-9-
[[[phenylmethyl)amino]acetyl]amino]-2-
naphthacenecarboxamide dihydrochloride.
EXAMPLE 126 [7S-(7alpha,10aalpha)]-N-[2-[[9-(Aminocarbonyl)-4,7-bis(dimethylamino)5,5a,6,6a,7,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-amino]-2-oxoethyl]glycine phenylmethyl ester
To 0.30 g of benzylglycine hydrochloride in 3 ml of 1,3-dimethyl-2-imidazolidinone is added 0.60 g of sodium bicarbonate. The mixture is stirred at room temperature for 15 minutes and filtered. To the filtrate is added 0.20 g of product from Example 100. The reaction mixture is stirred at room temperature for 1 hour and then added to diethyl ether. The resulting solid is collected.
EXAMPLE 127 [7S-(7alpha,10aalpha]]-N-[2-[[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-naphthacenyl]-amino]-2-oxoethyl]glycine
One-tenth of a gram of product from Example 126 in 10 ml of monomethyl ethylene glycol is reduced catalytically, in a Parr shaker, with 0.10 g of 10% palladium on carbon, at 30 psi of hydrogen, for 2 hours. The reaction mixture is filtered and the filtrate concentrated to give 0.050 g of the desired product.
CI-MS: m/z 588 (M+H).
General Procedure for the Preparation of Mannich Bases
A mixture of 0.5 g of product from Example 117, 3 ml of t-butyl alcohol, 0.55 ml of 37% formaldehyde, and 0.55 ml of pyrrolidine, morpholine or piperidine is stirred at room temperature for 30 minutes followed by heating at 100° C. for 15 minutes. The reaction mixture is cooled to room temperature and triturated with diethyl ether and hexane. The solid is collected, washed with diethyl ether and hexane, and dried to give the desired product.
In this manner the following compounds are made:
EXAMPLE 128 [4S-(4alpha12aalpha]]-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,122a-tetrahydroxy-1,11-dioxo-N-(1-pyrrolidinyl-methyl)-2-naphthacenecarboxamide EXAMPLE 129 [4S-(4alpha,12aalpha]]-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-N-(4-morpholinyl-methyl)-2-naphthacenecarboxamide EXAMPLE 130 [4S-(4alpha,12aalpha)-4,7-Bis(dimethylamino)-9-[[(dimethylamino)acetyl]amino]-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-N-(1-piperidinylmethyl)-2-naphthacenecarboxamide EXAMPLE 131 [7S-(7alpha,10aalpha)]-N-[9-(Aminocarbonyl)-4,7-bis(dimethylamino)-5,5a,6,6a,7,10,10a,12-octahydro-1,8,10a,11-tetrahydroxy-10,12-dioxo-2-napthacenyl]-1-azetidineacetamide
The title compound is prepared by the procedure of Example 105 using 0.20 g of product form Example 99, 0.50 g of azetidine and 5 ml of DMPU to give 0.126 g of the desired product.
MS(FAB): m/z 570(M+H).
EXAMPLE 132 [4S-(4alpha,12aalpha)]-9-[[(Cyclobutylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide hydrochloride
To a solution of 0.200 g of 9-(bromoacetylamino)-7-dimethylamino-6-demethyl-6-deoxytetracycline in 2 ml of 1,3-demethyl-2-imidazolidinone is added 0.1 ml of cyclobutylamine. The resulting solution is stirred at room temperature for 45 minutes and then added to 50 ml of diethyl ether. An oil layer is formed and the diethyl ether layer is decanted and the oil is dissolved in 5 ml of 0.1N methanolic hydrogen chloride. The resulting solution is added to 50 ml of diethyl ether, yielding 0.050 g of solid.
MS(FAB): m/z 584(M+H)

Claims (12)

1. A method for the treatment or control of bacterial infections in warm-blooded animals which comprises administering to said animal a pharmacologically effective amount of a compound of the formula:
Figure USRE040086-20080219-C00222
wherein:
X is selected from amino, NR1R2, or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine; R1 is selected from hydrogen, methyl, ethyl, n-propyl, 1-methylethyl, n-butyl and 1-methylpropyl; R2 is selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, and 1,1-dimethylethyl such that when X=NR1R2 and R1=hydrogen,
R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;
and when R1=methyl or ethyl,
R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R1=n-propyl,
R2=n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R1=1-methylethyl,
R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R1=n-butyl,
R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R1=1-methylpropyl,
R2=2-methylpropyl;
R is selected from R4(CH2)nCO— or R4′ (CH2)nSO2—; and n=0-4;
and when R=R4(CH2)n CO— and n−0 n=0,
R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-( 1,2,4triazolyl) 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C3-C6)cycloalkyl group with substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)alkoxy, trihalo (C1-C3)-alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl (C1-C3)alkylamino (C1-C 4)alkoxycarbonyl, (C1-C 3)alkylamino or carboxy; (C7-C9) aralkyl selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; α-amino-(C1-C4)alkyl selected from aminomethyl, α-aminoethyl, α-aminopropyl or α-aminobutyl; carboxy (C2-C4)-alkylamino selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and the optical isomers thereof; (C7-C9)aralklamino; (C1-C4)alkoxycarbonylamino substituted (C1-C4) alkyl group; α-hydroxy(C1-C3)alkyl selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; α-mercapto (C1-C3)alkyl selected from mercaptomethyl, α-mercaptoethyl, α-mercapto-1-methylethyl or α-mercaptopropyl; halo(C1-C3)alkyl group; a heterocycle selected from the group consisting of a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto, a five membered aromatic ring with two N, O, S, or Se heteroatoms optionally having a benzo or pyrido ring fused thereto, a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl; (C3-C6) cycloalcylcarbonyl cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or napthoyl; halo substituted (C6-C10)aroyl; (C1-C4) alkylbenzoyl, or (heterocycle)-carbonyl, the heterocycle as defined hereinabove; (C1-C4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl propoxycarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or a substituted vinyl group with substitution selected from (C1-C3) alkyl, halogen, (C6-C10)aryl selected from phenyl, α-napthyl, β-naphthyl, halo(C1-C3)alkyl, or a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C3)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy; (C1-C4)alkoxy group; C6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C1-C4) alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C10)aralkyloxy; vinyloxy or a substituted vinyloxy group with substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1methylethyl 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or (CH2)2 W(CH2)2— —(CH2)2 W(CH 2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)alkyl; or RaRbaminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, or 1,1-dimethylethyl or RaRb is (CH2)m, m=2-6, or —(CH2)2 W(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)alkyl; and when R=R4 (CH2)nCO— and n−1−4 n=1-4,
R4 is selected from hydrogen; amino; straight or branched (C1-C4) alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C3-C6)cycloalkyl group with substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted(C6-C10)-aryl group with substitution selected from halo, (C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy; (C7-C10)aralkyl; acyloxy or haloacyloxy group selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6) cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl, (C1-C4)alkylbenzoyl, or (heterocycle)-carbonyl, the heterocycle as defined hereinabove; (C1-C4)alkoxy; C6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C10)aralkyloxy; (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio with substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl with substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3) alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3) alkylamino or carboxy; (C7-C8)aralkylthio group; a heterocycle as defined hereinabove; hydroxy; mercapto; mono- or di-straight or branched chain (C1-C6)-alkylamino with the alkyl selected from methyl, ethyl, n-propyl, 1-methyethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl; (C2-C5)azacycloalkyl group; a carboxy(C2-C4)alkylamino group with the carboxy alkyl selected from aminoacetic acid, α-aminopropionic acid, α-aminobutyric acid and the optical isomers thereof; α-hydroxy(C1-C3)alkyl selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methyethyl or α-hydroxypropyl; halo(C1-C3)alkyl group; acyl or haloacyl selected from acetyl, propionyl, chloroacetyl, trifluroacetyl; (C3-C6) cycloalkylcarbonyl; (C6-C10)aroyl selected from benzoyl or naphthoyl; halo substituted (C6-C10)aroyl; (C1-C4)alkylbenzoyl, or (heterocycle)carbonyl, the heterocycle as defined hereinabove; (C1-C4)alkoxycarbonylamino, group (C1-C 4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; RaRb-amino(C1-C4)alkoxy group wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, methylpropyl, or 2-methylpropyl or RaRb is (CH)m (CH2)m, m=2-6 or —(CH2)2 W(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, —NOB, and B is selected from hydrogen or (C1-C3)alkyl; or RaRbaminoxy group, wherein RaRb is straight or branched (C1-C4)-alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)-alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)alkyl, and when R=R4′ (CH2)nSO2— and n=0
R4′ is selected from amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6) cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C3-C6)cycloalkyl group with substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3) acyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)-alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy; (C7-C9)aralkyl; halo(C1-C3)alkyl group; a heterocycle as defined hereinabove;
RaRb amino (C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)-alkyl selected from methyl, ethyl, n-propyl, 1-methyl-ethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W—(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)-alkyl; or RaRb aminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methyl-propyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2 W(CH2)2— wherein W is selected from —N(C1-C3) alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3) alkyl; and when R=R4′ (CH2)nSO2— and n=1-4,
R4′ is selected from hydrogen; straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1methylpropyl 1-methylpropyl, 2-methyl-propyl or 1,1-dimethylethyl; (C1-C4) carboxyalkyl; (C3-C6)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C3-C6) cycloalkyl group with substitution selected from (C1-C3) alkyl, cyano, amino or (C1-C3)-acyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)alkoxy, tri-halo(C1-C3) alkyl, nitro, amino, cyano, (C1-C4) alkoxy-carbonyl, (C1-C3) alkylamino or carboxy; (C7-C9)aralkyl selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; (C1-C4)alkoxy; C6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3) alkylamino; (C7-C10)aralkyloxy; RaRb amino (C1-C4) alkoxy wherein RaRb is a straight or branched (C1-C4)-alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2 W(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, or NOB —NOB and B is selected from hydrogen or (C1-C3)alkyl; or RaRb aminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)alkyl; (C1-C3) alkylthio selected from methylthio, ethylthio or n-propylthio; C6-arylthio selected from phenylthio or substituted phenylthio with substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C8) aralkylthio; a heterocycle as defined hereinabove; hydroxy; mercapto; mono- or di- straight or branched (C1-C6)alkyl- amino group with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl; halo (C1-C3) alkyl; acyl or haloacyl selected from acetyl, propionyl, chloro-acetyl, trifluoroacetyl; (C3-C6) cycloalkylcarbonyl; (C6-C10) aroyl selected from benzoyl or naphthoyl; halo substituted (C6-C10)aroyl, (C1-C4) alkylbenzoyl, or (heterocycle) carbonyl, the heterocycle as defined hereinabove; (C1-C4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl;
R5 is selected from hydrogen; straight or branched (C1-C3) alkyl selected from methyl, ethyl n-propyl ethyl, n-propyl or 1-methylethyl; (C6-C10) aryl selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9) aralkyl group; a heterocycle as defined hereinabove; or —(CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl;
R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected form from methyl, ethyl, n-propyl or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)-aralkyl group; a heterocycle as defined hereinabove; or —(CH2)nCOOR7′ where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen;
or R5 and R6 taken together are —(CH2)2 W(CH2)2— wherein W is selected from (CH2)q and q=0-1, —NH, —N(C1-C3)—alkyl —N(C1-C3)alkyl, —N(C1-C4) alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.
2. A method for the treatment or control of bacterial infections in warm-blooded animals caused by bacteria having the TetM and TetK resistant determinants which comprises administering to said animal a pharmacologically effective amount of a compound of the formula:
Figure USRE040086-20080219-C00223
wherein:
X is selected from amino, NR1R2 or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine; is R1 is selected from hydrogen, methyl, ethyl, n-propyl, 1-methylethyl, n-butyl and 1-methylpropyl; R2 is selected from methyl, ethyl n-propyl ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, and 1,1-dimethylethyl such that when X=NR1R2 and R1=hydrogen,
R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;
and when R1=methyl or ethyl,
R2=methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R1=n-propyl,
R2=n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R1=1-methylethyl,
R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R1=n-butyl,
R2=n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R1=1-methylpropyl,
R2=2-methylpropyl;
R is selected from R4(CH2)nCO— or R4′ (CH2)nSO2—; and n=0-4;
and when R=R4(CH2)n CO— and n−0 n=0,
R4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C3-C6)cycloalkyl group with substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)—alkyl trihalo(C1 -C 3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl (C1-C3)alkylamino (C1 -C 4)alkoxycarbonyl, (C1 -C 3)alkylamino or carboxy; (C7-C9) aralkyl selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; α-amino-(C1-C4)alkyl selected from aminomethyl, α-aminoethyl, α-aminopropyl or α-aminobutyl; carboxy (C2-C4)-alkylamino selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and the optical isomers thereof; (C7-C9)aralkylamino; (C1-C4)alkoxycarbonylamino substituted (C1-C4) alkyl group; α-hydroxy(C1-C3)alkyl selected from hydromethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; α-mercapto (C1-C3)alkyl selected from mercaptomethyl, α-mercaptoethyl, α-mercapto-1-methylethyl or α-mercaptopropyl; halo(C1-C3)alkyl group; a heterocycle selected from the group consisting of a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto, a five membered aromatic ring with two N, O, S, or Se heteroatoms optionally having a benzo or pyrido ring fused thereto, a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl; (C3-C6) cycloalcylcarbonyl (C3 -C 6)cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl; halo substituted (C6-C10)aroyl; (C1-C4) alkylbenzoyl, or (heterocycle)-carbonyl, the heterocycle as defined hereinabove; (C1-C4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxylcarbonyl propoxycarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or a substituted vinyl group with substitution selected from (C1-C3) alkyl, halogen, (C6-C10)aryl selected from phenyl, α-naphthyl, β-naphthyl, halo(C1-C3)alkyl, or a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)-alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy; (C1-C4)alkoxy group; C6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C1-C4) alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C10)aralkyloxy; vinyloxy or a substituted vinyloxy group with substitution selected from (C1-C4)alkyl, cyano, carboxy, or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; RaRbamino(C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1methylethyl 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or (CH2)2 W(CH2)2— —(CH2)2 W(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)alkyl; or RaRb aminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, or 1,1-dimethylethyl or RaRb is (CH2)m, m=2-6, or —(CH2)2 W(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O,S, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)alkyl;
and when R=R4 (CH2)nCO— and n−1−4 n=1-4,
R4 is selected from hydrogen; amino; straight or branched (C1-C4) alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl,, 1-methylpropyl, 2-methylpropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C3-C6)cycloalkyl group with substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)acyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphyhyl β-naphthyl; a substituted(C6-C10)aryl group with substitution selected from halo, (C1-C4)alkoxy (C1 -C 4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy; (C7-C10)aralkyl; acyloxy or haloacyloxy group selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C3-C6) cycloalkylcarbonyl, (C6-C10)aroyl selected from benzoyl or naphthoyl, halo substituted (C6-C10)aroyl, (C1-C4)alkylbenzyl or (heterocycle)-carbonyl, the heterocycle as defined hereinabove; (C1-C4)alkoxy; C6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C10)aralkyloxy; (C1-C3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C6-arylthio group selected from phenylthio or substituted phenylthio with substitution selected from halo, (C1-C4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; C6-arylsulfinyl C6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl with substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3) alkylamino or carboxy; (C7-C8)aralkylthio group; a heterocycle as defined hereinabove; hydroxy; mercapto; mono- or di-straight or branched chain (C1-C6)-alkylamino (C1 -C 6)alkylamino with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl; (C2-C5)azacycloalkyl group; a carboxy(C2-C4)alkylamino group with the carboxy alkyl selected from aminoacetic acid, α-aminopropionic acid, α-aminobutyric acid and the optical isomers thereof; α-hydroxy(C1-C3)alkyl selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C1-C3)alkyl group; acyl or haloacyl selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl; (C3-C6) cycloalkylcarbonyl; (C6-C10)aroyl selected from benzoyl or naphthoyl; halo substituted (C6-C10)aroyl; (C1-C4)alkylbenzoyl, or (heterocycle)carbonyl, the heterocycle as defined hereinabove; (C1-C4)alkoxycarbonylamino, (C1 -C 4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; (C1-C4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; RaRb-amino(C1-C4)alkoxy group wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH)mm=2-6 (CH2)m, m=2-6 or —(CH2)2W(CH2)2-wherein —(CH2)2 W(CH 2)2 —wherein W is selected from —N(C1-C3)-alkyl, O, S, —NH, —NOB, and B is selected from hydrogen or (C1-C3)alkyl; or RaRbaminoxy group, wherein RaRb is straight or branched (C1-C4)-alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)-alkyl, O,S, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)alkyl, and when R=R4′ (CH2)nSO2— and n=0
R4′ is selected from amino; monosubstituted amino selected from straight or branched (C1-C6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl(1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1-(1,2,3-triazolyl) or 4-(1,2,4-triazolyl); straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C3-C6)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C3-C6)cycloalkyl group with substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3) acyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl β-naphthyl or B-naphthyl ; a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)alkoxy, trihalo(C1-C3)alkyl, nitro, amino, cyano, (C1-C4)alkoxycarbonyl, (C1-C3)alkylamino or carboxy; (C7-C9)aralkyl; halo(C1-C3)alkyl group; a heterocycle as defined hereinabove; RaRb amino (C1-C4)alkoxy group, wherein RaRb is a straight or branched (C1-C4)-alkyl selected from methyl, ethyl, n-propyl, 1-methyl-ethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W—(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)-alkyl; or RaRb aminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methyl-propyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3) alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3) alkyl; and when R=R4′ (CH2)nSO2— and n=1-4,
R4′ is selected from hydrogen; straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methyl-propyl or 1,1-dimethylethyl; (C1-C4) carboxyalkyl; (C3-C6)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C3-C6) cycloalkyl group with substitution selected from (C1-C3)alkyl, cyano, amino or (C1-C3)-acyl; (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted (C6-C10)aryl group with substitution selected from halo, (C1-C4)alkoxy, tri-halo(C1-C3) alkyl, nitro, amino, cyano, (C1-C4)alkoxy-carbonyl, (C1-C3) alkylamino or carboxy; (C7-C9)aralkyl selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; (C1-C4)alkoxy; C6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3) alkylamino; (C7-C10)aralkyloxy; RaRb amino (C1-C4) alkoxy, wherein RaRb is a straight or branched (C1-C4)-alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, or NOB —NOB and B is selected from hydrogen or (C1-C3)alkyl; or RaRb aminoxy group, wherein RaRb is a straight or branched (C1-C4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or RaRb is (CH2)m, m=2-6, or —(CH2)2W(CH2)2— wherein W is selected from —N(C1-C3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C1-C3)alkyl; (C1-C3) alkylthio selected from methylthio, ethylthio or n-propylthio; C6-arylthio selected from phenylthio or substituted phenylthio with substitution selected from halo, (C1-C3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C1-C3)alkylamino; (C7-C8) aralkythio; a heterocycle as defined hereinabove; hydroxy; mercapto; mono- or di-straight or branched (C1-C6)alkyl- amino group with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl; halo (C1-C3) alkyl; acyl or haloacyl selected from acetyl, propionyl, chloro-acetyl, trifluoroacetyl; (C3-C6) cycloalkylcarbonyl; (C6-C10) aroyl selected from benzoyl or naphthoyl; halo substituted (C6-C10)aroyl, (C1-C4)alkylbenzoyl, or (heterocycle) carbonyl, the heterocycle as defined hereinabove; (C1-C4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; R5 is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl ethyl, n-propyl or 1-methylethyl; (C6-C10) aryl selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9) aralkyl group; a heterocycle as defined hereinabove; or —(CH2)nCOOR7 where n=0-4 and R7 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl;
R6 is selected from hydrogen; straight or branched (C1-C3)alkyl group selected form from methyl, ethyl, n-propyl, or 1-methylethyl; (C6-C10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C7-C9)-aralkyl group; a heterocycle as defined hereinabove; or —(CH2)nCOOR7′ where n=0-4 and R7′ is selected from hydrogen; straight or branched (C1-C3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C6-C10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R5 and R6 cannot both be hydrogen;
or R5 and R6 taken together are —(CH2)2W(CH2)2—, wherein W is selected from (CH2)q and q=0-1, —NH, —N(C1-C3)-alkyl, —N(C1-C4) alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.
3. A method for the treatment or control of bacterial infections in warm-blooded animals which comprises administering to said animal a pharmacologically effective amount of a compound of the formula:
Figure USRE040086-20080219-C00224
wherein:
X is selected from amino, NR 1 R 2 or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine; R 1 is selected from hydrogen, methyl, ethyl, n-propyl, 1-methylethyl, n-butyl and 1-methylpropyl; R 2 is selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1 -methylpropyl, 2-methylpropyl, and 1,1-dimethylethyl such that when X=NR 1 R 2 and R 1 =hydrogen,
R 2 =methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;
and when R 1 =methyl or ethyl,
R 2 =methyl, ethyl, n-propyl, 1-methylethyl, n-methylpropyl or 2-methylpropyl;
and when R 1 =n-propyl,
R 2 =n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl or 2 -methylpropyl;
and when R 1 =1 -methylethyl,
R 2 =n-butyl, 1 -methylpropyl or 2 -methylpropyl;
and when R 1 =n-butyl;
R 2 =n-butyl, 1 -methylpropyl or 2 -methylpropyl;
and when R 1 =1 -methylpropyl,
R 2 =2 -methylpropyl;
R is selected from R 4(CH 2)n CO— or R 4′ (CH 2)n SO 2 —; and n=0 - 4;
and when R=R 4(CH 2)n CO— and n=0,
R 4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C 1-C 6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl( 1 -methylethyl)amino, monomethylbenzylamino, piperidinyl, morphonlinyl, 1 -imidazolyl, 1 -pyrrolyl, 1 -( 1,2,3 -triazolyl) or 4 -( 1,2,4 -triazolyl); straight or branched (C 1-C 4)alkyl selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, 2 -methylpropyl or 1,1 -dimethylethyl; (C 3-C 6)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C 3-C 6)cycloalkyl group with substitution selected from (C 1-C 3)alkyl, cyano, amino or (C 1-C 3)acyl; (C 6-C 10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted (C 6-C 10)aryl group with substitution selected from halo, (C 1-C 4) alkoxy, trihalo(C 1-C 3)alkyl, nitro, amino, cyano, (C 1-C 4)alkoxycarbonyl, (C 1-C 3)alkylamino or carboxy; (C 7-C 9) aralkyl selected from benzyl, 1 -phenylethyl, 2 -phenylethyl or phenylpropyl; α-amino-(C 1-C 4)alkyl selected from aminomethyl, α-aminoethyl, α-aminopropyl or α-aminobutyl; carboxy (C 2-C 4)-alkylamino selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and the optical isomers thereof; (C 7-C 9)aralkylamino; (C 1-C 4)alkoxycarbonylamino substituted (C 1-C 4) alkyl group; α-hydroxy(C 1-C 3)alkyl selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy- 1 -methylethyl or α-hydroxypropyl; α-mercapto (C 1-C 3)alkyl selected from mercaptomethyl, α-mercaptoethyl, α-mercapto- 1 -methylethyl or α-mercaptopropyl; halo(C 1-C 3)alkyl group; a heterocycle selected from the group consisting of a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto, a five membered aromatic ring with two N, O, S, or Se heteroatoms optionally having a benzo or pyrido ring fused thereto, a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl; (C 3-C 6) cycloalkylcarbonyl, (C 6-C 10)aroyl selected from benzoyl or naphthoyl; halo substituted (C 6-C 10)aroyl; (C 1-C 4) alkylbenzoyl, or (heterocycle)-carbonyl, the heterocycle as defined hereinabove; (C 1-C 4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or a substituted vinyl group with substitution selected from (C 1-C 3) alkyl, halogen, (C 6-C 10)aryl selected from phenyl, α-naphthyl, β-naphthyl, halo(C 1-C 3)alkyl, or a substituted (C 6-C 10)aryl group with substitution selected from halo, (C 1-C 4)-alkoxy, trihalo(C 1-C 3)alkyl, nitro, amino, cyano, (C 1-C 4)alkoxycarbonyl, (C 1-C 3)alkylamino or carboxy; (C 1-C 4)alkoxy group; C 6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C 1-C 4) alkyl, nitro, cyano, thiol, amino, carboxy, di(C 1-C 3)alkylamino; (C 7-C 10)aralkyloxy; vinyloxy or a substituted vinyloxy group with substitution selected from (C 1-C 4)alkyl, cyano, carboxy, or (C 6-C 10)aryl selected from phenyl, α-naphthyl or β-naphthyl; R a R b amino(C 1-C 4)alkoxy group, wherein R a R b is a straight or branched (C 1-C 4)alkyl selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, or 2 -methylpropyl or R a R b is (CH 2)m , m=2 - 6, or —(CH 2)2 W(CH 2)2 — wherein W is selected from —N(C 1-C 3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C 1-C 3)alkyl; or R a R b aminoxy group, wherein R a R b is a straight or branched (C 1-C 4)alkyl selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, 2 -methylpropyl, or 1,1 -dimethylethyl or R a R b is (CH 2)m , m=2 - 6, or —(CH 2)2 W(CH 2)2 — wherein W is selected from —N(C 1-C 3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C 1-C 3)alkyl;
and when R=R 4 (CH 2)n CO— and n=1 - 4,
R 4 is selected from hydrogen; amino; straight or branched (C 1-C 4) alkyl group selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, 2 -methylpropyl or 1,1 -dimethylethyl; (C 3-C 6)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C 3-C 6)cycloalkyl group with substitution selected from (C 1-C 3)alkyl, cyano, amino or (C 1-C 3)acyl; (C 6-C 10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted(C 6-C 10)aryl group with substitution selected from halo, (C 1-C 4)alkoxy, trihalo(C 1-C 3)alkyl, nitro, amino, cyano, (C 1-C 4)alkoxycarbonyl, (C 1-C 3)alkylamino or carboxy; (C 7-C 10)aralkyl; acyloxy or haloacyloxy group selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C 3-C 6) cycloalkylcarbonyl, (C 6-C 10)aroyl selected from benzoyl or naphthoyl, halo substituted (C 6-C 10)aroyl, (C 1-C 4)alkylbenzyl or (heterocycle)-carbonyl, the heterocycle as defined hereinabove; (C 1-C 4)alkoxy; C 6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C 1-C 4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C 1-C 3)alkylamino; (C 7-C 10)aralkyloxy; (C 1-C 3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C 6-arylthio group selected from phenylthio or substituted phenylthio with substitution selected from halo, (C 1-C 4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C 1-C 3)alkylamino; C 6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl with substitution selected from halo, (C 1-C 4)alkoxy, trihalo(C 1-C 3)alkyl, nitro, amino, cyano, (C 1-C 4)alkoxycarbonyl, (C 1-C 3) alkylamino or carboxy; (C 7-C 8)aralkylthio group; a heterocycle as defined hereinabove; hydroxy; mercapto; mono- or di-straight or branched chain (C 1-C 6)alkylamino with the alkyl selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, 2 -methylpropyl, 1,1 -dimethylethyl, 2 -methylbutyl, 1,1 -dimethylpropyl, 2,2 -dimethylpropyl, 3 -methylbutyl, n-hexyl, 1 -methylpentyl, 1,1 -dimethylbutyl, 2,2 -dimethylbutyl, 2 -methylpentyl, 1,2 -dimethylbutyl, 1,3 -dimethylbutyl or 1 -methyl- 1 -ethylpropyl; (C 2-C 5)azacycloalkyl group; a carboxy(C 2-C 4)alkylamino group with the carboxy alkyl selected from aminoacetic acid, α-aminopropionic acid, α-aminobutyric acid and the optical isomers thereof; α-hydroxy(C 1-C 3)alkyl selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy- 1 -methylethyl or α-hydroxypropyl; halo(C 1-C 3)alkyl group; acyl or haloacyl selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl; (C 3-C 6) cycloalkylcarbonyl; (C 6-C 10)aroyl selected from benzoyl or naphthoyl; halo substituted (C 6-C 10)aroyl; (C 1-C 4)alkylbenzoyl, or (heterocycle)carbonyl, the heterocycle as defined hereinabove; (C 1-C 4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; (C 1-C 4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; R a R b-amino(C 1-C 4)alkoxy group wherein R a R b is a straight or branched (C 1-C 4)alkyl selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, or 2 -methylpropyl or R a R b is (CH 2)m , m=2 - 6 or —(CH 2)2 W(CH 2)2 — wherein W is selected from —N(C 1-C 3)-alkyl, O, S, —NH, —NOB, and B is selected from hydrogen or (C 1-C 3)alkyl; or R a R b aminoxy group, wherein R a R b is a straight or branched (C 1-C 4)-alkyl selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, 2 -methylpropyl or R a R b is (CH 2)m , m=2 - 6, or —(CH 2)2 W(CH 2)2 — wherein W is selected from —N(C 1-C 3)-alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C 1-C 3)alkyl, and when R=R 4′ (CH 2)n SO 2 — and n=0
R 4′ is selected from amino; monosubstituted amino selected from straight or branched (C 1-C 6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl( 1 -methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1 -imidazolyl, 1 -pyrrolyl, 1 -( 1,2,3 -triazolyl) or 4 -( 1,2,4 -triazolyl); straight or branched (C 1-C 4)alkyl selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, 2 -methylpropyl or 1,1 -dimethylethyl; (C 3-C 6) cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C 3-C 6)cycloalkyl group with substitution selected from (C 1-C 3)alkyl, cyano, amino or (C 1-C 3) acyl; (C 6-C 10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted (C 6-C 10)aryl group with substitution selected from halo, (C 1-C 4)alkoxy, trihalo(C 1-C 3)alkyl, nitro, amino, cyano, (C 1-C 4)alkoxycarbonyl, (C 1-C 3)alkylamino or carboxy; (C 7-C 9)aralkyl; halo(C 1-C 3)alkyl group; a heterocycle as defined hereinabove; R a R b amino (C 1-C 4)alkoxy group, wherein R a R b is a straight or branched (C 1-C 4)-alkyl selected from methyl, ethyl, n-propyl, 1 -methyl-ethyl, n-butyl, 1 -methylpropyl, or 2 -methylpropyl or R a R b is (CH 2)m , m=2 - 6, or —(CH 2)2 W—(CH 2)2 — wherein W is selected from —N(C 1-C 3) alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C 1-C 3)-alkyl; or R a R b aminoxy group, wherein R a R b is a straight or branched (C 1-C 4)alkyl selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methyl-propyl, or 2 -methylpropyl or R a R b is (CH 2)m , m=2 - 6, or —(CH 2)2 W(CH 2)2 — wherein W is selected from —N(C 1-C 3) alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C 1-C 3) alkyl; and when R=R 4′ (CH 2)n SO 2 — and n=1 - 4,
R 4′ is selected from hydrogen; straight or branched (C 1-C 4)alkyl selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, 2 -methyl-propyl or 1,1 -dimethylethyl; (C 1-C 4) carboxyalkyl; (C 3-C 6)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C 3-C 6) cycloalkyl group with substitution selected from (C 1-C 3)alkyl, cyano, amino or (C 1-C 3)-acyl; (C 6-C 10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted (C 6-C 10)aryl group with substitution selected from halo, (C 1-C 4)alkoxy, tri-halo(C 1-C 3) alkyl, nitro, amino, cyano, (C 1-C 4)alkoxy-carbonyl, (C 1-C 3) alkylamino or carboxy; (C 7-C 9)aralkyl selected from benzyl, 1 -phenylethyl, 2 -phenylethyl or phenylpropyl; (C 1-C 4)alkoxy; C 6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C 1-C 3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C 1-C 3) alkylamino; (C 7-C 10)aralkyloxy; R a R b amino (C 1-C 4) alkoxy, wherein R a R b is a straight or branched (C 1-C 4)-alkyl selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, or 2 -methylpropyl or R a R b is (CH 2)m , m=2 - 6, or —(CH 2)2 W(CH 2)2 — wherein W is selected from —N(C 1-C 3)alkyl, O, S, —NH, or —NOB and B is selected from hydrogen or (C 1-C 3)alkyl; or R a R b aminoxy group, wherein R a R b is a straight or branched (C 1-C 4)alkyl selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, or 2 -methylpropyl or R a R b is (CH 2)m , m=2 - 6, or —(CH 2)2 W(CH 2)2 — wherein W is selected from —N(C 1-C 3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C 1-C 3)alkyl; (C 1-C 3) alkylthio selected from methylthio, ethylthio or n-propylthio; C 6-arylthio selected from phenylthio or substituted phenylthio with substitution selected from halo, (C 1-C 3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C 1-C 3)alkylamino; (C 7-C 8) aralkylthio; a heterocycle as defined hereinabove; hydroxy; mercapto; mono- or di-straight or branched (C 1-C 6)alkyl- amino group with the alkyl selected from methyl, ethyl, n-propyl, 1 -methylethyl, n-butyl, 1 -methylpropyl, 2 -methylpropyl, 1,1 -dimethylethyl, 2 -methylbutyl, 1,1 -dimethylpropyl, 2,2 -dimethylpropyl, 3 -methylbutyl, n-hexyl, 1 -methylpentyl, 1,1 -dimethylbutyl, 2,2 -dimethylbutyl, 2 -methylpentyl, 1,2 -dimethylbutyl, 1,3 -dimethylbutyl or 1 -methyl- 1 -ethylpropyl; halo (C 1-C 3) alkyl; acyl or haloacyl selected from acetyl, propionyl, chloro-acetyl, trifluoroacetyl; (C 3-C 6) cycloalkylcarbonyl; (C 6-C 10) aroyl selected from benzoyl or naphthoyl; halo substituted (C 6-C 10)aroyl, (C 1-C 4)alkylbenzoyl, or (heterocycle) carbonyl, the heterocycle as defined hereinabove; (C 1-C 4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; R 5 is selected from hydrogen; straight or branched (C 1-C 3)alkyl selected from methyl, ethyl, n-propyl or 1 -methylethyl; (C 6-C 10)aryl selected from phenyl, α-naphthyl or β-naphthyl; (C 7-C 9) aralkyl group; a heterocycle as defined hereinabove; or —(CH 2)n COOR 7 where n=0 - 4 and R 7 is selected from hydrogen; straight or branched (C 1-C 3)alkyl group selected from methyl, ethyl, n-propyl or 1 -methylethyl; or (C 6-C 10)aryl group selected from phenyl, α-naphthyl or β-naphthyl;
R 6 is selected from hydrogen; straight or branched (C 1-C 3)alkyl group selected from methyl, ethyl, n-propyl or 1 -methylethyl; (C 6-C 10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C 7-C 9)-aralkyl group; a heterocycle as defined hereinabove; or —(CH 2)n COOR 7′ where n=0-4 and R 7′ is selected from hydrogen; straight or branched (C 1-C 3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C 6-C 10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R 5 and R 6 cannot both be hydrogen;
or R 5 and R 6 taken together are —(CH 2)2 W(CH 2)2 —, wherein W is selected from (CH 2)q and q=0 - 1, —NH, —N(C 1-C 3)-alkyl, —N(C 1-C 4) alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D) rolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.
4. A method for the treatment or control of bacterial infections in warm-blooded animals which comprises administering to said animal having a bacterial infection a pharmacologically effective amount of a compound of formula I:
Figure USRE040086-20080219-C00225
wherein X is selected from amino, NR 1 R 2 , or halogen, the halogen is selected from bromine, chlorine, fluorine or iodine, and when X is NR 1 R 2 , R 1 is methyl or ethyl and R 2 is methyl or ethyl; R is R 4(CH 2)n CO—; n is 1-4; and R 4 is monosubstituted or disubstitued amino selected from straight or branched (C 1-C 6)alkylamino with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl and pharmacologically acceptable organic and inorganic salts or metal complexes.
5. A method for the treatment or control of bacterial infections in warm-blooded animals which comprises administering to said animal having a bacterial infection a pharmacologically effective amount of a compound of formula I:
Figure USRE040086-20080219-C00226
wherein X is N(CH 3)2 and R is R 4(CH 2)n CO— where n=1-4 and R 4 is monosubstituted or disubstituted amino selected from straight or branched (C 1-C 6)alkylamino, with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl and pharmacologically acceptable organic and inorganic salts or metal complexes.
6. A method for the treatment or control of bacterial infections in warm-blooded animals which comprises administering to said animal having a bacterial infection a pharmacologically effective amount of a compound of formula I:
Figure USRE040086-20080219-C00227
wherein X is N(CH 3)2 and R is R 4(CH 2)n CO— where n is 1 and R 4 is monosubstituted or disubstituted amino selected from straight or branched (C 1-C 6)alkylamino, with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl and pharmacologically acceptable organic and inorganic salts or metal complexes.
7. A method for the treatment or control of bacterial infections in warm-blooded animals which comprises administering to said animal having a bacterial infection a pharmacologically effective amount of a compound of formula I:
Figure USRE040086-20080219-C00228
wherein R 4 is a monosubstituted straight or branched C 4-alkylamino, and pharmacologically acceptable organic and inorganic salts or metal complexes.
8. A method for the treatment or control of bacterial infections in warm-blooded animals caused by bacteria having the TetM and TetK resistant determinants which comprises administering to said animal a pharmacologically effective amount of a compound of the formula:
Figure USRE040086-20080219-C00229
wherein:
X is selected from amino, NR 1 R 2 or halogen; the halogen is selected from bromine, chlorine, fluorine or iodine; R 1 is selected from hydrogen, methyl, ethyl, n-propyl, 1-methylethyl, n-butyl and 1-methylpropyl; R 2 is selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, and 1,1-dimethylethyl such that when X=NR 1 R 2 and R 1 =hydrogen,
R 2 =methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl;
and when R 1 =methyl or ethyl,
R 2 =methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R 1 =n-propyl,
R 2 =n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R 1 =1-methylethyl,
R 2 =n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R 1 =n-butyl,
R 2 =n-butyl, 1-methylpropyl or 2-methylpropyl;
and when R 1 =1-methylpropyl,
R 2 =2-methylpropyl;
R is selected from R 4(CH 2)n CO— or R 4′ (CH 2)n SO 2 —; and n=0-4;
and when R=R 4(CH 2)n CO— and n=0,
R 4 is selected from hydrogen; amino; monosubstituted amino selected from straight or branched (C 1-C 6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl( 1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1 -( 1,2,3-triazolyl) or 4 -( 1,2,4-triazolyl); straight or branched (C 1-C 4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C 3-C 6)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C 3-C 6)cycloalkyl group with substitution selected from (C 1-C 3)alkyl, cyano, amino or (C 1-C 3)acyl; (C 6-C 10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted (C 6-C 10)aryl group with substitution selected from halo, (C 1-C 4) alkoxy, trihalo(C 1-C 3)alkyl, nitro, amino, cyano, (C 1-C 4)alkoxycarbonyl, (C 1-C 3)alkylamino or carboxy; (C 7-C 9) aralkyl selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; α-amino-(C 1-C 4)alkyl selected from aminomethyl, α-aminoethyl, α-aminopropyl or α-aminobutyl; carboxy (C 2-C 4)-alkylamino selected from aminoacetic acid, α-aminobutyric acid or α-aminopropionic acid and the optical isomers thereof; (C 7-C 9)aralkylamino; (C 1-C 4)alkoxycarbonylamino substituted (C 1-C 4) alkyl group; α-hydroxy(C 1-C 3)alkyl selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; α-mercapto (C 1-C 3)alkyl selected from mercaptomethyl, α-mercaptoethyl, α-mercapto-1-methylethyl or α-mercaptopropyl; halo(C 1-C 3)alkyl group; a heterocycle selected from the group consisting of a five membered aromatic or saturated ring with one N, O, S or Se heteroatom optionally having a benzo or pyrido ring fused thereto, a five membered aromatic ring with two N, O, S, or Se heteroatoms optionally having a benzo or pyrido ring fused thereto, a six membered aromatic ring with one to three N, O, S or Se heteroatoms, or a six membered saturated ring with one or two N, O, S or Se heteroatoms and an adjacent appended O heteroatom; acyl or haloacyl group selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl; (C 3-C 6) cycloalkylcarbonyl, (C 6-C 10)aroyl selected from benzoyl or naphthoyl; halo substituted (C 6-C 10)aroyl; (C 1-C 4) alkylbenzoyl, or (heterocycle)-carbonyl, the heterocycle as defined hereinabove; (C 1-C 4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, straight or branched butoxycarbonyl or allyloxycarbonyl; vinyl or a substituted vinyl group with substitution selected from (C 1-C 3) alkyl, halogen, (C 6-C 10)aryl selected from phenyl, α-naphthyl, β-naphthyl, halo(C 1-C 3)alkyl, or a substituted (C 6-C 10)aryl group with substitution selected from halo, (C 1-C 4)-alkoxy, trihalo(C 1-C 3)alkyl, nitro, amino, cyano, (C 1-C 4)alkoxycarbonyl, (C 1-C 3)alkylamino or carboxy; (C 1-C 4)alkoxy group; C 6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C 1-C 4) alkyl, nitro, cyano, thiol, amino, carboxy, di(C 1-C 3)alkylamino; (C 7-C 10)aralkyloxy; vinyloxy or a substituted vinyloxy group with substitution selected from (C 1-C 4)alkyl, cyano, carboxy, or (C 6-C 10)aryl selected from phenyl, α-naphthyl or β-naphthyl; R a R b amino(C 1-C 4)alkoxy group, wherein R a R b is a straight or branched (C 1-C 4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or R a R b is (CH 2)m , m=2-6, or —(CH 2)2 W(CH 2)2 — wherein W is selected from —N(C 1-C 3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C 1-C 3)alkyl; or R a R b aminoxy group, wherein R a R b is a straight or branched (C 1-C 4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, or 1,1-dimethylethyl or R a R b is (CH 2)m , m=2-6, or —(CH 2)2 W(CH 2)2 — wherein W is selected from —N(C 1-C 3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C 1-C 3)alkyl;
and when R=R 4 (CH 2)n CO— and n=1-4,
R 4 is selected from hydrogen; amino; straight or branched (C 1-C 4) alkyl group selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C 3-C 6)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C 3-C 6)cycloalkyl group with substitution selected from (C 1-C 3)alkyl, cyano, amino or (C 1-C 3)acyl; (C 6-C 10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted(C 6-C 10)aryl group with substitution selected from halo, (C 1-C 4)alkoxy, trihalo(C 1-C 3)alkyl, nitro, amino, cyano, (C 1-C 4)alkoxycarbonyl, (C 1-C 3)alkylamino or carboxy; (C 7-C 10)aralkyl; acyloxy or haloacyloxy group selected from acetyl, propionyl, chloroacetyl, trichloroacetyl, (C 3-C 6) cycloalkylcarbonyl, (C 6-C 10)aroyl selected from benzoyl or naphthoyl, halo substituted (C 6-C 10)aroyl, (C 1-C 4)alkylbenzyl or (heterocycle)-carbonyl, the heterocycle as defined hereinabove; (C 1-C 4)alkoxy; C 6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C 1-C 4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C 1-C 3)alkylamino; (C 7-C 10)aralkyloxy; (C 1-C 3)alkylthio group selected from methylthio, ethylthio, propylthio or allylthio; C 6-arylthio group selected from phenylthio or substituted phenylthio with substitution selected from halo, (C 1-C 4)alkyl, nitro, cyano, thiol, amino, carboxy, di(C 1-C 3)alkylamino; C 6-arylsulfonyl group selected from phenylsulfonyl or substituted phenylsulfonyl with substitution selected from halo, (C 1-C 4)alkoxy, trihalo(C 1-C 3)alkyl, nitro, amino, cyano, (C 1-C 4)alkoxycarbonyl, (C 1-C 3) alkylamino or carboxy; (C 7-C 8)aralkylthio group; a heterocycle as defined hereinabove; hydroxy; mercapto; mono- or di-straight or branched chain (C 1-C 6)alkylamino with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl; (C 2-C 5)azacycloalkyl group; a carboxy(C 2-C 4)alkylamino group with the carboxy alkyl selected from aminoacetic acid, α-aminopropionic acid, α-aminobutyric acid and the optical isomers thereof; α-hydroxy(C 1-C 3)alkyl selected from hydroxymethyl, α-hydroxyethyl or α-hydroxy-1-methylethyl or α-hydroxypropyl; halo(C 1-C 3)alkyl group; acyl or haloacyl selected from acetyl, propionyl, chloroacetyl, trifluoroacetyl; (C 3-C 6) cycloalkylcarbonyl; (C 6-C 10)aroyl selected from benzoyl or naphthoyl; halo substituted (C 6-C 10)aroyl; (C 1-C 4)alkylbenzoyl, or (heterocycle)carbonyl, the heterocycle as defined hereinabove; (C 1-C 4)alkoxycarbonylamino group selected from tert-butoxycarbonylamino, allyloxycarbonylamino, methoxycarbonylamino, ethoxycarbonylamino or propoxycarbonylamino; (C 1-C 4)alkoxycarbonyl group selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; R a R b-amino(C 1-C 4)alkoxy group wherein R a R b is a straight or branched (C 1-C 4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or R a R b is (CH 2)m , m=2-6 or —(CH 2)2 W(CH 2)2 — wherein W is selected from —N(C 1-C 3)-alkyl, O, S, —NH, —NOB, and B is selected from hydrogen or (C 1-C 3)alkyl; or R a R b aminoxy group, wherein R a R b is a straight or branched (C 1-C 4)-alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or R a R b is (CH 2)m , m=2-6, or —(CH 2)2 W(CH 2)2 — wherein W is selected from —N(C 1-C 3)-alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C 1-C 3)alkyl, and when R=R 4′ (CH 2)n SO 2 — and n=0
R 4′ is selected from amino; monosubstituted amino selected from straight or branched (C 1-C 6)alkylamino, cyclopropylamino, cyclobutylamino, benzylamino or phenylamino; disubstituted amino selected from dimethylamino, diethylamino, ethyl( 1-methylethyl)amino, monomethylbenzylamino, piperidinyl, morpholinyl, 1-imidazolyl, 1-pyrrolyl, 1 -( 1,2,3-triazolyl) or 4 -( 1,2,4-triazolyl); straight or branched (C 1-C 4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl or 1,1-dimethylethyl; (C 3-C 6) cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C 3-C 6)cycloalkyl group with substitution selected from (C 1-C 3)alkyl, cyano, amino or (C 1-C 3) acyl; (C 6-C 10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted (C 6-C 10)aryl group with substitution selected from halo, (C 1-C 4)alkoxy, trihalo(C 1-C 3)alkyl, nitro, amino, cyano, (C 1-C 4)alkoxycarbonyl, (C 1-C 3)alkylamino or carboxy; (C 7-C 9)aralkyl; halo(C 1-C 3)alkyl group; a heterocycle as defined hereinabove; R a R b amino (C 1-C 4)alkoxy group, wherein R a R b is a straight or branched (C 1-C 4)-alkyl selected from methyl, ethyl, n-propyl, 1-methyl-ethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or R a R b is (CH 2)m , m=2-6, or —(CH 2)2 W—(CH 2)2 — wherein W is selected from —N(C 1-C 3) alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C 1-C 3)-alkyl; or R a R b aminoxy group, wherein R a R b is a straight or branched (C 1-C 4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methyl propyl, or 2-methylpropyl or R a R b is (CH 2)m , m=2-6, or —(CH 2)2 W(CH 2)2 — wherein W is selected from —N(C 1-C 3) alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C 1-C 3) alkyl; and when R=R 4′ (CH 2)n SO 2 — and n=1-4,
R 4′ is selected from hydrogen; straight or branched (C 1-C 4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methyl-propyl or 1,1-dimethylethyl; (C 1-C 4) carboxyalkyl; (C 3-C 6)cycloalkyl selected from cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; a substituted (C 3-C 6) cycloalkyl group with substitution selected from (C 1-C 3)alkyl, cyano, amino or (C 1-C 3)-acyl; (C 6-C 10)aryl selected from phenyl, α-naphthyl or β-naphthyl; a substituted (C 6-C 10)aryl group with substitution selected from halo, (C 1-C 4)alkoxy, tri-halo(C 1-C 3) alkyl, nitro, amino, cyano, (C 1-C 4)alkoxy-carbonyl, (C 1-C 3) alkylamino or carboxy; (C 7-C 9)aralkyl selected from benzyl, 1-phenylethyl, 2-phenylethyl or phenylpropyl; (C 1-C 4)alkoxy; C 6-aryloxy selected from phenoxy or substituted phenoxy with substitution selected from halo, (C 1-C 3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C 1-C 3) alkylamino; (C 7-C 10)aralkyloxy; R a R b amino (C 1-C 4) alkoxy, wherein R a R b is a straight or branched (C 1-C 4)-alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or R a R b is (CH 2)m , m=2-6, or —(CH 2)2 W(CH 2)2 — wherein W is selected from —N(C 1-C 3)alkyl, O, S, —NH, or —NOB and B is selected from hydrogen or (C 1-C 3)alkyl; or R a R b aminoxy group, wherein R a R b is a straight or branched (C 1-C 4)alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, or 2-methylpropyl or R a R b is (CH 2)m , m=2-6, or —(CH 2)2 W(CH 2)2 — wherein W is selected from —N(C 1-C 3)alkyl, O, S, —NH, —NOB and B is selected from hydrogen or (C 1-C 3)alkyl; (C 1-C 3) alkylthio selected from methylthio, ethylthio or n-propylthio; C 6-arylthio selected from phenylthio or substituted phenylthio with substitution selected from halo, (C 1-C 3)alkyl, nitro, cyano, thiol, amino, carboxy, di(C 1-C 3)alkylamino; (C 7-C 8) aralkylthio; a heterocycle as defined hereinabove; hydroxy; mercapto; mono- or di-straight or branched (C 1-C 6)alkyl- amino group with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl; halo (C 1-C 3) alkyl; acyl or haloacyl selected from acetyl, propionyl, chloro-acetyl, trifluoroacetyl; (C 3-C 6) cycloalkylcarbonyl; (C 6-C 10) aroyl selected from benzoyl or naphthoyl; halo substituted (C 6-C 10)aroyl, (C 1-C 4)alkylbenzoyl, or (heterocycle) carbonyl, the heterocycle as defined hereinabove; (C 1-C 4)alkoxycarbonyl selected from methoxycarbonyl, ethoxycarbonyl, straight or branched propoxycarbonyl, allyloxycarbonyl or straight or branched butoxycarbonyl; R 5 is selected from hydrogen; straight or branched (C 1-C 3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; (C 6-C 10)aryl selected from phenyl, α-naphthyl or β-naphthyl; (C 7-C 9) aralkyl group; a heterocycle as defined hereinabove; or —(CH 2)n COOR 7 where n=0-4 and R 7 is selected from hydrogen; straight or branched (C 1-C 3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C 6-C 10)aryl group selected from phenyl, α-naphthyl or β-naphthyl;
R 6 is selected from hydrogen; straight or branched (C 1-C 3)alkyl group selected from methyl, ethyl, n-propyl or 1-methylethyl; (C 6-C 10)aryl group selected from phenyl, α-naphthyl or β-naphthyl; (C 7-C 9)-aralkyl group; a heterocycle as defined hereinabove; or —(CH 2)n COOR 7′ where n=0-4 and R 7′ is selected from hydrogen; straight or branched (C 1-C 3)alkyl selected from methyl, ethyl, n-propyl or 1-methylethyl; or (C 6-C 10)aryl selected from phenyl, α-naphthyl or β-naphthyl; with the proviso that R 5 and R 6 cannot both be hydrogen;
or R 5 and R 6 taken together are —(CH 2)2 W(CH 2)2 —, wherein W is selected from (CH 2)q and q=0-1, —NH, —N(C 1-C 3)-alkyl, —N(C 1-C 4) alkoxy, oxygen, sulfur or substituted congeners selected from (L or D)proline, ethyl(L or D)prolinate, morpholine, pyrrolidine or piperidine; and the pharmacologically acceptable organic and inorganic salts or metal complexes.
9. A method for the treatment or control of bacterial infections in warm-blooded animals caused by bacteria having the TetM and TetK resistant determinants which comprises administering to said animal a pharmacologically effective amount as of compound of formula I:
Figure USRE040086-20080219-C00230
wherein X is selected from amino, NR 1 R 2 , or halogen, the halogen is selected from bromine, chlorine, fluorine or iodine, and when X is NR 1 R 2 , R 1 is methyl or ethyl and R 2 is methyl or ethyl; R is R 4(CH 2)n CO—; n is 1-4; and R 4 is monosubstituted or disubstituted amino selected from straight or branched chain (C 1 -C 6)alkylamino with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl and pharmacologically acceptable organic and inorganic salts or metal complexes.
10. A method for the treatment or control of bacterial infections in warm-blooded animals caused by bacteria having the TetM and TetK resistant determinants which comprises administering to said animal a pharmacologically effective amount as of compound of formula I:
Figure USRE040086-20080219-C00231
wherein X is N(CH 3)2 and R is R 4(CH 2)n CO— where n=1-4 and R 4 is monosubstituted or disubstituted amino selected from straight or branched (C 1 -C 6)alkylamino, with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl and pharmacologically acceptable organic and inorganic salts or metal complexes.
11. A method for the treatment or control of bacterial infections in warm-blooded animals caused by bacteria having the TetM and TetK resistant determinants which comprises administering to said animal a pharmacologically effective amount as of compound of formula I:
Figure USRE040086-20080219-C00232
wherein X is N(CH 3)2 and R is R 4(CH 2)n CO— where n is 1 and R 4 is monosubstituted or disubstituted amino selected from straight or branched (C 1-C 6)alkylamino, with the alkyl selected from methyl, ethyl, n-propyl, 1-methylethyl, n-butyl, 1-methylpropyl, 2-methylpropyl, 1,1-dimethylethyl, 2-methylbutyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl, 3-methylbutyl, n-hexyl, 1-methylpentyl, 1,1-dimethylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl or 1-methyl-1-ethylpropyl and pharmacologically acceptable organic and inorganic salts or metal complexes.
12. A method for the treatment or control of bacterial infections in warm-blooded animals caused by bacteria having the TetM and TetK resistant determinants which comprises administering to said animal a pharmacologically effective amount as of compound of formula I:
Figure USRE040086-20080219-C00233
wherein R 4 is a monosubstituted straight or branched C 4-alkylamino, and pharmacologically acceptable organic and inorganic salts or metals complexes.
US11/318,390 1991-10-04 2005-12-23 Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines Expired - Lifetime USRE40086E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/318,390 USRE40086E1 (en) 1991-10-04 2005-12-23 Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US77157691A 1991-10-04 1991-10-04
US92609192A 1992-08-13 1992-08-13
US08/286,096 US5494903A (en) 1991-10-04 1994-08-04 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US08/455,446 US5529990A (en) 1991-10-04 1995-05-31 Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines
US11/318,390 USRE40086E1 (en) 1991-10-04 2005-12-23 Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/455,446 Reissue US5529990A (en) 1991-10-04 1995-05-31 Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines

Publications (1)

Publication Number Publication Date
USRE40086E1 true USRE40086E1 (en) 2008-02-19

Family

ID=27118487

Family Applications (4)

Application Number Title Priority Date Filing Date
US08/286,096 Ceased US5494903A (en) 1991-10-04 1994-08-04 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US08/455,923 Expired - Lifetime US5530117A (en) 1991-10-04 1995-05-31 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US08/455,446 Ceased US5529990A (en) 1991-10-04 1995-05-31 Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines
US11/318,390 Expired - Lifetime USRE40086E1 (en) 1991-10-04 2005-12-23 Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US08/286,096 Ceased US5494903A (en) 1991-10-04 1994-08-04 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US08/455,923 Expired - Lifetime US5530117A (en) 1991-10-04 1995-05-31 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
US08/455,446 Ceased US5529990A (en) 1991-10-04 1995-05-31 Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines

Country Status (1)

Country Link
US (4) US5494903A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090275660A1 (en) * 2008-05-01 2009-11-05 Chauhan Bhaskar Stable parenteral formulations of tigecycline
US20100105671A1 (en) * 2008-08-08 2010-04-29 Jingye Zhou C7-fluoro substituted tetracycline compounds
US9315451B2 (en) 2009-05-08 2016-04-19 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
US9573895B2 (en) 2012-08-31 2017-02-21 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
US9624166B2 (en) 2009-08-28 2017-04-18 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
US10961190B2 (en) 2016-10-19 2021-03-30 Tetraphase Pharmaceuticals, Inc. Crystalline forms of eravacycline

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506740B1 (en) * 1998-11-18 2003-01-14 Robert A. Ashley 4-dedimethylaminotetracycline derivatives
US6946453B2 (en) 1998-11-18 2005-09-20 Collagenex Pharmaceuticals, Inc. 4-dedimethylaminotracycline derivatives
CN102336680A (en) * 1999-09-14 2012-02-01 塔夫茨大学信托人 Methods of preparing substituted tetracyclines with transition metal-based chemistries.
US8106225B2 (en) * 1999-09-14 2012-01-31 Trustees Of Tufts College Methods of preparing substituted tetracyclines with transition metal-based chemistries
EP1272459B1 (en) * 2000-03-31 2007-06-27 Trustees Of Tufts College 7- and 9-carbamate, urea, thiourea, thiocarbamate, and heteroaryl-amino substituted tetracycline compounds
US20020132798A1 (en) * 2000-06-16 2002-09-19 Nelson Mark L. 7-phenyl-substituted tetracycline compounds
US20020128238A1 (en) * 2000-06-16 2002-09-12 Nelson Mark L. 7-phenyl-substituted tetracycline compounds
CN1690047B (en) * 2000-07-07 2010-10-06 塔夫茨大学信托人 9-substituted minocycline compounds
KR100997596B1 (en) * 2000-07-07 2010-11-30 파라테크 파마슈티컬스, 인크. 7-substituted tetracycline compounds
US7094806B2 (en) 2000-07-07 2006-08-22 Trustees Of Tufts College 7, 8 and 9-substituted tetracycline compounds
WO2002072506A2 (en) * 2001-03-13 2002-09-19 Paratek Pharmaceuticals, Inc. 7-pyrollyl tetracycline compounds and methods of use thereof
US7553828B2 (en) * 2001-03-13 2009-06-30 Paratek Pharmaceuticals, Inc. 9-aminomethyl substituted minocycline compounds
EP1241160A1 (en) * 2001-03-13 2002-09-18 Glaxo Group Limited Tetracycline derivatives and their use as antibiotic agents
EP2301914A1 (en) * 2001-03-13 2011-03-30 Paratek Pharmaceuticals, Inc. 7,9-Substituted tetracycline compounds
US20060194773A1 (en) * 2001-07-13 2006-08-31 Paratek Pharmaceuticals, Inc. Tetracyline compounds having target therapeutic activities
US20040063674A1 (en) 2001-07-13 2004-04-01 Levy Stuart B. Tetracycline compounds having target therapeutic activities
WO2003055441A2 (en) * 2001-08-02 2003-07-10 Paratek Pharmaceuticals, Inc. Medicaments
MY133403A (en) * 2001-10-05 2007-11-30 Tetragenex Pharmaceuticals Inc Tetracycline derivatives and methods of use thereof
US20030181371A1 (en) * 2001-12-28 2003-09-25 Angiotech Pharmaceuticals, Inc. Compositions and methods of using collajolie
EP2311799A1 (en) * 2002-01-08 2011-04-20 Paratek Pharmaceuticals, Inc. 4-dedimethylamino tetracycline compounds
US20030171340A1 (en) * 2002-02-07 2003-09-11 Jenefir Isbister Methods of disease treatment using metal-complexed tetracycline antibiotics
KR101014918B1 (en) * 2002-03-08 2011-02-15 파라테크 파마슈티컬스, 인크. Amino-Methyl Substituted Tetracycline Compounds
CN1653037A (en) 2002-03-21 2005-08-10 帕拉特克药品公司 Substituted tetracycline compounds
US20060287283A1 (en) * 2003-07-09 2006-12-21 Paratek Pharmaceuticals, Inc. Prodrugs of 9-aminomethyl tetracycline compounds
CN1845897A (en) 2003-07-09 2006-10-11 帕拉特克药品公司 Substituted tetracycline compounds
US20050148553A1 (en) * 2003-09-05 2005-07-07 Testa Raymond T. Use of tigecycline, alone, or in combination with rifampin to treat osteomyelitis and/or septic arthritis
UA83266C2 (en) 2003-12-08 2008-06-25 Уайет Oxazole derivatives of tetracyclines
KR101171408B1 (en) * 2004-05-21 2012-08-08 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Synthesis of tetracyclines and analogues thereof
EP2287140A3 (en) 2004-10-25 2011-09-21 Paratek Pharmaceuticals, Inc. Substituted tetracycline compounds
US7534766B2 (en) * 2004-11-05 2009-05-19 Wyeth Glucuronide metabolites and epimers thereof of tigecycline
EP1848685A1 (en) 2005-02-04 2007-10-31 Paratek Pharmaceuticals, Inc. 11a, 12-derivatives of tetracycline compounds
CN101119964A (en) 2005-02-15 2008-02-06 惠氏公司 9-substituted tetracyclines
US7879828B2 (en) 2005-03-14 2011-02-01 Wyeth Llc Tigecycline compositions and methods of preparation
KR20080005599A (en) * 2005-05-06 2008-01-14 와이어쓰 Delivery of tigecycline in the presence of heparin
CN101171036A (en) * 2005-05-06 2008-04-30 惠氏公司 Delivery of TIGECYCLINE in the presence of WARFARIN
AR057032A1 (en) * 2005-05-27 2007-11-14 Wyeth Corp TIGECICLINE AND PREPARATION METHODS
AR057324A1 (en) * 2005-05-27 2007-11-28 Wyeth Corp TIGECICLINE AND METHODS TO PREPARE 9-AMINOMINOCICLINE
AR057034A1 (en) * 2005-05-27 2007-11-14 Wyeth Corp METHODS TO PURIFY TIGECICLINE
AR057033A1 (en) * 2005-05-27 2007-11-14 Wyeth Corp TIGECICLINE AND METHODS TO PREPARE 9-NITROMINOCICLINE
PE20070072A1 (en) * 2005-06-16 2007-02-25 Wyeth Corp MANUFACTURING PROCESS FOR TIGECYCLINE AS RECONSTITUTABLE POWDER
AU2006285043A1 (en) * 2005-08-31 2007-03-08 Wyeth 9-aminocarbonylsubstituted derivatives of glycylcyclines
RU2008121238A (en) * 2005-12-22 2010-01-27 Вайет (Us) METHODS FOR TREATING GASTROINTESTINAL INFECTIONS WITH TAYGECYCLIN
AU2006331688A1 (en) * 2005-12-22 2007-07-05 Wyeth Oral formulations comprising tigecycline
JP5335664B2 (en) * 2006-04-07 2013-11-06 プレジデント アンド フェロウズ オブ ハーバード カレッジ Synthesis of tetracycline and its analogs.
CA2649221A1 (en) * 2006-04-17 2007-10-25 Evgeny Tsiperman Isolation of tetracycline derivatives
US8198470B2 (en) * 2006-04-24 2012-06-12 Teva Pharmaceutical Industries Ltd. Crystalline form II of tigecycline and processes for preparation thereof
DK2016045T3 (en) * 2006-04-24 2015-02-02 Teva Pharma TIGECYCLIN CRYSTAL FORM AND PROCEDURES FOR PREPARING IT
AU2007249695A1 (en) 2006-05-15 2007-11-22 Paratek Pharmaceuticals, Inc. Methods of regulating expression of genes or of gene products using substituted tetracycline compounds
US20070286817A1 (en) * 2006-06-07 2007-12-13 Wyeth Treating cystic fibrosis with antibiotics via a swirler delivery
US20070286818A1 (en) * 2006-06-07 2007-12-13 Wyeth Treating cystic fibrosis with antibiotics via an aerosol drug
WO2008127361A2 (en) 2006-10-11 2008-10-23 President And Fellows Of Harvard College Synthesis of enone intermediate
US8198469B2 (en) * 2006-11-29 2012-06-12 Teva Pharmaceutical Industries Ltd. Crystalline forms of tigecycline and processes for preparation thereof
BRPI0706517A2 (en) * 2006-11-30 2011-03-29 Teva Pharma processes for preparing 9-haloacetamidominocyclines
EP2114865A1 (en) * 2007-03-01 2009-11-11 Teva Pharmaceutical Industries Ltd. Processes for purification of tigecycline
US7939513B2 (en) * 2007-09-07 2011-05-10 Dr. Reddy's Laboratories Limited Tetracycline derivatives as antibacterial agents
WO2009069100A1 (en) 2007-11-29 2009-06-04 Actelion Pharmaceuticals Ltd Phosphonic acid derivates and their use as p2y12 receptor antagonists
PT2271348T (en) * 2008-03-28 2018-04-16 Paratek Pharm Innc Oral tablet formulation of tetracycline compound
ITMI20080807A1 (en) 2008-05-05 2009-11-06 Antibioticos Spa PROCEDURE FOR THE PREPARATION OF TIGECYCLINE IN THE AMORPHOUS FORM
TWI680117B (en) * 2008-05-23 2019-12-21 派洛泰克藥物股份有限公司 Tosylate salts and polymorphs of a tetracycline compound
PT104350A (en) 2009-01-23 2010-07-23 Hovione Farmaci Ncia S A TIGECYCIN ISOLATION PROCESS
WO2010126607A2 (en) 2009-04-30 2010-11-04 President And Fellows Of Harvard College Synthesis of tetracyclines and intermediates thereto
EP3135289B1 (en) 2010-05-12 2018-12-12 Rempex Pharmaceuticals, Inc. Tetracycline compositions
EP3976050A1 (en) 2019-05-24 2022-04-06 Stichting Radboud universitair medisch centrum Improved administration of glycylcyclines by inhalation
WO2023205388A1 (en) * 2022-04-22 2023-10-26 Board Of Regents, The University Of Texas System Inhaled antibacterial formulations for treating lung infections

Citations (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2482055A (en) 1948-02-11 1949-09-13 American Cyanamid Co Aureomycin and preparation of same
US2619420A (en) 1949-09-17 1952-11-25 American Cyanamid Co Animal and poultry feed containing aureomycin mash
US2731497A (en) 1954-05-14 1956-01-17 American Cyanamid Co Production of tetracycline
US2734018A (en) 1953-09-28 1956-02-07 Ircso
US2878289A (en) 1956-05-28 1959-03-17 American Cyanamid Co 6-demethyltetracyclines and methods for preparing the same
US2911339A (en) 1957-11-27 1959-11-03 American Cyanamid Co Streptomyces aureofaciens fermentation process
US2997471A (en) 1958-08-18 1961-08-22 Bristol Myers Co Tetracycline derivatives
US3007965A (en) 1959-02-13 1961-11-07 American Cyanamid Co New tetracyclines produced by streptomyces aureofaciens
US3023239A (en) 1959-12-09 1962-02-27 American Cyanamid Co Recrystallization of demethylchlortetracycline
US3026248A (en) 1959-09-11 1962-03-20 Pfizer & Co C Thioglycerol and formaldehyde sulfoxylate stabilized tetracycline antibiotics in polyhydric alcohol solvents
US3043875A (en) 1959-10-22 1962-07-10 Pfizer & Co C Halogenated tetracycline derivatives and processes for their preparation
GB901107A (en) 1959-06-29 1962-07-11 Pfizer Therapeutic composition and method of preparing same
US3050558A (en) 1959-12-09 1962-08-21 American Cyanamid Co Refining of demethylchlortetracycline
US3092556A (en) 1962-02-12 1963-06-04 American Cyanamid Co Tetracycline fermentation
US3128227A (en) 1954-06-17 1964-04-07 American Cyanamid Co Antibiotic intramuscular composition
US3145228A (en) 1962-09-06 1964-08-18 Pfizer & Co C 5-alkoxy-and 5-benzyloxy-tetracycline, derivatives and analogues thereof
US3148212A (en) 1961-12-22 1964-09-08 American Cyanamid Co Reductive alkylation process
US3200149A (en) 1960-05-23 1965-08-10 Pfizer & Co C alpha-6-deoxytetracycline derivatives and process
US3219529A (en) 1962-10-04 1965-11-23 American Cyanamid Co Stable tetracycline solutions
US3226436A (en) 1963-05-17 1965-12-28 American Cyanamid Co 7-and 9-alkylamino-6-deoxytetracycline
US3239499A (en) 1961-05-19 1966-03-08 Pfizer & Co C Tetracycline derivative
US3250810A (en) 1962-09-06 1966-05-10 Pfizer & Co C 6-hydroxy-6-halomethyl tetracyclines
US3250809A (en) 1962-09-06 1966-05-10 Pfizer & Co C 6-deoxy-6-demethyl-6-halomethylene tetracyclines and their 11a-chloro and fluoro derivatives
US3338963A (en) 1960-10-28 1967-08-29 American Cyanamid Co Tetracycline compounds
US3341585A (en) 1966-05-06 1967-09-12 American Cyanamid Co Substituted 7-and/or 9-amino-6-deoxytetracyclines
USRE26271E (en) 1967-09-26 Reductive alkylation process
US3345410A (en) 1966-12-01 1967-10-03 American Cyanamid Co Substituted 7- and/or 9-amino tetracyclines
US3360561A (en) 1967-06-19 1967-12-26 American Cyanamid Co Nitration of tetracyclines
US3360557A (en) 1963-05-10 1967-12-26 American Cyanamid Co 9-hydroxytetracyclines and a process of preparing same
US3373197A (en) 1967-04-27 1968-03-12 American Cyanamid Co Substituted 6-epitetracyclines and 5a-epi-6-epitetracyclines
US3373196A (en) 1967-03-21 1968-03-12 American Cyanamid Co 7-and/or 9-(lower alkyl) amino-5a, 6-anhydrotetracyclines
US3373198A (en) 1967-04-27 1968-03-12 American Cyanamid Co Substituted 5a, 11a-dehydro-6-epitetracyclines
US3397230A (en) 1966-03-14 1968-08-13 American Cyanamid Co Nitration of tetracyclines
US3403179A (en) 1967-01-10 1968-09-24 American Cyanamid Co Novel 7-(1, 2-bis-substituted-hydrazino)-tetracyclines and methods of preparing same
US3433834A (en) 1966-03-14 1969-03-18 American Cyanamid Co Nitration of 11a-chloro tetracyclines
US3483251A (en) 1967-03-03 1969-12-09 American Cyanamid Co Reductive alkylation process
US3502696A (en) 1961-08-18 1970-03-24 Pfizer & Co C Antibacterial agents
US3509184A (en) 1961-08-18 1970-04-28 Pfizer & Co C Anthracyclidine-acetic acid derivatives
US3515731A (en) 1966-06-17 1970-06-02 Pfizer & Co C Antibacterial agents
US3518306A (en) 1968-02-19 1970-06-30 American Cyanamid Co 7- and/or 9-(n-nitrosoalkylamino)-6-demethyl-6-deoxytetracyclines
US3526629A (en) 1968-04-02 1970-09-01 American Cyanamid Co Beta-hydroxyethylpiperazinocarboxymethyl - 7 - dimethylamino - 6 - deoxy-6-demethyltetracycline
US3579579A (en) 1968-04-18 1971-05-18 American Cyanamid Co Substituted 7- and/or 9-amino-6-demethyl-6-deoxytetracyclines
US3586483A (en) 1968-10-14 1971-06-22 American Cyanamid Co Method for detecting the presence of tetracycline antibiotics
US3697552A (en) 1961-08-18 1972-10-10 Pfizer Anthracyclidine-acetic acid derivatives
US3772363A (en) 1961-08-18 1973-11-13 Pfizer 3,4,10-trioxo octahydroanthracene-2-aminoacetic acids and derivatives thereof
US3809751A (en) 1969-02-25 1974-05-07 American Cyanamid Co Antibiotic-stable liquid protein supplements containing non-protein nitrogen,phosphorus and a tetracycline antibiotic
US3812188A (en) 1968-08-19 1974-05-21 American Cyanamid Co Purification of 7-chlorotetracycline
US3829453A (en) 1961-08-18 1974-08-13 Pfizer Octahydroanthracene-2-aminoacetic acids and esters and mixed anhydrides thereof
US3849493A (en) 1966-08-01 1974-11-19 Pfizer D-ring substituted 6-deoxytetracyclines
US3862225A (en) 1961-08-18 1975-01-21 Pfizer D-ring substituted tetracyclines
US3901942A (en) 1972-09-18 1975-08-26 Farmaceutici Italia Tetracycline derivatives substituted in the 7 position and process for preparing the same
US3978000A (en) 1975-03-19 1976-08-31 American Cyanamid Company Catalysts based on carbon supports
US4029600A (en) 1975-03-19 1977-06-14 American Cyanamid Company Carbon particulates with controlled density
US4038315A (en) 1972-05-11 1977-07-26 American Cyanamid Company Isolation and recovery of calcium chloride complex of 7-dimethylamino-6-dimethyl l-6-deoxytetracycline hydrochloride
US4081370A (en) 1976-05-20 1978-03-28 American Cyanamid Company Use of carbon particulates with controlled density as adsorbents
WO1984001895A1 (en) 1982-11-18 1984-05-24 Univ Tufts Tetracycline activity enhancement
EP0109850A2 (en) 1982-11-22 1984-05-30 Unisys Corporation Speed independent selector switch employing M-out-of-N codes
US4666897A (en) 1983-12-29 1987-05-19 Research Foundation Of State University Inhibition of mammalian collagenolytic enzymes by tetracyclines
WO1989002270A1 (en) 1987-09-16 1989-03-23 Theodore Krupin Method of lowering intraocular (eye) pressure
US4837030A (en) 1987-10-06 1989-06-06 American Cyanamid Company Novel controlled release formulations of tetracycline compounds
US4911924A (en) 1987-04-17 1990-03-27 University Of New Mexico Induction of antibiotic hypersensitivity in tetracycline-resistance microorganisms
US4918208A (en) 1987-07-28 1990-04-17 Nippon Kayaku Kabushiki Kaisha Process for producing 7-dimethylamino-6-demethyl-6-deoxytetracycline
US4925833A (en) 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
US4975271A (en) 1988-12-19 1990-12-04 Vipont Pharmaceutical, Inc. Muscosal delivery systems for treatment of periodontal disease
US5045538A (en) 1990-06-28 1991-09-03 The Research Foundation Of State University Of New York Inhibition of wasting and protein degradation of mammalian muscle by tetracyclines
US5122519A (en) 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
US5143661A (en) 1987-05-26 1992-09-01 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules
US5240272A (en) * 1991-09-17 1993-08-31 Deere & Company Vehicle hitch assembly
US5248797A (en) * 1992-08-13 1993-09-28 American Cyanamid Company Method for the production of 9-amino-6-demethyl-6-deoxytetracycline
US5280888A (en) 1991-04-05 1994-01-25 Societe Jacques Dubois Resilient buffer made of metal wire
US5281628A (en) 1991-10-04 1994-01-25 American Cyanamid Company 9-amino-7-(substituted)-6-demethyl-6-deoxytetracyclines
US5284963A (en) 1992-08-13 1994-02-08 American Cyanamid Company Method of producing 7-(substituted)-9-[(substituted glycyl)-amidol]-6-demethyl-6-deoxytetra-cyclines
US5328902A (en) 1992-08-13 1994-07-12 American Cyanamid Co. 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5384259A (en) 1991-12-06 1995-01-24 American Cyanamid Company Construct and method for expression of tetracycline resistance genes in E. Coli
US5386041A (en) 1992-08-13 1995-01-31 American Cyanamid Company 7-(substituted)-8-(substituted)-9-[(substituted glycyl) amido]-6-demethyl-6-deoxytetracyclines
US5430162A (en) 1992-08-13 1995-07-04 American Cyanamid Company 7-(substituted)-8-(substituted)-9-substituted amino)-6-demethyl-6-deoxytetracyclines
US5442059A (en) 1992-08-13 1995-08-15 American Cyanamid Company 9-[(substituted glycyl)amido)]-6-demethyl-6-deoxytetracyclines
US5675030A (en) 1994-11-16 1997-10-07 American Cyanamid Company Method for selective extracting a 7-(hydrogen or substituted amino)-9- (substituted glycyl) amido!-6-demethyl-6-deoxytetracycline compound
US5789188A (en) 1991-12-06 1998-08-04 American Cyanamid Company Tetracycline-efflux pump inhibitor screening methods

Patent Citations (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE26271E (en) 1967-09-26 Reductive alkylation process
US2482055A (en) 1948-02-11 1949-09-13 American Cyanamid Co Aureomycin and preparation of same
US2619420A (en) 1949-09-17 1952-11-25 American Cyanamid Co Animal and poultry feed containing aureomycin mash
US2734018A (en) 1953-09-28 1956-02-07 Ircso
US2731497A (en) 1954-05-14 1956-01-17 American Cyanamid Co Production of tetracycline
US3128227A (en) 1954-06-17 1964-04-07 American Cyanamid Co Antibiotic intramuscular composition
US2878289A (en) 1956-05-28 1959-03-17 American Cyanamid Co 6-demethyltetracyclines and methods for preparing the same
US2911339A (en) 1957-11-27 1959-11-03 American Cyanamid Co Streptomyces aureofaciens fermentation process
US2997471A (en) 1958-08-18 1961-08-22 Bristol Myers Co Tetracycline derivatives
US3007965A (en) 1959-02-13 1961-11-07 American Cyanamid Co New tetracyclines produced by streptomyces aureofaciens
GB901107A (en) 1959-06-29 1962-07-11 Pfizer Therapeutic composition and method of preparing same
US3026248A (en) 1959-09-11 1962-03-20 Pfizer & Co C Thioglycerol and formaldehyde sulfoxylate stabilized tetracycline antibiotics in polyhydric alcohol solvents
US3043875A (en) 1959-10-22 1962-07-10 Pfizer & Co C Halogenated tetracycline derivatives and processes for their preparation
US3023239A (en) 1959-12-09 1962-02-27 American Cyanamid Co Recrystallization of demethylchlortetracycline
US3050558A (en) 1959-12-09 1962-08-21 American Cyanamid Co Refining of demethylchlortetracycline
US3200149A (en) 1960-05-23 1965-08-10 Pfizer & Co C alpha-6-deoxytetracycline derivatives and process
US3338963A (en) 1960-10-28 1967-08-29 American Cyanamid Co Tetracycline compounds
US3239499A (en) 1961-05-19 1966-03-08 Pfizer & Co C Tetracycline derivative
US3862225A (en) 1961-08-18 1975-01-21 Pfizer D-ring substituted tetracyclines
US3772363A (en) 1961-08-18 1973-11-13 Pfizer 3,4,10-trioxo octahydroanthracene-2-aminoacetic acids and derivatives thereof
US3509184A (en) 1961-08-18 1970-04-28 Pfizer & Co C Anthracyclidine-acetic acid derivatives
US3697552A (en) 1961-08-18 1972-10-10 Pfizer Anthracyclidine-acetic acid derivatives
US3829453A (en) 1961-08-18 1974-08-13 Pfizer Octahydroanthracene-2-aminoacetic acids and esters and mixed anhydrides thereof
US3502696A (en) 1961-08-18 1970-03-24 Pfizer & Co C Antibacterial agents
US3148212A (en) 1961-12-22 1964-09-08 American Cyanamid Co Reductive alkylation process
US3092556A (en) 1962-02-12 1963-06-04 American Cyanamid Co Tetracycline fermentation
US3250810A (en) 1962-09-06 1966-05-10 Pfizer & Co C 6-hydroxy-6-halomethyl tetracyclines
US3145228A (en) 1962-09-06 1964-08-18 Pfizer & Co C 5-alkoxy-and 5-benzyloxy-tetracycline, derivatives and analogues thereof
US3250809A (en) 1962-09-06 1966-05-10 Pfizer & Co C 6-deoxy-6-demethyl-6-halomethylene tetracyclines and their 11a-chloro and fluoro derivatives
US3219529A (en) 1962-10-04 1965-11-23 American Cyanamid Co Stable tetracycline solutions
US3360557A (en) 1963-05-10 1967-12-26 American Cyanamid Co 9-hydroxytetracyclines and a process of preparing same
USRE26253E (en) 1963-05-17 1967-08-15 And z-alkylamino-g-deoxytetracycline
US3226436A (en) 1963-05-17 1965-12-28 American Cyanamid Co 7-and 9-alkylamino-6-deoxytetracycline
US3397230A (en) 1966-03-14 1968-08-13 American Cyanamid Co Nitration of tetracyclines
US3433834A (en) 1966-03-14 1969-03-18 American Cyanamid Co Nitration of 11a-chloro tetracyclines
US3341585A (en) 1966-05-06 1967-09-12 American Cyanamid Co Substituted 7-and/or 9-amino-6-deoxytetracyclines
US3515731A (en) 1966-06-17 1970-06-02 Pfizer & Co C Antibacterial agents
US3849493A (en) 1966-08-01 1974-11-19 Pfizer D-ring substituted 6-deoxytetracyclines
US3345410A (en) 1966-12-01 1967-10-03 American Cyanamid Co Substituted 7- and/or 9-amino tetracyclines
US3403179A (en) 1967-01-10 1968-09-24 American Cyanamid Co Novel 7-(1, 2-bis-substituted-hydrazino)-tetracyclines and methods of preparing same
US3483251A (en) 1967-03-03 1969-12-09 American Cyanamid Co Reductive alkylation process
US3373196A (en) 1967-03-21 1968-03-12 American Cyanamid Co 7-and/or 9-(lower alkyl) amino-5a, 6-anhydrotetracyclines
US3373197A (en) 1967-04-27 1968-03-12 American Cyanamid Co Substituted 6-epitetracyclines and 5a-epi-6-epitetracyclines
US3373198A (en) 1967-04-27 1968-03-12 American Cyanamid Co Substituted 5a, 11a-dehydro-6-epitetracyclines
US3360561A (en) 1967-06-19 1967-12-26 American Cyanamid Co Nitration of tetracyclines
US3518306A (en) 1968-02-19 1970-06-30 American Cyanamid Co 7- and/or 9-(n-nitrosoalkylamino)-6-demethyl-6-deoxytetracyclines
US3526629A (en) 1968-04-02 1970-09-01 American Cyanamid Co Beta-hydroxyethylpiperazinocarboxymethyl - 7 - dimethylamino - 6 - deoxy-6-demethyltetracycline
US3579579A (en) 1968-04-18 1971-05-18 American Cyanamid Co Substituted 7- and/or 9-amino-6-demethyl-6-deoxytetracyclines
US3812188A (en) 1968-08-19 1974-05-21 American Cyanamid Co Purification of 7-chlorotetracycline
US3586483A (en) 1968-10-14 1971-06-22 American Cyanamid Co Method for detecting the presence of tetracycline antibiotics
US3809751A (en) 1969-02-25 1974-05-07 American Cyanamid Co Antibiotic-stable liquid protein supplements containing non-protein nitrogen,phosphorus and a tetracycline antibiotic
US4038315A (en) 1972-05-11 1977-07-26 American Cyanamid Company Isolation and recovery of calcium chloride complex of 7-dimethylamino-6-dimethyl l-6-deoxytetracycline hydrochloride
US3901942A (en) 1972-09-18 1975-08-26 Farmaceutici Italia Tetracycline derivatives substituted in the 7 position and process for preparing the same
US3978000A (en) 1975-03-19 1976-08-31 American Cyanamid Company Catalysts based on carbon supports
US4029600A (en) 1975-03-19 1977-06-14 American Cyanamid Company Carbon particulates with controlled density
US4031137A (en) 1975-03-19 1977-06-21 American Cyanamid Company Catalysts based on carbon supports and use in catalytic deoxidation process
US4081370A (en) 1976-05-20 1978-03-28 American Cyanamid Company Use of carbon particulates with controlled density as adsorbents
WO1984001895A1 (en) 1982-11-18 1984-05-24 Univ Tufts Tetracycline activity enhancement
US5021407A (en) 1982-11-18 1991-06-04 Trustees Of Tufts College Tetracycline activity enhancement
EP0109850A2 (en) 1982-11-22 1984-05-30 Unisys Corporation Speed independent selector switch employing M-out-of-N codes
US4925833A (en) 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
US4666897A (en) 1983-12-29 1987-05-19 Research Foundation Of State University Inhibition of mammalian collagenolytic enzymes by tetracyclines
US4911924A (en) 1987-04-17 1990-03-27 University Of New Mexico Induction of antibiotic hypersensitivity in tetracycline-resistance microorganisms
US5143661A (en) 1987-05-26 1992-09-01 American Cyanamid Company Silicone-hardened pharmaceutical microcapsules
US4918208A (en) 1987-07-28 1990-04-17 Nippon Kayaku Kabushiki Kaisha Process for producing 7-dimethylamino-6-demethyl-6-deoxytetracycline
WO1989002270A1 (en) 1987-09-16 1989-03-23 Theodore Krupin Method of lowering intraocular (eye) pressure
US4837030A (en) 1987-10-06 1989-06-06 American Cyanamid Company Novel controlled release formulations of tetracycline compounds
US4975271A (en) 1988-12-19 1990-12-04 Vipont Pharmaceutical, Inc. Muscosal delivery systems for treatment of periodontal disease
US5122519A (en) 1989-06-27 1992-06-16 American Cyanamid Company Stable, cosmetically acceptable topical gel formulation and method of treatment for acne
US5045538A (en) 1990-06-28 1991-09-03 The Research Foundation Of State University Of New York Inhibition of wasting and protein degradation of mammalian muscle by tetracyclines
US5280888A (en) 1991-04-05 1994-01-25 Societe Jacques Dubois Resilient buffer made of metal wire
US5240272A (en) * 1991-09-17 1993-08-31 Deere & Company Vehicle hitch assembly
US5281628A (en) 1991-10-04 1994-01-25 American Cyanamid Company 9-amino-7-(substituted)-6-demethyl-6-deoxytetracyclines
US5326759A (en) 1991-10-04 1994-07-05 American Cyanamid Company 9-amino-7-(substituted)-6-demethyl-6-deoxytetracyclines
US5401863A (en) 1991-10-04 1995-03-28 American Cyanamid Company 9-amino-7-(substituted)-6-demethyl-6-deoxytetracyclines
US5384259A (en) 1991-12-06 1995-01-24 American Cyanamid Company Construct and method for expression of tetracycline resistance genes in E. Coli
US5789188A (en) 1991-12-06 1998-08-04 American Cyanamid Company Tetracycline-efflux pump inhibitor screening methods
US5420272A (en) 1992-08-13 1995-05-30 American Cyanamid Company 7-(substituted)-8-(substituted)-9-](substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5466684A (en) 1992-08-13 1995-11-14 American Cyanamid Company 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5386041A (en) 1992-08-13 1995-01-31 American Cyanamid Company 7-(substituted)-8-(substituted)-9-[(substituted glycyl) amido]-6-demethyl-6-deoxytetracyclines
US5328902A (en) 1992-08-13 1994-07-12 American Cyanamid Co. 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5401729A (en) 1992-08-13 1995-03-28 American Cyanamid Company 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5284963A (en) 1992-08-13 1994-02-08 American Cyanamid Company Method of producing 7-(substituted)-9-[(substituted glycyl)-amidol]-6-demethyl-6-deoxytetra-cyclines
US5430162A (en) 1992-08-13 1995-07-04 American Cyanamid Company 7-(substituted)-8-(substituted)-9-substituted amino)-6-demethyl-6-deoxytetracyclines
US5442059A (en) 1992-08-13 1995-08-15 American Cyanamid Company 9-[(substituted glycyl)amido)]-6-demethyl-6-deoxytetracyclines
US5457096A (en) 1992-08-13 1995-10-10 American Cyanamid Company 7-(substituted)-8-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5380888A (en) * 1992-08-13 1995-01-10 American Cyanamid Company 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5495030A (en) 1992-08-13 1996-02-27 American Cyanamid Company 9-[(substituted glycyl)amido)]-6-demethyl-6-deoxytetracyclines
US5495031A (en) 1992-08-13 1996-02-27 American Cyanamid Company Process for the production of 7-(substituted)-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5495018A (en) 1992-08-13 1996-02-27 American Cyanamid Company 7-(substituted-9-(substituted amino)-6-demethyl-6-deoxytetracyclines
US5495032A (en) 1992-08-13 1996-02-27 American Cyanamid Company Process for producing 7-(substituted)-8-(substituted-9-[(substituted glycyl)amido]-6-demethyl-6-deoxytetracyclines
US5512553A (en) 1992-08-13 1996-04-30 American Cyanamid Company 7-(substituted)-8-(substituted)-9-(substituted amino)-6-demethyl-6-deoxytetracyclines
US5567692A (en) 1992-08-13 1996-10-22 American Cyanamid Company 9-[(substituted glycyl) amido)]-6-demethyl-6-deoxytetracyclines
US5886175A (en) 1992-08-13 1999-03-23 American Cyanamid Company 7-(substituted)-8-(substituted)-9-(substitued amino)-6-demethyl-6-deoxytetracyclines
US5248797A (en) * 1992-08-13 1993-09-28 American Cyanamid Company Method for the production of 9-amino-6-demethyl-6-deoxytetracycline
US5675030A (en) 1994-11-16 1997-10-07 American Cyanamid Company Method for selective extracting a 7-(hydrogen or substituted amino)-9- (substituted glycyl) amido!-6-demethyl-6-deoxytetracycline compound

Non-Patent Citations (72)

* Cited by examiner, † Cited by third party
Title
Adamson et al., "Aplastic Anemia," Hematology 4<SUP>th </SUP>ed., Williams WJ et al, eds.; McGraw Hill, New York (1990) pp. 158-174.
Allen, "Minocycline," Ann. Intern. Med. 85:482-487 (1976).
Altemeier et al., "Intra-abdominal Abscesses," American Journal of Surgery 125:70-79 (1973).
Bell, "Oral Penicillins in the Treatment of Chronic Staphylococcal Osteomyelitis," Lancet 10:295-297 (1968).
Benitz et al., "Morphologic Effects of Minocycline in Laboratory Animals," Toxicol. Appl. Pharmacol. 11:150-170 (1967).
Bennion et al., "Gangrenous and Perforated Appendicitis with Peritonitis: Treatment and Bacteriology," Clinical Therapeutics 12(Suppl C):31-44 (1990).
Bocker et al., "Identification and Determination of the Principal Metabolites of Minocycline in Humans," J. Chromatogr. 568:363-374 (1991).
Bohnen et al., "Prognosis in Generalized Peritonitis. Relation to Cause and Risk Factors," Archives of Surgery 118:285-290 (1983).
Boothe et al., "6-Deoxytetracyclines, I. Chemical Modification by Electrophilic Substitution" J. Am. Chem. Soc., 82:1253-1254 (1960).
Bryant et al., "Increased Frequency of Doxycycline Side Effects," Pharmacotherapy 7:125-129 (1987).
Buyske et al., "Concentration and Persistence of Tetracycline and Chlortetracycline in Bone," J. Pharmacol. Exper. Ther. 130:150-156 (1960).
Chopra, Handbook of Experimental Pharmacology, vol. 78, pp. 317-392, Springer-Verlay (1985). *
Ciancio et al., "An Evaluation of Minocycline in patients with Periodontal Disease", Journal of Periodontology 51:530-534 (1980).
Collins, "Cell-Free Synthesis of Proteins Coding for Mobilisation function of colE1 and Transportation" Gene 6:28-42 (1979).
Conte et al., "Steady-State Serum and Intrapulmonary Pharmacokinetics and Pharmacodynamics of Tigecycline," Int. J. Antimicrob. Agents 25(6):523-529 (2005).
Degenkolb et al., "Structural Requirements of Tetracycline-tet Repressor Interaction: Dermination of Equilibrium Binding Constants for Tetracycline Analogs with the Tet Repressor", Antimicrob. Agents Chemother. 35:1591-1595 (1991).
DeJonge et al., "Inhibition of Mitochondrial-Protein Synthesis in Rat Small-Intestinal Epithelium," Eur. J. Biochem. 32:356-364 (1973).
Dietz et al., "Comparative Toxicity and Carcinogenicity Studies of Tetracycline and Oxytetracycline in Rats and Mice," Fund. Appl. Toxicol. 17:335-346 (1991).
Entwistle et al. ",Reduction of Nitro-compounds", J. Chem. Soc. 1:443 (1977).
Fanning et al., "Distressing Side-effects of Minocycline Hydrochloride," Arch Intern Med. 136:761-762 (1976).
Feigin, "Clindamycin Treatment of Osteomyelitis and Septic Arthritis in Children," Pediatr. 55:213-223 (1975).
Fry et al., "Determinants of Death in Patients with Intraabdominal Abscess," Surgery 88:517-523 (1980).
Garrison, "Histamine, Bradykinin, 5-Hydroxytryptamine, and Their Antagonists," In: Gilman AG, Rall TW et al., eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics 8<SUP>th </SUP>ed. Elmsford, NY: Pergamon Press pp. 575-582 (1990).
Gibaldi et al., Pharmacokinetics, 2<SUP>nd </SUP>ed., "One-Compartment", Marcel Dekker, Inc., NY, 1982, pp. 1-43.
Gorbach, "Antimicrobial Prophylaxis for Appendectomy and Colorectal Surgery," Reviews of Infectious Diseases 13(Suppl 10):S815-S820 (1991).
Gugler et al., "Effects of Antacids on the Clinical Pharmacokinetics of Drugs. An Update," Clin. Pharmacokinet. 18:210-219 (1990).
Gump et al., "Side Effects of Minocycline: Different Dosage Regimen," Antimicrob Agents Chemother. 12:642-646 (1977).
Hlavka et al., "The 6-Deoxytetracyclines. III Electrophilipic and Nucleophilic Substitution", J. Am. Chem. Soc., 84:1426-1430 (1962).
Jonas et al., "Minocycline," Ther. Drug Monit. 4:137-145 (1982).
Kantrowitz et al., "Histamine-Mediated Myocardial Damage in Rabbits," J. Mol. Cell. Cardiol. 14:551-555 (1982).
King, "Animal Models in the Study of Vomiting," Can. J. Physiol. Pharmacol. 68:260-268 (1990).
Larock, Comprehensive Organic Transformations, VCH Publishers, 411-415, (1989).
Levy, Antimicrobial Agents & Chemotherapy, vol. 33(8), pp. 1373-1374, (Aug. 1989). *
Loeliger et al., "Reliability and Clinical Impact of the Normalization of the Prothrombin Times in Oral Anticoagulant Control", Thrombosis & Haemostasis 53:148-154 (1985).
MacDonald et al., "Pharmacokinetic Studies on Minocycline in Man," Clinical Pharmacology and Therapeutics 14:852-861 (1973).
Misgen, "Compatibilities and Incompatibilities of Some Intravenous Solution Admixtures", Am. J. Hosp. Pharm. 22:92-94 (1965).
Mitscher, "The Chemistry of the Tetracycline Antiobiotic", Marcel Dekker, Inc. Chapter 6.3, p. 172-173 and Chapter 2, p. 53-54, (1978).
Monnier et al., "Visual Compatibility of Heparin with Selected Intravenous Admixtures", ASHP Midyear Clinical Meeting, vol. 25, p. P-186E (Dec. 1990).
Morrison et al., "Amines I. Preparation and Physical Properties", Organic Chemistry, 4<SUP>th </SUP>ed., pp. 894, 898-900, 902 (1983).
Mosdell et al., "Antibiotic Treatment for Surgical Peritonitis," Annals of Surgery 214:543-549 (1991).
Nelis et al., "Metabolism of Minocyclinein Humans," Drug Metab Dispos. 10:142-146 (1982).
Noble et al., "Short-term Toxicity and Observations on Certain Aspects of the Pharmacology of a Unique Tetracycline-Minocycline," Toxicol. Appl. Pharmacol. 11:128-149 (1967).
Norden et al., "Clindamycin Treatment of Experimental Chronic Osteomyelitis Due to Staphylococcus Aureus," J. Infect. Dis. 153:956-959 (1986).
Norden et al., "Treatment of Experimental Chronic Osteomyelitis Due to Staphylococcus Aureus with Ampicillin/Sulbactam," J. Infect. Dis. 161:52-53 (1990).
Norden et al., "Treatment of Experimental Chronic Osteomyelitis Due to Staphylococcus Aureus with Vancomycin and Rifampin," J. Infect. Dis. 147:352-357 (1983).
Norden, "Experimental Chronic Staphylococcal Osteomyelitis in Rabbits: Treatment with Rifampin Alone and in Combination with Other Antimicrobial Agents," Rev. Infect. Dis. 5(Suppl 3):S491-494 (1983).
Norden, "Lessons Learned from Animal Models of Osteomyelitis," Rev. Infect. Dis. 10:103-110 (1988).
Pawelczyk et al., "Kinetics of Drug Decomposition Part 74.Kinetics of Degradation of Minocycline in Aqueous Solution", Pharmacol. Pharm. 34:409-421 (1982).
Pratt, Coupled TranScription-translation in Prokaryotic Cell-free Systems, Transcription and Translation, a Practical Approach, (B.D. Hames and S.J. Higgins, eds.) p. 179-209, IRL Press, Oxford-Washington, (1984).
Raasch,"Interaction of Oral Antibiotics and Common Chronic Medications" Geriatrics 42:69-74 (1987).
Remmers et al., "Some Observations on the Kinetics of the C.4 Epimerization of Tetracycline," J. Pharm. Sci. 52:752-756 (1963).
Rissing, "Animal Models of Osteomyelitis: Knowledge, Hypothesis and Speculation," Infect. Dis. Clin. North Am. 4:377-390 (1990).
Robertson, "p-Aminophenyllacetic Acid", Org. Syn. Coll. 1:52 (1941).
Salyers, Molecular Microbiology, vol. 4(1), pp. 151-156 (1990). *
Skillman et al., "Respiratory Failure, Hypotension, Sepsis, and Jaundice. A Clinical Syndrome Associated with Lethal Hemorrhage from Acute Stress Ulceration of the Stomach," American Journal of Surgery 117:523-530 (1969).
Slama et al., "Oral Ciprofloxacin Therapy for Osteomyelitis Caused by Aerobic Gram Negative Bacilli," Am. J. Med. 82(Suppl 4A):259-261 (1987).
Solomkin et al., "Results of a Multicenter Trial Comparing Imipenem/Cilastatin to Tobramycin/Clindamycin for Intra-abdominal Infections," Annals of Surgery 212:581-591 (1990).
Spencer et al., "6-Deocytetracyclines,. V. 7,9-Disubstituted Products", J. Med. Chem. 6:405-407 (1963).
Sum et al., "Synthesis of Novel Tetracycline Derivatives with Substitution at the C-8 Position," Tetrahedron Letters vol. 35, No. 12, pp. 1835-1836 (1994).
Swenson et al. "The Bacteriology of Intra-abdominal Infections," Archives of Surgery 109:398-399 (1974).
Tapp et al., "Tetracycline Toxicity," Experientia 22:530-531 (1966).
The Merck Index, Entries #2111 and 5936 10<SUP>th </SUP>Ed. (1983) pp. 300,301, & 869.
Tice, "Outpatient Parenteral Antimicrobial Therapy for Osteomyelitis," Infect. Dis. Clin. North Am. 12:903-919 (1998).
Van Den Bogert et al., "Tissue distribution and Effects on Mitochondrial Protein Synthesis of Tetracyclines After Prolonged Continuous Intravenous Administration to Rats," Biochem. Pharmacol. 30:1706-1709 (1981).
Waldvogel, "Osteomyelitis," In Gorbach SL et al., eds. Infectious Diseases, Saunders, Philadelphia 1339-1344 (1988).
Watson, "Chloramphenicol Toxicity in Dogs," Research in Veterinary Science 23:66-69 (1977).
Westfall et al., "Formulation of a Stable Trace Element Solution for TPN" Am. J. Hosp. Pharm. 37:1620 (1980).
Williams et al., "Minocycline: Possible Vestibular Side-Effects," Lancet. 2:744-746 (1974).
Woodward, "m-Hydroxybenzaldehyde", Org. Syn. Coll. 3:453 (1955.
World Health Organization Technical Report Series 687:1-184 (1983).
Yuen, et al., "Kinetics of Concomitatnt Degradation of Tetracycline to Epitetracycline to Epitetracycline, Anhydrotetracycline, and Epianhydrotetracycline in Acid Phosphate Solution", J. Pharm. Sci. 66:1648-1650 (1977).
Zubay, "In-vitro Synthesis of Protein in Microbial Systems", Ann. Rev. Genet. 7:267-287 (1973).

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090275660A1 (en) * 2008-05-01 2009-11-05 Chauhan Bhaskar Stable parenteral formulations of tigecycline
US9107929B2 (en) 2008-05-01 2015-08-18 Ranbaxy Laboratories Limited Stable parenteral formulations of tigecycline
US20100105671A1 (en) * 2008-08-08 2010-04-29 Jingye Zhou C7-fluoro substituted tetracycline compounds
US8501716B2 (en) 2008-08-08 2013-08-06 Tetraphase Pharmaceuticals, Inc. C7-fluoro substituted tetracycline compounds
US8796245B2 (en) 2008-08-08 2014-08-05 Tetraphase Pharmaceuticals, Inc. C7-fluoro substituted tetracycline compounds
US8906887B2 (en) 2008-08-08 2014-12-09 Tetraphase Pharmaceuticals, Inc. C7-fluoro substituted tetracycline compounds
US9315451B2 (en) 2009-05-08 2016-04-19 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
US10072007B2 (en) 2009-05-08 2018-09-11 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
US9624166B2 (en) 2009-08-28 2017-04-18 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
US9573895B2 (en) 2012-08-31 2017-02-21 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
US10315992B2 (en) 2012-08-31 2019-06-11 Tetraphase Pharmaceuticals, Inc. Tetracyline compounds
US10913712B2 (en) 2012-08-31 2021-02-09 Tetraphase Pharmaceuticals, Inc. Tetracycline compounds
US10961190B2 (en) 2016-10-19 2021-03-30 Tetraphase Pharmaceuticals, Inc. Crystalline forms of eravacycline
US11578044B2 (en) 2016-10-19 2023-02-14 Tetraphase Pharmaceuticals, Inc. Crystalline forms of eravacycline

Also Published As

Publication number Publication date
US5530117A (en) 1996-06-25
US5529990A (en) 1996-06-25
US5494903A (en) 1996-02-27

Similar Documents

Publication Publication Date Title
USRE40086E1 (en) Method for treating bacterial infection with novel 7-substituted-9-substituted amino 6-demethyl-6-deoxytetracyclines
EP0536515B1 (en) Novel 7-substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
JP3639313B2 (en) Novel 7- (substituted) -8- (substituted) -9- (substituted amino) -6-demethyl-6-deoxytetracyclines
EP0535346B1 (en) 9-amino-7-substituted-6-demethyl-6-deoxytetracyclines
AU680616B2 (en) 9-{substituted glycyl)amido}-6-demethyl-6-deoxyte tracyclines
AU673366B2 (en) Novel 7-(substituted)-8-(substituted-9-{(substituted glycyl) amido}-6-demethyl-6-deoxytetracyclines
USRE40183E1 (en) 7-Substituted-9-substituted amino-6-demethyl-6-deoxytetracyclines
JP3583449B2 (en) 7- (Substituted) -9-[(substituted glycyl) amido] -6-demethyl-6-deoxytetracyclines
US20130029943A1 (en) Methods of Preparing Substituted Tetracyclines with Transition Metal-Based Chemistries
US8101590B2 (en) 9-aminocarbonylsubstituted derivatives of glycylcyclines

Legal Events

Date Code Title Description
CC Certificate of correction